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Abstract 
Non-ribosomal peptide synthetases (NRPSs) are multi-modular biosynthetic enzymes that are 
responsible for the production of many bioactive secondary metabolites produced by 
microorganisms. They are activated by phosphopantetheinyl transferase (PPTase) enzymes, which 
attach an essential prosthetic group to a specific site within a “carrier protein” (CP) domain that 
is an integral part of each NRPS module. Of particular importance in this work is the NRPS BpsA, 
which produces a blue pigment called indigoidine; but only when BpsA has first been activated by 
a PPTase. BpsA can be used as a reporter for PPTase activity, to identify PPTases and/or measure 
their activity. Several CP-substituted BpsA variants were used, in order to study and identify 
PPTases which may recognise different CP domains. The first part of the research described in this 
thesis examined the features of foreign CP interactions within BpsA that made these functional 
substitutions possible. Two key residues, the +4 and +24 positions relative to an invariant serine, 
were found to be highly important; with appropriate substitutions at these positions yielding 
active CP-substituted variants. 
Wild type BpsA and the CP-substituted variants were then used as the basis of a screen to discover 
new PPTase genes, and associated natural product biosynthetic genes, from metagenomic 
libraries. The vast majority of bacteria that produce bioactive secondary metabolites are unable 
to be cultured under laboratory conditions; screening metagenomic libraries is a way to access 
this untapped biodiversity in order to discover new natural products. Two environmental DNA 
libraries were screened, and PPTase genes were identified via their ability to activate BpsA, giving 
rise to blue colonies in high throughput agar plate screens. This screen proved to be a powerful 
enrichment strategy with almost half of the novel 21 PPTase genes recovered also linked to 
biosynthetic gene clusters. Using the evolved CP-substituted BpsA variants (and thereby altering 
the PPTase recognition site) enabled a wider variety of hits to be found. This led to the hypothesis 
that some of the PPTases discovered via this screening method would have non-overlapping 
substrate specificities, a beneficial property for certain PPTase applications.  
The 21 PPTase genes discovered via metagenomic screening were characterised further, using a 
series of assays involving BpsA to measure their activity. As is common for PPTase enzymes, there 
were difficulties in obtaining enough soluble protein via purification to perform a detailed analysis 
of each. Those that were able to be purified had much lower activity than other previously 
characterised PPTases, and were also not as specific for their CP substrates as they had first 
appeared to be. Due to these low activity levels, several other previously characterised PPTases 
were also studied further using the BpsA methods. All PPTases showed a relatively broad activity 
across a range of CP substrates. 
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The desire to obtain PPTases with more specific substrate specificities led to the development of 
a directed evolution screen to alter PPTase CP specificity. In a proof-of-principle study the E. coli 
PPTase EntD was evolved to lose activity with the BpsA CP while retaining activity with its native 
CP. This screen, the first of its kind to evolve PPTases for greater CP substrate specificity, was 
successful in recovering several improved variants. These variants had either completely abolished 
or vastly decreased activity for the WT BpsA CP while retaining the ability to activate the native 
(EntF) CP domain. The general strategy developed here can be applied to the evolution of other 
PPTases and CP substrates. 
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Chapter 1: Introduction 
1.1 Nonribosomal peptide synthetases 
Non-ribosomal peptide synthetases (NRPSs) are large complex enzymes, present in many bacteria 
and fungi, that are responsible for the synthesis of a range diverse peptides that often possess 
bioactive properties (Finking and Marahiel, 2004). For example, this diverse group of products 
includes antibiotics such as penicillin and vancomycin, the immunosuppressant cyclosporine, and 
the anti-cancer drugs epothilone and bleomycin.  Synthesis of NRPS enzymes is a widespread 
feature of many microorganisms (Schwarzer et al., 2003) and it is thought that they provide a 
competitive advantage over rival microorganisms (Finking and Marahiel, 2004). The NRPS 
structure is modular, whereby each module of the enzyme is responsible for the incorporation of 
an amino acid monomer into the final peptide structure. The enzymes themselves are usually large 
and energy-intensive for the microorganisms to produce, for example the gene for cyclosporine 
production is 45.8 kb in size, coding for a 1.6 MDa sized protein, all to produce a product which 
consists of only 11 amino acid monomers (Weber et al., 1994). The fact that these enzymes 
represent such a huge investment of energy and resources reflects that their peptide products are 
often highly bioactive, i.e. provide essential offensive or defensive capabilities under certain 
conditions (Fischbach and Walsh, 2006). 
The vast diversity of possible NRPS products stems from two key differences between ribosomal 
and nonribosomal synthesis; the use by NRPS enzymes of a wide variety of amino acids (beyond 
the usual proteinogenic 20), and the potential for these to be incorporated into the final peptide 
product in an unusual manner. NRPSs can incorporate over 500 unique monomers into their 
peptide products, with the sizes of most of these peptides ranging from 2-23 monomers (Caboche 
et al., 2010). Tailoring domains that are present in addition to the standard domains required for 
peptide product formation also help to increase the chemical diversity of the products. For 
example many NRPSs contain epimerisation domains which alter the stereochemistry of the 
corresponding amino acids from their L to D forms. Penicillin is an example of a peptide product 
which contains an unusual amino acid, L-α-aminoadipic acid, as well as an amino acid with altered 
stereochemistry, D-valine, and an unusual intramolecular cyclisation between the sidechains of 
the D-valine and the third amino acid monomer, L-cysteine (Felnagle et al., 2008). As a means of 
providing yet further diversity, NRPS enzymes can also exist as hybrids with polyketide synthetases 
(PKSs). PKSs are a class of enzymes that have a similar modular structure to NRPSs, but use acetate 
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and propionate as their monomeric building blocks as opposed to amino acids. Hybrid NRPS/PKS 
contain combinations of discrete NRPS and PKS modules, allowing for even greater diversity in 
products. For example the two anti-cancer drugs mentioned earlier (epothilone and bleomycin) 
are both examples of hybrid products (Schwarzer and Marahiel, 2001). Ultimately, NRPS 
synthesised peptides have the potential to be much more structurally diverse than traditional 
peptides (Finking and Marahiel, 2004).  
1.1.1 NRPS structure and function 
Structurally NRPSs are large enzymes that consist of a series of smaller enzymatic subunits known 
as modules, with each module responsible for the incorporation of one amino acid into the final 
peptide product (Schwarzer et al., 2003). Each module is in turn made up of several core catalytic 
domains that perform the key reactions necessary for the formation of the peptide product. These 
core domains are the Adenylation (A) domain, responsible for the selection and activation of a 
specific amino acid substrate; the peptidyl carrier protein (PCP) domain, the site of attachment 
responsible for transfer of the growing peptide between modules; and the condensation (C) 
domain, responsible for the condensation of adjacent amino acids via peptide bond formation. 
The final domain in the terminal module of nearly every NRPS enzyme is the thioesterase or TE 
domain, which is responsible for catalysing the release of the final peptide product from the larger 
NRPS complex (Figure 1.1). In addition to these core domains, many NRPSs contain additional 
tailoring domains which can result in further modifications to the product. One example is the 
epimerisation (E) domain which, as mentioned above, catalyses the epimerisation of bound L-
amino acids into D-amino acids. Another tailoring domain is the oxidation (Ox) domain which can 
catalyse oxidation reactions using a bound FMN cofactor (Schwarzer et al., 2003).  
When an NRPS enzyme is first synthesised, it is in an inactive (apo) form and needs to be activated 
into the active (holo) form in order to function. To be active, the PCP domain of the NRPS must 
have a phosphopantetheine (Ppant) arm attached, which acts as the point of attachment for the 
growing peptide product. This attachment reaction is catalysed by a phosphopantetheinyl 
transferase (PPTase) enzyme, which catalyses the transfer of the Ppant arm, derived from CoA, 
onto an invariant serine residue within the PCP (Marahiel et al., 1997). The intermediate peptide 
products are connected via an energy rich thioester linkage at the tip of the Ppant arm, which 
facilitates hydrolysis during peptide synthesis. This arm is a 20 Å long moiety, which serves as a 
flexible linker, allowing the transfer of the growing peptide chain along the different catalytic 
domains of the NRPS enzyme (Finking and Marahiel 2004). 
3 
 
 
Figure 1.1 Basic NRPS structure and function. NRPS enzymes consist of several domains (represented in 
blue, green, and purple) which each govern incorporation of one amino acid (                  ) into the final 
product. First each CP must be activated by a PPTase, which adds the 4’-phosphopantetheine arm. The A 
domains recognise each amino acid and catalyse the attachment to the 4’-phosphopantetheine arm. C 
domains then catalyse peptide bond formation between adjacent amino acids, and the growing peptide 
product is passed along to the next module. Finally, the TE domain releases the final product. Adapted from 
(Calcott, 2014). 
 
1.1.1.1 Carrier protein domains 
The domain of most relevance to the work described in this thesis is the PCP domain (sometimes 
referred to as just a PCP, or as a Thiolation or T domain), which will be described in more detail 
here. The PCP domain in NRPSs serves as the specific site of attachment for the Ppant arm 
(covalently attached to an invariant serine residue by a PPTase), which in turn serves as the point 
of attachment for the intermediate products during the synthesis process, transferring the 
product between the different catalytic domains. After a PCP has been activated by a PPTase it 
transforms from its inactive, or apo-enzyme state to the active, or holo-enzyme state.  PCPs are 
one form of carrier protein (CP), so named because they specifically carry amino acid or peptidyl 
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substrates. The wider CP family also comprises aryl carrier proteins (ArCPs), which carry aryl acid 
substrates; and acyl carrier proteins (ACPs), which carry acetate, propionate or malonate 
monomers. ArCPs are a subset of the PCP domains, which are also found in NRPSs and are usually 
involved in siderophore biosynthesis (Crosa and Walsh, 2002). Siderophores are another common 
NRPS product, molecules for iron scavenging that are often key virulence factors in infection. In 
contrast, ACPs are found in PKSs as well as fatty acid synthases (FAS). CP domains are further 
defined by whether they exist as part of a larger polypeptide (type I) or are themselves standalone 
proteins (type II). Most of the PCPs in NRPSs appear to be type I and are part of the larger NRPS 
unit, but several type II PCPs have also been found (Du and Shen, 1999; Lohman et al., 2014) 
CP domains are typically small protein domains (75-90 bp) that contain a small, identifying region 
of highly conserved sequence, consisting of the invariant serine residue that is the site of Ppant 
attachment and the amino acids immediately surrounding it, GX(D/H)S(L/I)(D/K), (Mercer and 
Burkart, 2007; Mofid et al., 2002). The first PCP to have its structure solved, using NMR, was TycC3 
from the tyrocidine synthetase NRPS in Bacillus brevis (Weber et al., 2000). This structure 
appeared as a four helix bundle, a very similar structure to that of previously solved ACP domains, 
with three longer helices that are parallel to each other and a shorter forth helix (Crosby and 
Crump, 2012). All CPs to date have this conserved 4 helix structure (Finking and Marahiel, 2004). 
The helices are joined by loop regions, and the invariant serine is on the loop between helix I and 
II, near the start of helix II. In particular helix II of the CP has been found to be important for 
interactions between PPTases and CP domains (Mofid et al., 2002; Parris et al., 2000; Tufar et al., 
2014). One of the main differences between ACP and PCP domains is the overall charge of the 
protein, with PCPs being neutral and ACPs negatively charged (Weber et al., 2000). The CP 
domains will be discussed further in Chapter 3. 
1.1.2 New natural products via NRPS engineering or discovery 
The highly bioactive nature of many of the NRPS peptides means there is great interest in 
discovering new natural products, through either the engineering or discovery of NRPS genes. The 
modular structure of NRPSs suggests it should be possible to perform a straightforward 
manipulation of the order and number of modules to create novel peptides (Mootz et al., 2002a). 
This strategy, while promising, usually results in vastly decreased yields (Calcott and Ackerley, 
2014; Sieber and Marahiel, 2005). A greater understanding of the interactions between different 
domains and modules is required in order to improve the outcome of these manipulation 
experiments. In particular, the interactions between CP domains and downstream TE domains are 
a primary focus of the research described in Chapter 3. Another approach is the discovery of 
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entirely new NRPS genes that have not been found before, this is discussed further in section 1.3.2 
and is the subject of the work presented in Chapter 4. 
1.2 Phosphopantetheinyl transferase enzymes 
The PPTase superfamily of enzymes was first described by Lambalot et al. (1996), and more 
recently has been the subject of an extensive review (Beld et al., 2013). PPTases catalyse the 
transfer of the 4’-phosphopantetheinyl arm of CoA onto a CP domain, thereby activating the CP 
domain (Figure 1.2). These CP domains may belong to NRPS, PKS, or FAS enzymes, and all require 
this activation by a PPTase in order to function. PPTases are essential enzymes found in all living 
cells, from microorganisms to mammals, and are divided into different subtypes (types I-III) 
defined by differing sequences, physical characteristics and activities (Copp and Neilan, 2006; 
Joshi et al., 2003). All organisms contain at least one PPTase, necessary to activate the essential 
FAS of primary metabolism, and often contain at least one additional PPTase, specialised for 
activation of the NRPS and PKS enzymes of secondary metabolism. PPTases have low sequence 
homology, though they do contain several conserved motifs (Lambalot et al., 1996; Sanchez et al., 
2001; Walsh et al., 1997). Recently the signature sequence of bacterial PPTases has been extended 
and redefined as (I/V/L)G(I/V/L/T)D(I/V/L/A)(x)n(F/W)(A/S/T/C)xKE(S/A)h(h/S)K(A/G) where x is 
any amino acid, h is any hydrophobic amino acid and n is 42-48 for type I PPTases and 38-41 for 
type II PPTases. There is also another less well conserved region within this middle stretch, 
(L/I/V/M/F)(x)3(V/I/Y/F)h(x)3E(x)3h, which contains a highly conserved glutamine residue (Asghar 
et al., 2011).  
PPTases themselves are used as tools in many biotechnological applications, due to their ability to 
transfer a host of molecules from CoA analogues onto CP domain substrates (Figure 1.2). 
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Figure 1.2 PPTases function. A) PPTases catalyse the reaction whereby the 4’-phosphopantetheine arm of 
CoA is transferred onto the sidechain of an invariant serine residue within a CP. B) Many PPTases are also 
capable of utilising modified CoA analogues that have various chemical moieties covalently in place of the 
free sulfhydryl group on the phosphopantetheine arm. 
 
1.2.1 PPTase subtypes 
PPTase enzymes are classified into three subtypes, depending on their sequence, structure and 
activity. Type I PPTases are typified by the E. coli PPTase AcpS, and are usually involved in pathways 
of primary metabolism, and as a result are often essential. Type II PPTases are twice the size of 
type I, are typified by the Bacillus subtilis PPTase Sfp, and are usually involved in pathways of 
secondary metabolism. Type III PPTases are the least well studied of the subtypes, and are 
generally only found in fungi. These PPTases are integrally associated with their larger target 
enzymes, for instance in Saccharomyces cerevisiae a type III PPTase domain was identified as part 
of the FAS enzyme complex (Fichtlscherer et al., 2000). These integrated type III PPTases have a 
similar sequence to type I PPTases, and will not be discussed further as they are outside the scope 
of this thesis. 
1.2.1.1 Type I PPTases 
Type I, or AcpS-like PPTases, are found in almost all organisms, and activate the ACP domains of 
FAS and PKS enzymes. AcpS from E. coli was one of the first PPTase enzymes to be discovered 
(Elovson and Vagelos, 1968) and is one of the best characterised (Gehring et al., 1997; Lambalot 
and Walsh, 1995).  Type I PPTases are the smallest enzymes in the family at approximately 120 
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amino acids, and form a homotrimer (Parris et al., 2000). They are usually more specific for ACP 
domains, and generally do not exhibit substantial levels of activity with PCP domains.  
1.2.1.2 Type II PPTases 
Type II, or Sfp-like PPTases primarily activate the PCP or ArCP domains found in NRPSs. These 
PPTases are around twice the size (at approximately 240 amino acids) of type I enzymes, and have 
a pseudo-homodimer structure (a single peptide chain that folds into two symmetrical units 
resembling two separate domains which have formed a dimer). In addition to Sfp, the first type II 
PPTases described were Gsp from Bacillus brevis and EntD from E. coli  (Lambalot et al., 1996). 
Sfp, whose native substrates are the NRPS responsible for surfactin production, is in particular 
known for its broad substrate specificity, and has been shown to activate many PCP domains from 
foreign NRPSs as well as ACP domains, although it has a much lower efficiency with ACP domains 
(Lambalot et al., 1996; Nakano et al., 1992). Due to the broad specificity of Sfp, it has been widely 
used for the heterologous expression of NRPS and PKS enzymes in E. coli (Kealey et al., 1998; 
Pfeifer et al., 2001). While E. coli is very amenable to genetic manipulation, its own PPTases are 
relatively specific for endogenous substrates, hence a need for broadly specific PPTases like Sfp to 
activate foreign enzymes. The E. coli type II PPTase, EntD is a good example of a class II enzyme 
that is more specific for its cognate substrates, the NRPSs responsible for production of the 
siderophore enterobactin. EntD shows little crossover in terms of substrates with AcpS (Flugel et 
al., 2000; Lambalot et al., 1996), which are involved in FAS and primary metabolism, and also 
relatively poor activation of other bacterial NRPS enzymes when these are expressed in E. coli 
(Caffrey et al., 1991; Pfeifer et al., 1995; Roberts et al., 1993).  
An unusual type II PPTase that is relevant to this thesis is PcpS from Pseudomonas aeruginosa, 
which is the only PPTase present in P. aeruginosa, and as such is responsible for modifying both 
ACP and PCP domains present in this organism. Though PcpS is clearly a type II PPTase, it shows a 
higher activity with its endogenous ACP domains compared to its endogenous PCP domains, and 
hence substantially higher activity with ACP domains than is generally seen with other type II 
PPTases. This  may emphasise the essential role of PcpS in primary metabolism (Barekzi et al., 
2004). Because of this unusual property PcpS is sometimes referred to as a subtype of type the 
type II class (Finking et al., 2002).  
1.2.2 PPTase structure 
A number of PPTases have had their structures described. Many of these structures have been 
solved in the presence of various ligands, e.g. CoA, their native CP substrate, or the essential Mg2+ 
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ion. Only four type II PPTases have had their crystal structure solved (with two of these being very 
recent (Jung et al., 2014; Vickery et al., 2014)), the majority of solved structures have been for 
type I PPTases. Despite low sequence homology being shared among the PPTases, the basic 
structure is very similar, with each subunit of the type I PPTases and each half of the 
pseudohomodimeric type II PPTases having the same basic fold structure.  
1.2.2.1 Structure of type I PPTases 
Type I PPTases are the most well structurally characterised PPTases to date. AcpS from B. subtilis 
and AcpS from Streptococcus pneumoniae were the first type I PPTases crystallised, and these 
structures showed that AcpS family members exist in a trimeric configuration (Chirgadze et al., 
2000; Parris et al., 2000). Each subunit is about 15 kDa, with an α/β fold, and these come together 
to form a tightly packed trimer. At each interface between the subunits an active site is formed, 
resulting in three active sites per enzyme. Site directed mutagenesis was used to confirm the 
importance of this secondary structure, as when AcpS was unable to trimerise it displayed no 
activity. The structure of the B. subtilis AcpS in complex with CoA showed that the interactions 
between the 4’-phosphopantetheine arm and the protein are weak (with the Ppant resting in a 
shallow hydrophobic pocket on the protein’s surface), and that the 4’-phosphopantetheine arm 
extends away from the base of the CoA molecule. Interactions between AcpS and ACP were 
observed between helix I of AcpS and helix II of ACP, these interactions being mostly hydrophilic 
in nature (Parris et al., 2000).  
1.2.2.2 Structure of type II PPTases 
Sfp was the first PPTase from any family to have its crystal structure solved (Reuter et al., 1999). 
The structure of Sfp was found to be unique, with a novel α/β fold and a pseudohomodimeric 
structure, with the N terminal and C terminal halves of the protein separated by a short flexible 
polypeptide loop.  Each half of the protein is very similar to one of the type I PPTase monomers. 
Because of this structure it is thought that type II PPTases may have evolved from an ancient 
duplication event (Mootz et al., 2001). The C terminal half of Sfp more closely resembles an AcpS 
monomer than does the N-terminal half, as it contains the three residues that coordinate the Mg2+ 
ion (Asp107, Glu109 and Glu151 in Sfp). The C-terminus does however also contain an extra loop 
relative to AcpS, thought to confer stability to the pseudodimer (Beld et al., 2013). This crystal 
structure was solved in the presence of CoA, which bound in the pocket formed between the N-
terminal and C-terminal halves. The pantetheine arm appeared to be quite flexible in the crystal 
structure, and did not appear to have any strong interactions with the Sfp enzyme. This was 
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thought to explain the earlier observation that Sfp had shown promiscuity towards a number of 
different CoA analogues that contained modified phosphopantetheine arms (Quadri et al., 1998). 
A recently solved structure of the Sfp/PCP complex showed the two proteins associated via a 
hydrophobic interaction between helix II of the PCP and the first and third helices in the C-terminal 
domain of Sfp. The binding of the PCP caused a shift in the C-terminal domain of Sfp, opening up 
a cavity between the two domains (Tufar et al., 2014). 
The second type II PPTase to be crystallised, the human PPTase AASDHPPT (Bunkoczi et al., 2007) 
has some notable differences from other type II PPTases that are known, primarily that it is a lot 
larger (almost 100 residues longer), with a larger “tail” wrapping around the back of the PPTase. 
The CoA molecule and ACP domain were found to bind in a similar manner to Sfp, in an active site 
located between the N- and C-terminal domains.  
More recently two groups have solved the crystal structure of the Mycobacterium tuberculosis 
PPTase, PptT (Jung et al., 2014; Vickery et al., 2014), with Vickery et al. also solving another 
mycobacterial type II PPTase, MuPPT from M. ulcerans. These mycobacterial PPTases were found 
to have similar folding and overall structure to Sfp and AASDHPPT but did display some notable 
differences in the active site, most notably in the binding of CoA. In both of the mycobacterial 
PPTases, the pantetheine arm bound to the PPTase in a deep hydrophobic pocket, forming a close 
bond with the PPTase. The adenine base of CoA is also found in a deep hydrophobic pocket 
whereas in both Sfp and AASDHPPT this pocket was a lot shallower. This may explain the 
observation that unlike many other PPTases, PptT is poorly able to accommodate modified CoA 
substrates (Leblanc et al., 2012). 
1.2.3 Methods for assessing PPTase activity 
PPTases are generally classified by their ability to activate different CP substrates. In vivo 
complementation studies can be performed for confirmation of a gene’s identity as a PPTase 
(Borchert et al., 1994; Mootz et al., 2002b; Nakano et al., 1992). The ability of PPTases to activate 
various CP domains can also be tested in vitro, although traditional methods can be laborious and 
time consuming and generally are only able to be performed on a low throughput scale. 
PPTases can be qualitatively assessed to determine whether they are capable of activating a given 
CP substrate, by using various assays to look at the amount of the CP that is 
phosphopantetheinylated within a set period of time.  The PPTase and CP are expressed in the 
same cell, or in an in vitro mixture, and the CP is isolated so that the ratio of 
phosphopantetheinylated to unphosphopantetheinylated can be determined, either through a 
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radiometric assay, HPLC or by using mass spectroscopy (Copp et al., 2007; Lambalot and Walsh, 
1997; Liu et al., 2005). Full kinetics are more time intensive and technically challenging. Many 
PPTases are also very difficult to express as soluble proteins. Due to the laborious methods for 
characterisation, only seven PPTases have been kinetically characterised by these means (Beld et 
al., 2013). These are E. coli AcpS, Sfp, PcpS, AASDHPPT (the human PPTase), Lys5, Svp and FdmW. 
A new approach to assess the kinetic parameters of PPTases was developed in our lab (Owen, 
2010). PPTase activity is measured via their ability to activate BpsA (described in section 1.4), an 
NRPS which synthesises a coloured product, indigoidine. This method was used to assess three 
PPTases- Sfp, PcpS and  PP1183 (Owen et al., 2011).  This approach will be discussed further in 
Chapter 5. 
1.3 Biotechnological applications of PPTases 
The flexibility of the PPTase catalysed reaction - the transfer of the Ppant arm of CoA onto a CP 
domain - can be exploited for use in many different biotechnological applications. This utility 
largely stems from the promiscuity of PPTases towards different substrates, in particular their 
ability to accommodate a wide variety of CoA analogues. This property is thought to be explained 
by the mode of CoA binding seen in both Sfp and AcpS type PPTase crystal structures, where the 
phosphate groups of CoA provide the main interaction with the PPTase active site and the Mg2+ 
cofactor, while the terminal thiol end of CoA extends out of the binding pocket in the case of Sfp, 
or rests in a shallow pocket with weak force interactions in the case of AcpS (Parris et al., 2000; 
Reuter et al., 1999). This has meant the pantetheine end of CoA can be modified dramatically with 
little effect on overall catalytic activity (Quadri et al., 1998). The range of different molecules that 
have been incorporated into these CoA analogues includes peptides, fluorophores, carbohydrates, 
biotin, quantum dots, and DNA (George et al., 2004; La Clair et al., 2004; Maillard et al., 2011; 
Meier and Burkart, 2009; Meier et al., 2006; Sieber et al., 2003; Sunbul et al., 2008). The fact that 
PPTases can transfer any of these molecules onto any CP domain-like substrate makes them 
versatile in a wide range of applications including site-specific protein labelling and protein 
immobilisation. 
1.3.1 Heterologous expression of NRPS and PKS enzymes 
One of the first biotechnological applications of PPTases utilised the fact that some PPTases are 
able to activate a broad range of CP substrates. In order to characterise or manipulate NRPS or 
PKS enzymes, their genes are often heterologously expressed in a host strain such as E. coli.  
However the native PPTases of E. coli do not have a sufficiently broad activity to routinely activate 
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foreign NRPS/PKS, leading to the expression of inactive apo-enzymes (Caffrey et al., 1991; Pfeifer 
et al., 1995; Roberts et al., 1993). Co-expression of a PPTase that has a broad substrate range such 
as Gsp (Ku et al., 1997) or Sfp (Kealey et al., 1998) can resolve this problem. Despite the incredibly 
broad substrate range of Sfp, there have been cases documented where it has been unable to 
activate or fully activate all heterologous CPs (Allen and Bartlett, 2002; Gokhale et al., 1999), 
indicating it may yet be beneficial to test multiple broad range PPTases or even to find new 
PPTases that possess a broader substrate specificity.  
1.3.2 PPTases in natural product discovery 
Natural products account for a large number of drugs currently on the market. Microorganisms 
are the source of many of these natural products, which are often secondary metabolites 
synthesised by NRPS or PKS enzymes (Li and Vederas, 2009; Osbourn, 2010). The fact that these 
have evolved to have a biological activity is likely the reason that the “hit rate” for compounds 
that go on to become therapeutic drugs is orders of magnitude higher for libraries of natural 
product compounds  compared to chemically synthesised compounds (Berdy, 2005). For practical 
reasons, the majority of the microbially sourced drugs in clinical use today have been discovered 
from cultivable microbes, yet these are estimated to make up less than 1% of total microbial 
diversity in existence (Keller and Zengler, 2004; Rappé and Giovannoni, 2003; Torsvik et al., 2002). 
Efforts to tap into this vast resource of uncultivable microorganisms, by isolating DNA from 
environments known to be rich in microbial diversity and mining it for genes of interest, are known 
as metagenomic screening (Daniel, 2004). 
The idea of utilising the activity of PPTases in this effort was first described by Yin et al. (2007) who 
used Sfp to identify CP domains from a library of genome fragments, with the aim of connecting 
these to the wider NRPS or PKS genes they were associated with. Phage display was used to 
express protein fragments on phage surfaces, with the gene for the protein of interest  contained 
within the phage. If the displayed protein fragment was recognised by the PPTase Sfp it was then 
labelled with a CoA biotin analogue, enabling subsequent recovery of the phage particle via 
streptavidin binding. The effectiveness of this method was demonstrated using a libraries created 
from B. subtilis or Myxococcus xanthus DNA. This approach proved to be an effective enrichment 
method for CP-containing NRPS and PKS genes, finding almost half of the CPs present in B. subtilis 
and almost 20% of the CPs present in Myxococcus xanthus. However, the fact that the broad 
activity PPTase Sfp could only recover half of the CPs in its own genome, and even fewer in a 
foreign genome, indicates that the approach may work better with an even broader activity 
PPTase, or using a panel of different PPTases (Yin et al., 2007). The same group then repeated this 
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experiment with metagenomic DNA, and found it enriched for CP proteins in this metagenomic 
sample, one of which appeared to be part of a larger NRPS cluster (Zhang et al., 2009).  
An interesting side effect of this approach was that it was not only CP domains that were 
recovered, but also a number of other proteins that turned out to be capable of being recognised 
by Sfp and labelled with biotin. These proteins appeared to have no relation to CPs but did all bear 
the recognition sequence DSL (or in some cases the alternative ESL), where S is the serine for the 
point of phosphopantetheine attachment (Yin et al., 2007; Zhang et al., 2009). The sequence of 
one of these proteins, YbbR was used to determine a minimal sequence of 11 residues that is 
capable of being modified by a PPTase, called ybbR or the ybbR tag (Yin et al., 2005). This has been 
utilised as an alternative to full CP domains in many PPTase labelling applications, as covered in 
the next section. 
Complementary to searching a metagenomic DNA sample to recover CP domains, another 
approach is to screen for PPTase genes. PPTase genes are often found in the same gene cluster as 
the biosynthetic genes that they activate, so the discovery of these genes is likely to lead to the 
discovering of associated NRPS or PKS gene clusters. This was first proposed as an approach by 
(Mootz et al., 2002b), where it was suggested unknown PPTase genes could be found through 
complementation screening with Lys5, a PPTase from Saccharomyces cerevisiae that is essential 
under conditions of lysine starvation. A novel approach for the discovery of PPTase genes and 
associated biosynthetic gene clusters will be the subject of the work presented in Chapter 4 of this 
thesis. 
1.3.3 The development of PPTase-mediated site specific protein 
labelling 
CP domains or CP domain derivatives (like the ybbR tag) can be attached to a protein of interest 
and subsequently serve as substrates for a PPTase, which are then able to label this tag with any 
molecule present on a CoA analogue. For site specific labelling of target proteins, these labels can 
be fluorophores or quantum dots, which then enable visualisation of proteins or potentially FRET 
measurements. This technique is used in the study of proteins and their interactions, allowing 
visualisation of protein movements and interactions with other proteins and molecules, 
facilitating the elucidation of protein function (Sunbul and Yin, 2009). 
One of the first studies to demonstrate this technique tagged two cell surface receptors with ACP 
tags, α-agglutinin receptor (Aga2p) on yeast cells and human G protein-coupled receptor 
neurokinin 1 (NK1) in mammalian cells. AcpS was then used to label these with both fluorophore 
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and biotin CoA analogues. Highly specific labelling was seen in this in vivo system (George et al., 
2004). Around the same time, another group created a series of fusion proteins, combining one 
of two different PCP domains with one of three other proteins, enhanced green fluorescent 
protein (EGFP), maltose binding protein (MBP) and glutathione-S-transferase (GST). The PCP tags 
did not appear to affect any of the functions of these proteins. The tags were then successfully 
labelled with a biotin CoA analogue, confirmed by ELISAs and western blotting (Yin et al., 2004). 
The potential to label proteins with CP tags was then subsequently improved upon with the 
serendipitous discovery of the ybbR tag, as noted in the previous section. The ybbR tag was shown 
to be able to be fused to other proteins, on either the C- or N- terminus, as well as on internal 
flexible loops. This tag also retained the ability to be labelled with multiple CoA analogues, 
demonstrated using several fluorescent tags as well as biotin (Yin et al., 2005). This technology 
was then further improved by a different application of the phage display method, seeking to 
deliberately identify small peptide tags capable of recognition and labelling by a PPTase (Zhou et 
al., 2007a). A library consisting of peptides that were 12 residues long, all being combinatorial 
variants of the core ybbR sequence, was created and then divided in two. The two libraries were 
then screened in parallel for peptides that could be recognised by either Sfp or AcpS. This resulted 
in the discovery of two separate peptides, S6 and A1, which were able to be specifically labelled 
by Sfp and AcpS respectively. Sfp had a 442-fold higher kcat/Km with S6 than did AcpS, whereas 
AcpS had a 30-fold higher kcat/Km with A1 than Sfp. It was shown that these tags could also be 
added to cell surface proteins without affecting their functions, and that they could then 
specifically be separately labelled with fluorescent CoA analogues. The A1 tag was then improved 
even further still, shortening it to only 8 amino acids (Zhou et al., 2008).  
One limitation of the technology is that CoA analogues are unable to pass through the cell 
membrane, so at this stage are primarily used for labelling of cell surface proteins. This can, 
however, also be an advantage, as cell surface proteins are then able to be labelled and 
distinguished with no background fluorescence inside the cell. One study labelled an odorant 
receptor (a G protein-coupled receptor) using an ACP tag on the N-terminus of the receptor, 
labelled by a fluorophore CoA analogue added by AcpS, thereby labelling the receptors on the cell 
surface. Some receptors were also labelled with a GFP protein tag, fused to the intracellular C-
terminus of the protein, which labelled all receptors including those internal to the cell. This 
enabled a visualisation and comparison of cell surface vs. total receptor population at any one 
time, and allowed the tracking of single molecules, following their movement through the 
membrane as well as their internalisation (Jacquier et al., 2006). 
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1.3.3.1 Recent examples of PPTases being applied for site 
specific protein labelling 
The past two years have seen an increase in the use of PPTases for site specific labelling of 
proteins. Due to the limitation of CoA analogues not being able to pass through the cell 
membrane, the technique is still mainly used for the labelling of cell surface proteins, although 
there have been some instance of in vitro labelling as well. 
Various chemokine receptors have been labelled using PPTases. The chemokine receptor CXCR7 
was tagged with PCP, then labelled with a fluorescent CoA analogue using Sfp, confirming the 
expression of this receptor on human B cells. It was also used to differentiate between a full length 
and truncated form of the receptor, showing that the truncated version could not be internalised 
(Humpert et al., 2012). In another instance, the chemokine receptor CXCR4 was labelled using a 
PCP tag and a fluorescent CoA, and time-lapse video microscopy was used to track receptors in 
real time, showing how the receptors reacted to different stimulants. Cells were also treated with 
viral proteins (from the Herpes simplex virus), which were found to affect chemokine function 
(Martinez-Martin et al., 2015). Another group labelled several different chemokine molecules with 
the S6 tag, and used fluorophores to visualise the interactions of the receptors, demonstrating 
how this varied for different combinations of chemokine and chemokine receptor (Kawamura et 
al., 2014). 
PPTases have also been used in the study of neurotrophin nerve growth factor (NGF) receptors, 
which are involved in the development and survival of neurons, as well as neuronal plasticity. The 
first study used an ACP tag on one of these receptors, tropomyosin receptor kinase A (TrkA), and 
labelled this with quantum dots and Sfp. The labelled receptor had identical properties to an 
unmodified protein, and the quantum dots enabled study of protein dynamics and tracking of 
single molecules on living cells (Callegari et al., 2012). This same technique was subsequently used 
by the same group, to look at how TrkA responded to different ligands, again using quantum dots 
to allow long-term tracking of single molecules. This allowed determination of the oligomeric state 
of the receptor, as well as showing that different ligands resulted in different patterns of receptor 
movement within the membrane (Marchetti et al., 2013). More recently still, this group has used 
a dual labelling approach, with the A1 tag on the TrkA and the S6 tag on another NGF receptor, 
p75NTR (Marchetti et al., 2014). NGF itself was also tagged with A4 (the 8 amino acid residue AcpS 
specific tag (Zhou et al., 2008)). The tagged and biotinylated NGF was found to be fully functional 
and still able to interact with receptors. However, it was noted that AcpS had a lower efficiency of 
labelling than Sfp with their respective tags, and some non-specific labelling was seen. 
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Nonetheless, it was concluded this type of dual labelling will allow for further study of the 
interactions between NGF and its receptors, as tracked on living cells.  An important advantage of 
the PPTase system over traditional methods of labelling for these receptors was the stoichiometry 
of the reaction; previously neurotrophins had been labelled by mainly chemical methods, which 
give inconsistently labelled proteins (Marchetti et al., 2014). 
PPTase mediated site specific labelling has also been used in the study of HIV. The HIV envelope 
protein, Env, mediates viral entry into human cells. Env was dual labelled with both the A1 tag and 
a Q3 tag (used for transglutaminase labelling), at two separate locations within the protein. This 
allowed for labelling with two different fluorophores, a donor and acceptor fluorophore, thereby 
enabling FRET measurements. The dynamics of the protein were tracked in real time, tracking the 
different conformations of the protein as it interacted with the human CD4 receptor, including 
examination of the effects of adding an antibody that decreased the virus’s ability to infect cells. 
HIV Env is an target for vaccines, and it was argued that the information collected from this real-
time visualisation could facilitate development of HIV vaccines or other targeted therapies (Munro 
et al., 2014a; Pancera et al., 2014). The Gag proteins from HIV, which drive virus assembly, have 
also been studied using this method, in this instance being dual labelled with the S6 and A1 tags 
and using two different fluorophores for FRET analysis. This enabled the Gag reaction to be 
monitored in vitro, revealing the conformational state of the protein before and during virus 
assembly (Munro et al., 2014b).    
These and a few other examples of other recent uses of PPTases for site-specific labelling are 
summarised in Table 1.1 
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Table 1.1 Recent examples of proteins labelled by PPTase mediate site specific labelling 
Target Protein PPTase/tag Notes Reference 
TrkA Sfp/ACP Single molecule tracking over long time 
periods 
(Callegari et al., 
2012) 
CXCR7 Sfp/PCP Confirmed expression of receptor on 
human cells, differentiated from truncated 
receptor 
(Humpert et al., 
2012) 
EGFR Sfp/ACP Studied conformational states and ligand 
induced structural changes 
(Ziomkiewicz et al., 
2013) 
TrkA Sfp/ACP Response to different ligands via single 
molecule tracking 
(Marchetti et al., 
2013) 
IgE and IgE 
receptor 
Sfp/S6 Dual labelling with a different, chemical, 
method with FRET measurement between 
IgE and its receptor 
(Grünewald et al., 
2014) 
Interferon Sfp/ybbR Visualisation of the targeting of interferon 
to specific cells 
(Garcin et al., 2014) 
Histone 
methyltransferase 
Sfp/ybbR Elucidation of dimeric protein structure (Davidovich et al., 
2014) 
Synaptotagmin  Sfp/S6 Interaction of protein domains with the 
plasmid membrane 
(Vasquez et al., 2014) 
CXCL12, CCL2, 
CCL21 
Sfp/S6 Visualisation of reactions between 
multiple chemokine/receptor 
combinations 
(Kawamura et al., 
2014) 
TrkA 
P75NTR 
NGF 
AcpS/A1 
Sfp/S6 
AcpS/A4 
Multiple labelling of different receptors 
and ligands 
(Marchetti et al., 
2014) 
Gag Sfp/S6 
AcpS/A1 
FRET analysis of viral Gag assembly in vitro (Munro et al., 2014b) 
Env AcpS/A1 Also labelled with transglutaminase tag for 
dual labelling and FRET measurements 
(Munro et al., 2014a) 
(Pancera et al., 2014) 
Interferon Sfp/ybbR Single molecule tracking and receptor 
assembly 
(Wilmes et al., 2015) 
CXCR4 Sfp/PCP Receptors tracked in real time, in response 
to multiple stimulants 
(Martinez-Martin et 
al., 2015) 
EGFR Sfp/ACP Dynamics of mutant EGFR proteins 
implicated in non-small cell lung 
carcinoma 
(Valley et al., 2015) 
Insulin receptors Sfp/S6 Interaction between protein domains (Cabail et al., 2015) 
  
1.3.3.2 Immobilisation 
As a subset of site specific labelling applications, immobilisation occurs when proteins are labelled 
with a molecule (e.g. biotin) that can be used to immobilise said protein onto a solid surface. 
Immobilisation is an important step in applications such as drug screening or medical diagnostics 
(Ebisu et al., 2009). Early protein immobilisation for these applications involved non-specific 
binding, which was problematic as a very pure protein was required to begin with and it resulted 
in heterogeneous display of the protein. More recently site-specific covalent protein 
immobilisation has been explored. In one of the first instances of using PPTases to immobilise 
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enzymes, Sfp was used to attach a biotin-CoA analogue to a PCP domain that had been fused to a 
target protein. These biotin-labelled fusions could then be immobilised onto avidin glass slides 
(Yin et al., 2004). The proteins of interest were able to be isolated from cell lysates and did not 
lose any activity in the process. This method of immobilisation required two steps, the labelling of 
the protein of interest and subsequent attachment to a solid support. In a study by Wong et al 
(2008), a one-step immobilisation was performed. In this case CoA was already covalently 
attached to a solid support matrix and through the action of Sfp a recombinant protein (containing 
the ybbR tag) was directly immobilised on the surface. It was shown that proteins could also be 
immobilised directly from cell lysate (Wong et al., 2008).  
Recently these immobilisation techniques have been applied to molecular force assays, which 
measure the strength of the interactions either between protein molecules or between protein 
and DNA. This usually requires the protein in question to be immobilised to a solid support. YbbR 
fusion proteins for enzymes involved in cellulose degradation were immobilised onto solid 
surfaces, via CoA attached to a surface, in order to study the forces withstood by these enzymes, 
which has implications in the field of biofuels (Schoeler et al., 2014). Molecular force assays 
between protein and DNA (as of might be of interest to understand gene expression regulatory 
mechanisms) were performed again by immobilising ybbR fusion proteins onto CoA coated 
surfaces. Multiple proteins can be immobilised to the same surface, for high throughput parallel 
screening (Limmer et al., 2014). Otten et al. (2014) performed a high throughput ybbR mediated 
immobilisation of multiple proteins, to perform single molecule force assays to characterise the 
mechanical properties of multiple proteins. 
1.3.3.3 PPTases in the formation of hydrogels 
PPTases can be used in the formation of bioactive hydrogels. In a proof-of-principle study, ACP 
dimers were used as the base and point of attachment for CoA-polyethylene glycol (PEG) 
molecules. Mixing the ACP dimers and CoA-PEG in the presence of Sfp caused a gel to form. Many 
chemical methods of gel formation lack selectivity and can negatively affect cells and other 
biomolecules. PPTases avoid these problems as their labelling is specific and controllable, and cells 
and other biomolecules were successfully incorporated into the PPTase catalysed gels with little 
loss in activity (Mosiewicz et al., 2009).  
1.3.4 Discovery of PPTase inhibitors 
The essential nature of PPTases in many pathogenic species has led to PPTases becoming a 
potential target for inhibitors, with the aim being to recover inhibitors that can be used as 
18 
 
antibiotics. PcpS, the only PPTase in the pathogenic species Pseudomonas aeruginosa, was 
identified as a potential antibiotic target as it is the only PPTase present in the organism so it is 
essential for primary metabolism, as well as playing a key role in synthesis of  a number of 
virulence factors (including the siderophores pyoverdine and pyochelin) (Finking et al., 2002). The 
PPTase in M. tuberculosis, PptT, has also been identified as a potential antibiotic target (Chalut et 
al., 2006; Leblanc et al., 2012), and is required for growth and persistence of M. tuberculosis in a 
mouse model (Leblanc et al., 2012). Other PPTases have also been shown to be involved in the 
virulence of a certain pathogenic E. coli strain, which contains the PPTase ClbA, required for 
production of the genotoxin colibactin. At least one PPTase from this pathogenic E. coli, either 
ClbA or EntD, needs to be present for the survival of this organism in a mouse model; a knockout 
of both PPTases had its virulence abolished (Martin et al., 2013). Owing to the promise of PPTases 
as an antibiotic target, several screening methods have been developed to find new inhibitors. 
Screening for these inhibitors has also utilised the activity of PPTases to accept fluorescent CoA 
analogues, using fluorescence based assays to determine the effect of any potential PPTase 
inhibitors (Duckworth and Aldrich, 2010; Foley and Burkart, 2009; Yasgar et al., 2010).  
1.4 Blue pigment synthetase A as a model NRPS 
One NRPS of particular relevance to this project is Blue pigment synthetase A (BpsA) from 
Streptomyces lavendulae. BpsA is a single module NRPS which synthesises the blue pigment 
indigoidine (Takahashi et al., 2007). The structure of BpsA is unusual in that it consists of a single 
module, which has an oxidation domain located in the middle of the A domain (Fig 1.3 A). This 
single module catalyses a reaction wherein two molecules of L-glutamine are individually cyclised 
and then dimerised to form a molecule of indigoidine (Fig 1.3 B). This pigment is easily visualised 
on either solid (Fig 1.3 C) or in liquid (Fig 1.3 D) media. The advantages of working with BpsA are 
numerous. The bpsA gene is small (for an NRPS) at 3800 bp, making it relatively easy to work with 
and genetically manipulate. Perhaps in part due to this small size the protein can be purified 
relatively easily, again unusual for an NRPS. This allows BpsA to be employed in both in vivo and 
in vitro colourimetric assays. Like all NRPS, BpsA first needs to be activated by a PPTase (Fig 1.3 A), 
and the native PPTases of E. coli do not activate BpsA (Owen, 2010; Takahashi et al., 2007) (Fig 1.3 
D). The exact role of indigoidine in its natural setting is not known, though it has been shown to 
have some antimicrobial and antioxidant properties (Cude et al., 2012; Reverchon et al., 2002). 
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1.4.1 Applications of BpsA 
BpsA has been utilised for several different flexible and elegant applications within our lab, based 
primarily on the ability to measure BpsA function via indigoidine production. This can provide a 
measure of the function of BpsA itself, for example when bpsA has been manipulated via 
substitution of foreign CP domains. The activity of such substitutions can subsequently be 
improved via directed evolution by screening for the production of indigoidine (Owen, 2010). 
Directed evolution is a process whereby mutations are introduced into a gene and new or altered 
properties are then screened for and selected, thereby allowing the discovery of new and 
improved variants. Indigoidine production can be easily screened for in a high throughput manner 
meaning that this system is adaptable to a range of directed evolution strategies. In Chapter 3, the 
interactions between the different domains of BpsA were investigated via directed evolution of 
CP-substituted variants, in order to highlight important residues.  
BpsA can also be used to measure PPTase activity. The native PPTases in E. coli do not recognise 
BpsA, enabling purification of BpsA in its inactive, or apo, form. This apo-BpsA can then either be 
co-expressed with a PPTase in vivo or incubated with a PPTase in vitro and indigoidine synthesis 
used as a measure of activation of BpsA by that PPTase. This approach was utilised to discover 
PPTases from metagenomic DNA (investigated further in Chapter 4), as well as to characterise the 
kinetic activity of various PPTases (relevant to work described in Chapter 5) (Owen, 2010; Owen 
et al., 2011). Another application of BpsA is its use in assays to discover PPTase inhibitors, where 
potential inhibitors are identified and validated through their ability to block indigoidine 
production (Owen et al., 2011).  
More recently we found that the amount of indigoidine produced in the BpsA catalysed reaction 
is proportional to the amount of L-glutamine present, and developed an assay for the 
quantification of L-glutamine, resulting in a PCT patent filing (Ackerley et al., 2015). I contributed 
to the development of this assay, which while not directly related to the research presented in 
this thesis is summarised in Appendix 1.  
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Figure 1.3 The NRPS BpsA and its product, indigoidine. A) Gene and protein domain structure of the NRPS 
BpsA, with (*) indicating that the Ppant arm is required for activation and is added by a PPTase; B) structure 
of indigoidine; C) indigoidine synthesised by colonies expressing both bpsA and an activating PPTase on agar 
plates containing L-glutamine; D) indigoidine production in L-glutamine containing liquid cultures by E. coli 
expressing bpsA and either co-expressing an activating PPTase (Sfp from B. subtilis; left) or expressing bpsA 
in the absence of an activating PPTase (right).  
1.5 Aims of this study 
The first aim of this thesis was to use BpsA to elucidate some of the mechanisms involved in CP 
interactions with the CPs downstream domain partner, enabling understanding of key factors that 
contribute to successful CP substitutions. Several foreign CP domains were swapped into BpsA to 
further investigate important residue positions that had been previously identified by Dr Jeremy 
Owen as playing an important role in determining the functionality of domain substituted NRPS 
constructs. In addition to this, site directed mutagenesis was applied to fully investigate the 
contributions of two particular residues within the CP domain. This work was the subject of 
Chapter 3. 
The second aim of this thesis was to use WT BpsA, together with two BpsA variants possessing 
alternative CP domains, and use these to screen two metagenomic libraries for the presence of 
novel PPTase and secondary metabolite producing genes. This work was the subject of Chapter 4. 
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Following the successful discovery of new PPTase genes as part of the work in Chapter 4, the next 
aim was to characterise these PPTases further, using a series of BpsA based assays to define their 
activity and substrate specificity. When these were found to be of generally low activity a number 
of other, already known, PPTase enzymes were selected for additional characterisation using 
these same assays. This work is presented in Chapter 5. 
The final aim of this thesis was to develop a directed evolution strategy in order to alter PPTase 
substrate specificity, using the PPTase EntD in a proof of principle screening method. The aim here 
was to lose activity with one CP substrate while retaining it with another, in order to engineer a 
PPTase that had a narrow substrate specificity. Different CP-substituted variants of BpsA were 
again used to achieve this, based on the ability to monitor either retention or loss of indigoidine 
production by different PPTase variants.
22 
 
  
23 
 
Chapter 2: Material and Methods 
2.1 General chemical reagents, enzymes and media 
Chemicals, reagents and media used in this study were obtained from Sigma-Aldrich (St Louis, MO, 
USA) or Thermo Fisher Scientific (Waltham, MA, USA), unless otherwise stated. L-glutamine was 
purchased from iHerb (Perris, CA, USA). Restriction enzymes were purchased from New England 
Biolabs (NEB; Ipswich, MA, USA). IPTG (isopropyl β-D-thiogalactoside) and BioMix™ Red 
Polymerase Mastermix were supplied by Bioline (London, UK). Phusion™ high-fidelity DNA 
polymerase was supplied by Finnzymes (Espoo, Finland). T4 DNA ligase was supplied by either 
Bioline or Invitrogen (Carlsbad, CA, USA). Mutazyme was obtained from Agilent Technologies 
(Santa Clara, CA, USA). 
2.2 Bacterial strains and plasmids 
2.2.1 Bacterial Strains 
All bacterial strains used in this study are given in Table 2.1. 
Table 2.1 E. coli strains used in this study 
Strain Relevant characteristics Source 
DH5α λpir F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ(pir)  
Invitrogen 
BL21 F– ompT gal dcm lon hsdSB(rB- mB-) λ(DE3)  Novagen 
BL21  ΔentD  BL21 ΔentD This study 
EcoBlue1 BL21 ΔentD + pCDFDuet1::bpsA (wild-type) This study 
EcoBlueP BL21 ΔentD + pCDFDuet1::bpsA (pvdD carrier protein domain 
substitution) 
This study 
EcoBlueE BL21 ΔentD + pCDFDuet1::bpsA (entF carrier protein domain 
substitution) 
This study 
 
2.2.2 Plasmids 
All plasmids used in this study are given in Table 2.2. 
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Table 2.2 Plasmids used in this study 
Plasmid Relevant characteristics Source 
pET28a(+) KanR, expression vector for His-tagged enzyme purification, 
T7 promoter, ColE1 origin of replication  
Novagen 
pCDFDuet1 lacIq ,T7prom, specR, CDFori  Novagen 
pETDuet1 lacIq, T7 promoter, ampR, ColE1 origin of replication Novagen 
pRSETB lacIq, T7 promoter, ampR, ColE1 origin of replication Invitrogen 
pLBPSA3 pCDFDuet based staging vector allowing introduction of 
foreign CP domains into bpsA with silent restriction sites 
(Owen, 2010) 
pBAD AmpR, araBAD promoter, araC, pBR322 origin of replication Invitrogen 
pKD4 AmpR, KanR, Pir-origin of replication, kanR gene template for 
KO-PCR  
(Datsenko and Wanner, 
2000) 
pKD46 AmpR, Heat sensitive origin of replication, recombinase 
expression vector, ara operon promoter 
(Datsenko and Wanner, 
2000) 
pCP20 AmpR, heat sensitive origin of replication, encodes FLP 
recombinase 
(Datsenko and Wanner, 
2000) 
 
2.3 Oligonucleotide primers 
Oligonucleotide primers used in this study were synthesised by Integrated DNA Technologies (IDT; 
Carlsbad, CA, USA). Primers were supplied lyophilised and on receipt were made up to 100 µM 
stock solutions with 1x TE buffer, pH 8.0 (10 mM Tris-Cl pH 8.0, 0.1 mM EDTA). Working stocks 
were diluted to 10 µM in filter sterilised autoclaved ddH2O and both working and stock solutions 
were stored at -20 °C. The names and sequences of primers used in this study are listed in Table 
2.3, with restriction sites underlined. 
Table 2.3 Oligonucleotide primers used in this study 
Primer Name Sequence (5’ → 3’) 
PPTase specific primers  
Ps1448a_PPT_fwd CTAGCATATGCTGGTCAGTGG 
Ps1448a_PPT_rev GTACGTCGACTCAGCCTTCG 
entD_pBAD_fwd AGCTCTCGAGATGGTCGATATG 
entD_pBAD_rev AGCTAAGCTTTTAATCGTGTTGG 
entD_pET_fw AGCTCATATGATGGTCGATAT 
entD_pET_rev AGCTGTCGACTTAATCGTGTT 
Swhit1_fwd GTACCATATGGATTGTCTCGC 
Swhit1_rev GTACAAGCTTTCACAGCTCGGT 
Swhit2_fwd GTACCATATGAAGCCATGGTC 
Swhit2_rev GTACCTCGAGCTACCTCGCTG 
Swhit3_fwd GTACCATATGGACAGCAAATGG 
Swhit3_rev GTACGTCGACTCAGTCCCCGCGAA 
Swhit4_fwd1 GTACCATATGCGTTCGCCGAGT 
Swhit4_fwd2 GTACCATATGGGCTGCTCCGTA 
Swhit4_rev GTACGTCGACCTACGAACTCGA 
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Swhit5_fw GTACCATATGACCGGCATTGAA 
Swhit5_rev GTACGTCGACTCAAGGGCAGTG 
Swhit6_fwd GTACCATATGAGCGGAGGC 
Swhit6_rev GTACAAGCTTCTACTTGATCCG 
Swhit7_fwd1 GTACCATATGGCGCTCCCGGTC 
Swhit7_fwd2 GTACCATATGATGTTGCATGTCGGG 
Swhit7_rev GTACCTCGAGTCATTTGGTTGA 
NZhit1_fwd GTACCATATGGAGGAGCTGCTT 
NZhit1_rev GTACGTCGACTCAGGCGCCG 
NZhit2_fwd GTACCATATGAAGCCATGGTC 
NZhit2_rev GTACCTCGAGCTACCTCGCTGA 
NZhit3_fwd1 GTACCATATGGACTACCAAGC 
NZhit3_fwd2 GTACCATATGGCCCGGTTGG 
NZhit3_rev GTACCTCGAGCTAGTGCACC 
NZhit4_fwd GTACCATATGCACGACGAGGAT 
NZhit4_rev GTACCTCGAGTCACGCGCC 
NZhit5_fwd GTACCATATGGCAGATCTCAAT 
NZhit5_rev GTACGTCGACTCAGGGCAT 
NZhit6_fwd GTACCATATGAGCGCGGCAC 
NZhit6_rev GTACCTCGAGTCAGGCCCA 
NZhit7_fwd GTACCATATGACCCGCTATC 
NZhit7_rev GTACGTCGACTCAATCAGTC 
NZhit8_fwd GTACCATATGCCTGTCGTAT 
NZhit8_rev GTACGAATTCTTAGGTCCATG 
NZhit9_fwd GTACCATATGATCACCTCGC 
NZhit9_rev GTACGTCGACTCACTCTATTAG 
NZhit10_fwd GTACCATATGAGCAGGCATAAC 
NZhit10_rev GTACGTCGACCTAAGCAGGC 
NZhit11_fwd GTACCATATGACCATCTGGCCG 
NZhit11_rev GTACCTCGAGTTATTTCGGCTG 
NZhit12_fwd GTACCATATGCGAAGAACCG 
NZhit12_rev GTACGTCGACCTAAGGTTCC 
NZhit13_fwd GTACCATATGGAAACGGCATC 
NZhit13_rev GTACGTCGACTCAGGCCATG 
NZhit14_fwd GTACCATATGCTGCACCAAC 
NZhit14_rev GTACGTCGACTCAGCTGCG 
  
entD KO primers  
EntDKOFw ATGGTCGATATGAAAACTACGCATACCTCCCTCCCCTGTGTAGGCT
GGAGCTGCTTC 
EntDKORv TTAATCGTGTTGGCACAGCGTTATGACTATCTTTTCCATATGAATA
TCCTCCTTAG 
EntDExnFw CGTTTGTCATCAGTCTCGAATATGGTCGATATGAAA 
EntDExnRv AATCGTACCAGATGTTGTCAATTAATCGTGTTGGCA 
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CP primers  
EntF_fwd CTAGCATATGGGGCGTGCGCCGAAAG 
EntF_rev GTACGTCGACTCATTCGAATCC 
  
For PvdDCP1 substitutions  
slPvdDT_Fwd AGCTCTGCAGAGCTCGTCGAGCGCCCCTATCGAGCGCCCGGTAGC 
slPvdDT_Rev AGCTTCTAGACTCCTGGGCGACCTCGCGTTCCAATCCCTGGGCGA
A 
PvdDT1_NNK4_ultramer GCGCCCGGTAGCGAGCTGGAGCAGCGCATCGCAGCGATCTGGTC
GGAGATCCTGGGAGTGGAACGGGTCGGCCTGGACGACAACTTCT
TCGAACTGGGCGGTCATTCGTTGCTGGCTNNKCGGGTGATTTCTC
GGGTTCGCCAGGAGCAGCAGTTGGACGCAAGCCTGAAGGCGTTG
T 
PvdDT1_NNK_rev TCCCTGGGCGAACGCTTCCAGAACCGGCCGCTCGAACAACGCCTT
CAGGC 
PvdDT1_NNK_fwd GCGCCCGGTAGCGAGCTGGAGCAGCGCATCGCAGCGATCTGGTC
GGAGAT 
PvdD_NNK24_ultra TCCCTGGGCGAACGCTTCCAGAACCGGCCGCTCMNNCAACGCCT
TCAGGCTTGCGTCCAACTGCTGCTCCTGGCGAACCCGAGAAATCA
CCCGGGTAGCCAGCAACGAATGACCGCCCAGTTCGAAGAAGTTG
TCGTCCAGGCCGACCCGTTCCACTCCCAGGATCTCCGACCAGATC 
PvdDT1_NNK4_NNK24_ultra TCCCTGGGCGAACGCTTCCAGAACCGGCCGCTCMNNCAACGCCT
TCAGGCTTGCGTCCAACTGCTGCTCCTGGCGAACCCGAGAAATCA
CCCGMNNAGCCAGCAACGAATGACCGCCCAGTTCGAAGAAGTTG
TCGTCCAGGCCGACCCGTTCCACTCCCAGGATCTCCGACCAGATC 
  
Miscellaneous primers   
T7 promoter TAATACGACTCACTATAGGG  
T7 terminator GCTAGTTATTGCTCAGCGG  
pET Upstream ATGCGTCCGGCGTAGA 
DuetUP2 TTGTACACGGCCGCATAATC 
BpsA_T_screen ACGAGCAGATCGGCCACGA 
PBAD-F ATGCCATAGCATTTTTATCCA 
PBAD-R GATTTAATCTGTATCAGG 
 
2.4 Synthesis of genes 
The genes synthesised in this study are listed in Table 2.4. The PPTases Svp and Gsp were 
synthesised by GenScript (Piscataway, NJ, USA) and the remainder were synthesised as gBlocks by 
Integrated DNA Technologies (IDT; Carlsbad, CA, USA). All genes were codon optimised for E. coli 
using OPTIMIZER (Puigbò et al., 2007, 2008), using the guided random method. The sequences for 
all codon optimised synthesised genes are listed in Appendix 1. 
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Table 2.4 Genes synthesised in this study 
Gene 
PPTases 
Sfp 
Svp 
Gsp 
MtaA 
Carrier protein domains 
ACMSIII 
GrsB 
TycC 
Pris3 
BlmI 
SgcC2 
MtaF 
TcmM 
 
2.5 Bacterial growth and maintenance 
2.5.1 Media 
Unless otherwise stated all media was made up to the appropriate volume with ddH2O and 
autoclaved for 30 min at 121 °C to sterilise prior to use. Media was stored at room temperature 
or at 4 °C if containing heat sensitive supplements.  
2.5.1.1 Lysogeny Broth (LB)* 
Component  Final Concentration 
Tryptone 10 g.L-1 
Yeast extract 5 g.L-1 
NaCl 10 g.L-1 
*LB was supplied as a premixed powder by the manufacturer. 
2.5.1.2 ZYP5052 auto-induction medium 
2.5.1.2.1 ZY base 
Component  Final Concentration 
N-Z Amines AS 10 g.L-1 
Yeast extract 5 g.L-1   
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2.5.1.2.2 20x NPS 
Component  Final Concentration 
NH4SO4 66 g.L-1  
KH2PO4 136 g.L-1   
Na2HPO4 142 g.L-1  
 
2.5.1.2.3 50x 5052 
Component  Final Concentration 
Glycerol 250 g.L-1 (200 ml.L-1)  
D-glucose 25 g.L-1  
L α-lactose 100 g.L-1  
 
2.5.1.2.4 Autoinduction media 
Component  Final Concentration 
ZY base* 929 ml.L-1 
20x NPS* 50 ml.L-1  
50x 5052* 20 ml.L-1  
MgSO4** 1 mM 
*Solutions were prepared and autoclaved separately, then mixed immediately prior to use. 
**Filter sterilised and added post-autoclave. 
 
2.5.1.3 SOC* 
Component  Final Concentration 
Tryptone 20 g.L-1   
Yeast extract 5 g.L-1  
NaCl 0.5 g.L-1 
KCl 2.5 mM 
MgCl2** 10 mM 
Glucose** 20 mM 
*pH adjusted to 7.0 using NaOH pre-autoclave 
**Filter sterilised and added post-autoclave 
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2.5.1.4 GYT medium* 
Component  Final Concentration 
Glycerol 100 ml.L-1  
Yeast extract 1.25 g.L-1  
Tryptone 2.5 g.L-1  
*Filter sterilised 
2.5.1.5 Solid Media 
For solid media, agar was added to media at a concentration of 1.5% (w/v) prior to autoclaving. 
Any necessary supplements were added after the agar had cooled to <50 °C post-autoclave. Agar 
was then poured in approximately 20 ml aliquots into sterile 90 mm diameter Petri dishes and left 
to solidify at room temperature. Plates were stored at 4 °C.   
2.5.1.5.1 Iron limited pigment production solid medium 
Component  Final concentration 
M9 salts* 1X  
Agar* 1.7% (w/v) 
L-glutamine* 100 mM  
Glycerol** 0.4% (v/v) 
MgSO4 ** 2 mM 
2,2-dipyridyl** 100 µM  
L-arabinose** 0.01% (w/v) 
CaCl2**  0.1 mM 
*M9 salts were autoclaved separately to agar and L-glutamine (each in half total volume ddH2O) 
**Filter sterilised and added post autoclave 
2.5.2 Media supplements 
Antibiotic stock solutions were made up to 1000x final concentration in the appropriate solvent 
and filter sterilised using a 0.22 µM filter before being stored at -20 °C. Antibiotics and relevant 
concentration are given in Table 2.5. IPTG stocks were prepared to a final concentration of 
100mg.ml-1.  L-arabinose stocks were prepared to a final concentration of 200 mg.ml-1. Stocks of 
2,2-dipyridyl were made to a final concentration of 100 mg.ml-1. 
Table 2.5 Antibiotic supplements used in this study 
Antibiotic Stock solution Solvent 
Ampicillin 100 mg.ml-1 ddH2O   
Kanamycin  50 mg.ml-1  ddH2O  
Spectinomycin 50-100 mg.ml-1  ddH2O  
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2.5.3 Bacterial growth and storage 
Unless otherwise stated, bacteria were grown at 37 °C, and aerated at 200 rpm when grown in 
liquid culture. For short term maintenance, bacteria on agar plates were stored at 4 °C. For long 
term storage 600-700 µl of overnight liquid culture was mixed in a 1:1 ratio with autoclaved 80% 
(v/v) glycerol and stored at -80 °C indefinitely.    
2.6 Routine molecular biology 
2.6.1 Polymerase chain reaction (PCR) 
PCR amplification reactions for cloning were performed using PhusionTM high fidelity polymerase. 
For other applications including colony screening, Biomix RedTM was employed. PCR reactions 
were set up according to the manufacturer’s protocols, as outlined in Table 2.6. Standard PCR 
parameters are given in Table 2.7. Parameters were optimised as required for individual genes. 
Table 2.6 Composition of PCR reactions 
PhusionTM  
Component Volume per 20 µl reaction 
5x PhusionTM HF buffer 4 µl  
10 mM dNTPs 0.4 µl 
10 µM fwd primer 1 µl 
10 µM rev primer 1 µl  
50 ng/µl Template DNA 0.5 µl  
DMSO 1 µl 
ddH2O   to 20 µl  
  
Biomix RedTM  
Component Volume per 20 µl reaction 
2x BiomixTM master mix 10 µl  
10 µM fwd primer 1 µl 
10 µM rev primer 1 µl 
50 ng/µl Template DNA* 0.5 µl  
ddH2O  to 20 µl  
*For colony screen PCR reactions, a small amount of E. coli colony picked from an agar plate with 
a sterile pipette tip was used as the template 
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Table 2.7 Standard PCR cycling parameters 
Temperature (°C) Time  
PhusionTM   
98 1 min  
98 10 s  
56 20 s 20-25 cycles 
72 30 s/kb  
72 5 min  
   
Biomix RedTM   
95 5 min  
95 20 s  
56 30 s 10-15 cycles 
72 30 s/kb  
   
95 20 s  
52 30 s 15-20 cycles 
72 30 s/kb  
72 5 min  
 
2.6.2 Agarose gel electrophoresis 
To assess the size and quality of DNA products including those of PCR reactions, DNA was run on 
a 1% (w/v) agarose gel, containing 1 µg.ml-1 ethidium bromide. Gels were run submerged in 1x 
TAE buffer (40 mM Tris-acetate, pH 8.0, 1 mM EDTA) at 120-130 V for 30-40 min. Hyperladder I 
(Bioline, London, UK) was run alongside the samples for size comparison and bands were 
visualised under ultra-violet (UV) light. 
2.6.3 PCR product purification 
PCR products were purified using a Zymo-SpinTM column (Zymo Research; Irvine, CA, USA) 
according to the manufacturer’s instructions. Products were eluted in autoclaved ddH2O and 
stored at -20 °C. 
2.6.4 Restriction enzyme digests 
Restriction digests were performed according to the manufacturer’s instructions and heat 
inactivated at 65 °C for 20 min prior to use in further ligation reactions. Where enzymes were 
unable to be heat inactivated, digests were immediately clean and concentrated using a Zymo-
SpinTM column. Digests that were not used immediately were stored at -20 °C.  
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2.6.5 Ligation 
Ligations were performed according to the manufacturer’s instructions, using a 1:3 molar ratio of 
vector to insert, with each reaction containing 100-150 ng of total DNA. Reactions were incubated 
at 25 °C for 90 min. Ligations were then used to transform competent cells or else stored at -20 °C. 
2.6.6 Bacterial cell transformation and electroporation 
2.6.6.1 Preparation of chemically competent cells 
The E. coli strain to be made competent was inoculated from a glycerol stock and grown in 3 ml 
LB amended with 10 mM MgCl2 and any relevant antibiotics at 37 °C, 200 rpm overnight. The 
following day 50 ml of LB supplemented with 10 mM MgCl2 and any relevant antibiotics was 
inoculated from this overnight culture to give a final OD600 of 0.05. Cells were incubated at 37 °C, 
200 rpm until an OD600 of 0.4-0.6 was reached. Cells were then cooled on ice for 15 min then 
centrifuged at 2700 g for 15 min at 4 °C. The cell pellet was resuspended in 1 volume of ice cold 
TFBI buffer (buffers used in this protocol are given in Table 2.8. Cells were then incubated on ice 
for 2 h before being centrifuged again at 2700 g for 15 min at 4 °C. The resultant cell pellet was 
resuspended in 0.1 volume ice cold TFBII buffer. Cells were transferred into sterile, pre-chilled 1.5 
ml microcentrifuge tubes in 100-200 µl aliquots, snap frozen and stored indefinitely at -80 °C.  
Table 2.8 Competent cell protocol buffer recipes 
Component  Final concentration 
TFBI  
Potassium Acetate 30 mM 
MnCl2  50 mM 
CaCl2   10 mM 
Glycerol  15% (v/v) 
TFBII  
Na-MOPS, pH 7.0 10 mM 
CaCl2  75 mM 
KCl 10 mM 
Glycerol 15% (v/v) 
 
2.6.6.2 Transformation of chemically competent cells 
Frozen cell aliquots were removed from -80 °C storage and thawed on ice prior to addition of 
plasmid DNA. For each transformation, DNA in a volume of less than 10 µl was added to 100 µl of 
cells. This mixture was left on ice for at least 20 min after which transformation was induced by 
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by heat shock at 42 °C for 90 s. Cells were then returned to ice for 1-2 min and then recovered in 
900 µl LB at 37 °C, 200 rpm for 60-90 min. Finally cells were spread on LB agar plate supplemented 
with appropriate antibiotics and grown overnight at 37 °C. 
2.6.6.3 Preparation of electrocompetent cells 
The E. coli strain to be made competent was inoculated from a glycerol stock and grown in 10 ml 
LB supplemented with any relevant antibiotics at 37 °C, 200 rpm overnight. This overnight culture 
was then used to inoculate 400 ml LB containing any relevant antibiotics. This culture was grown 
until an OD600 of 0.30-0.35 was reached, at which point it was transferred to 8 sterile 50 ml tubes 
and cooled on ice for 30 min. Cells were then centrifuged for 30 min at 1000 g, 4 °C. For the first 
wash step, pellets were resuspended in a total volume of 400 ml ice cold sterile ddH2O by gentle 
pipetting. Cells were then centrifuged again for 30 min at 1000 g, 4 °C and the resulting pellet was 
washed in 200 ml ice cold sterile 10% (v/v) glycerol. Cells were pelleted again through 
centrifugation, and this time the pellet was resuspended in 100 ml ice cold sterile 10% (v/v) 
glycerol. Cells were then finally collected through centrifugation and the pellet was resuspended 
in 300-500 µl of ice cold sterile GYT. The OD600 of a 1/100 dilution was then measured (OD600 of 
1.0 = 2.5x108 cells/ml) and the final concentration of cells was adjusted to 2-3 x 1010 cells/ml with 
the addition of further GYT if required. 40 µl aliquots were transferred to pre-chilled 1.5 ml 
microfuge tubes on ice. Cell aliquots were then snap frozen in a metal tube block which had been 
pre-chilled to -80 °C. Aliquots of competent cells were stored at -80 °C until needed.  
2.6.6.4 Transformation of electrocompetent cells  
Frozen cell aliquots were removed from -80 °C storage and thawed on ice. Plasmid DNA was then 
added to the cells, typically 50 ng in a volume of sterile ddH2O not exceeding 1/10th of the cell 
aliquot. Contents of the tube were then gently mixed and transferred to an ice cold sterile 2 mm 
gap electroporation cuvette. Cells were left on ice for 15 min. Cells were then electroporated at 
2.5 kV, 25 µF, 100 Ω, following which 10 volumes of SOC broth were immediately added to the 
cuvette, which was subsequently transferred to a sterile 15 ml tube. Cells were incubated at 37 
°C, 200 rpm for 1 h for recovery. Finally, cells were plated on LB agar plates containing the 
appropriate antibiotics. Undiluted cells (100 µl), as well as 1/10 and 1/100 dilutions, were plated 
initially to determine the optimal dilution for single colonies to be obtained on agar plates. The 
remainder of the transformation was mixed in a 1:1 ratio with sterile 80% (v/v) glycerol and stored 
at -80 °C until needed.    
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2.6.7 Isolation of plasmid DNA 
2.6.7.1 Miniprep 
Isolation of plasmid DNA was achieved using either the ZyppyTM Plasmid Miniprep Kit (Zymo 
Research; Irvine, CA, USA) or the High-Speed Plasmid Mini Kit (Geneaid Biotech Ltd; New Taipei 
City, Taiwan) according to the manufacturer’s instructions. 
2.6.7.2 Midiprep 
Where high concentrations of plasmid were required for library generation, midipreps were 
performed using the GeneaidTM Midi Plasmid Kit (Geneaid) according to the manufacturer’s 
instructions. 
2.6.8 DNA quantification 
Measurement of the concentration and purity of DNA was achieved using a Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific; Waltham, MA, USA), according to the 
manufacturer’s instructions.  
2.6.9 DNA sequencing 
All DNA sequencing performed in this study was carried out by Macrogen Inc. (Seoul, South Korea). 
2.7 Gene knock out in E. coli   
Gene knock out of entD in E. coli was based on the protocol developed by Datsenko and Wanner 
(2000). Primers were designed to contain a 30 bp sequence homologous to the start and end of 
the gene at the 5’ end and 20 bp homologous to the pKD4 plasmid at the 3’ end. These primers 
were used to amplify a ~1500 bp section of the pKD4 plasmid, resulting in the amplification of a 
kanamycin resistance gene flanked by FRT (FLP recognition target) sites, with regions of the entD 
gene flanking this. This PCR product was concentrated to ensure a final concentration of ≥ 100 
ng.µl-1. Meanwhile the E. coli strain to be altered, BL21, was transformed by the heat sensitive 
plasmid pKD46, and transformation plates were grown at 30 °C. BL21 containing pKD46 was then 
induced using L-arabinose before being made electrocompetent and transformed by the pKD4 
derived PCR product where, through homologous recombination between the regions of gene 
homology on the outside of the kanamycin cassette, the gene entD was knocked out and replaced 
by the kanamycin cassette. The pKD46 plasmid was then cured through growth at 42 °C. To 
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remove the kanamycin resistance cassette, the heat sensitive plasmid pCP20 was transformed 
into this strain. This plasmid contains the FLP recombinase gene which recognises the FRT sites to 
remove the kanamycin resistant cassette, leaving a 200 bp “scar” in the place of the entD gene. 
Finally the pCP20 plasmid was cured via growth at 42 °C.   
2.8 Protein expression and purification 
All proteins to be expressed were cloned into His-tag vectors for purification via nickel affinity 
chromatography. 
2.8.1 Expression in LB at low temperatures 
A single colony or glycerol stock of the expression strain was used to inoculate 10 ml LB 
supplemented with appropriate antibiotics and grown overnight at 37 °C, 200 rpm. The following 
day this overnight culture was used to inoculate 400 ml of LB containing any appropriate 
antibiotics, giving a final OD600 of 0.05-0.1. This was incubated at 37 °C, 200 rpm until an OD600 of 
0.4-0.6 was reached. Cultures were then transferred to 18 °C for 30-60 min before addition of 0.5 
mM IPTG. Cultures were then grown for an additional 24 h before cells were harvested through 
centrifugation at 2700 g, 20 min, 4 °C. The supernatant was discarded and cell pellets were stored 
at -20 °C until required. 
2.8.2 Expression in LB containing additional supplements at low 
temperatures 
A single colony or glycerol stock of expression strain was used to inoculate 10 ml of LB 
supplemented with appropriate antibiotics as well as 2.5 mM betaine and 1 M D-sorbitol  and 
grown overnight at 37 °C, 200 rpm. The following day 400 ml of the same medium was inoculated 
by the overnight culture to give a final OD600 of 0.05-0.1. This was incubated at 37 °C, 200 rpm 
until an OD600 of 0.4-0.6 was reached. Cultures were then transferred to 18 °C for 30-60 min before 
addition of 0.5 mM IPTG. Cultures were then grown for an additional 24-28 h before cells were 
harvested through centrifugation at 2700 g, 20 min, 4 °C. The supernatant was discarded and cell 
pellets were stored at -20 °C until needed. 
2.8.3 Expression using auto-induction media 
A single colony or glycerol stock was used to inoculate 10 ml of LB supplemented with the 
appropriate antibiotics and grown overnight at 37 °C, 200 rpm. The following day 400 ml ZYP5052 
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medium containing appropriate antibiotics was inoculated by the overnight culture to give a final 
OD600 of 0.05-0.10. This was incubated at 18 °C, 200 rpm for 24-48 h before being harvested by 
centrifugation as in 2.8.1. 
2.8.4 Cell lysis and soluble fraction separation 
For protein purification, cell pellets were resuspended in 1/20 vol of the expression culture of 1x 
His•bindTM binding buffer, minus imidazole. For BpsA purification this binding buffer contained 
12.5% (v/v) glycerol, and for PPTase purification this binding buffer contained 25% (v/v) glycerol. 
Cells were lysed by 2-3 passages through a French press chamber, at 40,000 psi. The French press 
chamber was cooled to 4 °C prior to use and buffer was kept ice cold. Following lysis the soluble 
and insoluble fractions were separated by centrifugation at 26890 g, 30 min, 4 °C.  
2.8.5 Protein purification via Ni-NTA affinity chromatography 
2.8.5.1 Purification of BpsA 
Purification of His6-tagged proteins was achieved using Novagens His•bindTM Ni-NTA 
chromatography kit. The following changes to the manufacturer’s instructions were made for the 
purification of BpsA (due to the weak binding of BpsA to the resin). All elution buffers contained 
12.5% (v/v) glycerol and all reagents and equipment were kept at ice cold temperatures for the 
duration of the purification. A large volume, approximately 6-7 ml, of resin was used. The first pass 
through of the soluble fraction through the resin was collected, and passed through the column a 
second time. Columns were washed using 15 ml of binding buffer containing no imidazole and 
then 50 ml of standard binding buffer. The wash buffer step that is usually employed at this stage 
of purification was omitted for BpsA. For the elution the resin was resuspended in 8 ml elution 
buffer, and protein was eluted in an 8-10 ml total volume. Buffer exchange and concentration of 
the eluted protein was performed in 100 kDa molecular mass cut-off Millipore Amicon® ultra-15 
centrifugal filter units (Merck Millipore, Billerica, MA, USA), into 50 mM sodium phosphate buffer, 
pH 7.8, 12.5% (v/v) glycerol. Final buffer composition was then adjusted to 40% (v/v) glycerol and 
aliquots were stored at -20 °C. 
2.8.5.2 Purification of PPTases 
Amendments were also made to the standard protocol for PPTase purification, due to the 
instability and low yield typically observed with these proteins. All elution buffers contained 25% 
(v/v) glycerol and all reagents and equipment were kept at 4 °C for the duration of the experiment.  
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As with BpsA, the soluble fraction for PPTase purification was also passed through the resin 
column twice. Columns were washed using 10-15 ml binding buffer (no imidazole), 10-15 ml 
standard binding buffer, 10-15 ml wash buffer (half standard imidazole concentration), and 5 ml 
standard wash buffer. Following elution, protein was immediately desalted using GE Healthcare 
HiTrap™ desalting columns, according to the manufacturer’s protocol. Desalting buffer for 
PPTases was 50 mM Tris-Cl pH 7.5, 12.5% (v/v) glycerol. Glycerol was added to desalted 
protein to bring final concentration to 50% (v/v) glycerol and aliquots were stored at -80 °C.  
2.8.5.3 Purification of carrier proteins 
CPs were purified following the same protocol as for PPTases. 
2.8.6 Determination of protein concentration 
The final concentration of the purified PPTase proteins was determined using a DC™ protein assay 
kit (Bio-Rad, Hercules, CA, USA), following the manufacturer’s instructions. Protein standards were 
made with bovine serum albumin (BSA) in the appropriate buffer and glycerol concentrations, 
ranging from 0.25-1.5 mg.ml-1. The concentration of BpsA was first determined using absorbance 
at 280 nm using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific), according to 
the manufacturer’s instructions.  
2.9 SDS PAGE 
For qualitative assessment of proteins, 15-17% SDS PAGE gels were run to visualise proteins. These 
were cast and run on a 1 mM thickness Bio-Rad Protean II™ apparatus. For each gel 5 ml of 
separating gel was loaded into the apparatus before being overlaid with sterile ddH2O and left to 
set for 45 min. The ddH2O was then removed and 1.5 ml of stacking gel was poured on top. A 
multi-well comb was inserted and this was left to set for at least 45 min. If not used immediately 
gels were stored for up to three days at 4 °C, wrapped in wet paper towel and tin foil. Samples 
were added to 3x loading buffer in a 2:1 ratio, and incubated at 95 °C for 10 min. Gels were run in 
1x SDS run buffer, at a constant voltage (180 V) for 60 - 75 min, until the dye front reached the 
end of the gel. Gels were then stained in Coomassie blue stain and gentle shaking was applied for 
30-60 min. Gels were then rinsed using tap water and left in destain solution with gentle rocking 
until the desired level of destain was reached. All recipes for SDS protocol can be found in Table 
2.9. 
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Table 2.9 Recipes for SDS PAGE materials 
Component  Final concentration 
15% separating gel Per 10 ml 
40% acrylamide solution (w/v) 3.65 ml 
2% Bis-acrylamide solution (w/v) 2.0 ml 
1.5 M Tris-Cl pH 8.8  2.5 ml 
10% SDS (w/v) 100 µl 
10% APS* (w/v) 100 µl  
TEMED* 6 µl  
ddH2O   1.75 ml 
  
17% Separating gel Per 10 ml 
40% acrylamide solution (w/v) 4.14 ml 
2% Bis-acrylamide solution (w/v)  2.28 ml 
1.5 M Tris-Cl pH 8.8  2.28 ml 
10% SDS (w/v) 100 µl  
10% APS* (w/v) 76 µl  
TEMED* 7.5 µl  
ddH2O  1.12 ml 
  
5% stacking gel Per 6 ml 
40% acrylamide solution (w/v)  310 µl 
2% Bis-acrylamide solution (w/v) 580 µl  
0.5 M Tris-Cl pH 6.8 1.5 ml 
10% SDS (w/v) 60 µl 
10% APS* (w/v) 46 µl 
TEMED* 7.5 µl 
ddH2O   3.5 ml 
  
3x SDS loading buffer Final concentrations 
Tris-Cl pH 6.8 150 mM 
SDS 6% (w/v) 
Bromophenol blue 0.3% (w/v) 
Glycerol 30% (w/v) 
β-mercaptoethanol 300 mM 
  
1x run buffer Per 1 L 
Glycine  14.4 g 
Tris 3.03 g 
SDS 1 g 
  
Coomassie blue stain Per 1 L 
Coomassie brilliant blue 2.5 g 
100% ethanol 450 ml 
100% acetic acid 100 ml 
ddH2O   450 ml 
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Destain solution Per 1 L 
100% methanol 400 ml 
Acetic acid 100 ml 
ddH2O   500 ml  
*Added immediately prior to pouring gel 
APS is Ammonium persulfate 
2.10 In vivo assessment of indigoidine production 
2.10.1 Indigoidine production as assessed on solid media 
Strains to be tested were plated out on either LB or auto-induction agar plates containing 
appropriate antibiotics and 100 mM L-glutamine, at a density of approximately 100 colonies per 
plate, and incubated overnight at 37 °C. For LB plates, following overnight growth, LB agar slabs 
were lifted out from the Petri dish and placed on a sterile lid. For each plate, 100 µl of 2.5% IPTG 
(w/v) was spread evenly across the base of the empty Petri dish and the agar slab was replaced 
on top. For auto-induction agar plates no further action was required. Plates were then incubated 
at room temperature for up to four days to observe development of pigmentation.  
2.10.2 Indigoidine production as assessed in liquid media 
Glycerol stocks of appropriate strains were used to inoculate 350 µl of LB containing appropriate 
antibiotics and then incubated overnight at 37 °C, 200 rpm. 20 µl of each culture were used to 
inoculate quadruplicate wells within a 96-well microplate, each containing 130 µl LB amended 
with 100 mM L-glutamine, 0.6 mM IPTG, and appropriate antibiotics. Plates were wrapped in foil 
and incubated at 18 °C, 200 rpm for 24-48 h. At appropriate time points, OD590 and OD800 values 
were recorded using an EnSpire 2300 Multilabel Reader (Perkin Elmer; Waltham, MA, USA). After 
a reading was taken the plate was again incubated at 18 °C, 200 rpm.  
2.10.2.1 Normalisation of indigoidine absorbance 
A normalised value for indigoidine absorbance was calculated using the method described by 
(Beer et al., 2014), as adapted from (Myers et al., 2013). The OD values recorded represent the 
indigoidine sensitive wavelength (ODS) of 590 nm; as well as the robust wavelength (ODR) of 800 
nm, which accounts for the cellular components present. ODSB,+I is the OD at 590 nm which 
contains absorption from both bacterial cells and the indigoidine pigment, while ODSB,-I accounts 
for the scattering of just the cellular components at ODS (i.e. at 590 nm). ODSB,-I is calculated as: 
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ODSB,-I = δ.ODR 
where δ is the correction factor and is calculated by measuring the ratio of pure cell culture at 
both ODS (590 nm) and ODR (800 nm). The normalised calculation for indigoidine is then 
calculated as: 
relative indigoidine = ODSB,+I – δ.ODR 
Background correction was achieved by first subtracting the mean of “culture medium alone” 
replicates from every value.  
2.11 In vitro purified protein assays 
2.11.1 Activation of BpsA by 4’-phosphopantetheine attachment 
For pre-activation of BpsA, reactions were set up containing the following: 3.4 µM BpsA, 0.25 µM 
Sfp, 10 mM MgCl2, 100 µM CoA and 50 mM sodium phosphate buffer pH 7.8. Reactions were 
incubated for 20-30 min at 30 °C. 
2.11.2 Determination of kinetic parameters for BpsA 
For determination of the kinetic parameters of BpsA with L-glutamine as the substrate, a triplicate 
2-fold serial dilution of L-glutamine from 8 to 0.004 mM, in a final volume of 50 µl, was established 
in a 96-well microplate. 100 µl of reaction mix (5 mM ATP, 15 mM MgCl2, and 75 mM Tris-Cl pH 
7.8) was then added to each well. Reactions were initiated via the addition of 50 µl pre-activated 
BpsA mix to each well. The microplate was mixed at 1000 rpm for 10 s then OD590 values were 
recorded every 8-10 s for 15-30 min using an EnSpire 2300 Multilabel Reader. Data was analysed 
in Microsoft Excel, with the slope function employed to determine the reaction velocity. The 
maximum velocity for each reaction, as determined by the steepest gradient, was analysed using 
GraphPad Prism® to derive the kinetic parameters as described by Owen et al. (Owen et al., 2011). 
2.11.3 Preliminary assessment of PPTase activity 
For initial assessment of PPTase activity levels, reactions were set up in triplicate two-fold serial 
dilutions of the PPTase to be tested, across 6 columns of a 96-well microplate. The initial wells in 
the series contained 50 µl of undiluted enzyme. Reaction mix (100 µl total, 100 mM Tris-Cl, pH 8.0, 
8 mM L-glutamine, 5 mM ATP, 20 mM MgCl2, 50 µM CoA) was then added to each well. Reactions 
were initiated via the addition of 50 µl of 3.2 µM BpsA to each well, after which plates were mixed 
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at 1000 rpm for 10 s. Reaction progress was measured via the recording of OD590 values every 15-
30 s for 30-90 min (depending on the activity of the PPTase).  
2.11.4 Determination of kinetic parameters for PPTases via BpsA 
Reactions were set up in a triplicate two-fold serial dilution from 100-0.049 µM CoA in 50 µl 
volumes in a 96-well microplate. 100 µl of reaction mix (100 mM Tris-Cl pH 8.0, 8 mM L-glutamine, 
5 mM ATP, 20 mM MgCl2, and 0.1-1 µM PPTase (depending on activity level of PPTase)) was added 
to each well. To start the reaction, 50 µl of 3.2 µM BpsA was added to each well. The plate was 
mixed at 1000 rpm for 10 s and OD590 values were recorded every 15-30 s for 30-90 min using an 
EnSpire 2300 Multilabel Reader. Data was analysed in Microsoft Excel using the slope function to 
derive velocity values. The slope function was then applied to these velocity values, and the 
maximum value for each reaction taken as the maximum PPTase velocity. For lower activity 
enzymes, the slope function measured a larger number of data points. The maximum velocity for 
each reaction was analysed using GraphPad Prism® to derive kinetic parameters as described by 
Owen et al. (2011). 
2.11.5 CP competition assay 
A triplicate 2-fold serial dilution of carrier protein in a final volume of 50 µl was set up in a 96-well 
microplate. 50 µl of reaction mix (3 µM apo-BpsA, 0.75 µM CoA, 40 mM MgCl2 and 400 mM Tris-
Cl pH 8.0) was added to each well. Reactions were initiated via the addition of 50 µl of a PPTase 
solution (at a final concentration of 0.1-0.25 µM PPTase) to each well. Plates were mixed at 1000 
rpm for 10 s and incubated for 15-30 min at 30 °C, allowing the PPTase reactions to proceed until 
completion. Following this, indigoidine synthesis was initiated via addition of 50 µl of a reaction 
mix containing 4 mM L-glutamine and 4 mM ATP. Plates were mixed at 1000 rpm for 10 s and 
OD590 values were recorded every 15 s for 50 min using an EnSpire 2300 Multilabel Reader. 
Velocity values were derived using the Microsoft Excel slope function and these were converted 
into percentage of maximum velocity for a triplicate reaction. For generation of IC50 curves, data 
from each experiment was analysed in GraphPad Prism® using four-parameter dose-response 
curves.  
2.12 Screening of metagenome libraries 
Two small insert environmental DNA (eDNA) libraries, each described in section 4.1.4., were 
screened during the course of this study. Each was transformed into electrocompetent EcoBlue1, 
EcoBlueP and EcoBlueE cells, with 50 ng of DNA used for each transformation. Following recovery 
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cells were mixed 1:1 with sterile 80% (v/v) glycerol, and 0.5 ml aliquots were dispensed and stored 
at   -80 °C. When required for use a single aliquot was thawed on ice and serial dilutions plated on 
auto-induction agar plates containing 100 mM L-glutamine and appropriate antibiotics, in order 
to determine the optimal dilutions that would result in approximately 5,000 to 10,000 insert 
containing clones per plate. Libraries were stored as frozen transformation aliquots and found to 
remain viable in this state for at least 3 months. 
For screening, cells were thawed on ice and plated using an optimal (empirically determined, as 
above) dilution on auto-induction agar plates containing 100 mM L-glutamine and appropriate 
antibiotics. After 16 h of incubation at 37 °C plates were then maintained at room temperature 
and monitored for pigment development. Hits were taken as colonies that developed a visible 
blue pigmentation. Where single colonies were unable to be recovered directly clones were picked 
as accurately as possible, resuspended in 100 µl GYT, and then streaked on to a new auto-
induction agar plate. Isolated hits were picked from plates and grown in 3 ml LB cultures 
containing 0.2% glucose (w/v) and appropriate antibiotics. Glycerol stocks were made from 500 µl 
of overnight culture and plasmid DNA was isolated from the remainder of the culture via plasmid 
miniprep. The resulting DNA was transformed into chemically competent DH5α cells in order to 
separate the insert-containing pRSETB or pETDuet1 plasmids from the pCDFDuet1 plasmid bearing 
the co-expressed bpsA reporter, with cells being plated on to LB agar plates containing ampicillin 
only. 
2.12.1 Analysis of eDNA hits 
Sequencing was performed by Macrogen Inc. DNA samples and primers for sequencing were 
prepared according to the company’s specifications of concentration and purity. Inserts were 
sequenced using the T7 promoter and T7 terminator primers for the pRSETB inserts or the 
DuetUP2 and T7 terminator primers for the pETDuet1 inserts, which anneal to plasmid sequences 
immediately upstream and downstream of the insert respectively. Internal primers for sequence 
extension by primer walking were then designed as required. Individual sequences were 
assembled into contiguous sequences using the CAP3 program (Huang and Madan, 1999). 
Sequences were then entered into the GENtle software (http://gentle.magnusmanske.de/) and 
ORFs within each eDNA insert were identified. These were then annotated by BLASTX searching 
and alignment (http://blast.ncbi.nlm.nih.gov/). The sequences of the eDNA inserts recovered in 
this study were submitted to GenBank under the continuous accession numbers JN886564 
through to JN886585. 
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2.13 Directed evolution of EntD 
2.13.1 Vector preparation 
The pBAD vector was isolated as in section 2.6.7.2. For digestion, 16 µg plasmid DNA was heated 
to 70 °C for 20 min, to relieve supercoiling, and was digested using 50 U of each restriction enzyme 
(XhoI and HindIII) in a final volume of 400 µl, following the manufacturer’s instructions for buffer 
composition and temperature. After 6 h incubation a further 20 U of each enzyme was added and 
reactions were incubated for an additional 16 h. Digests were then heat inactivated at 80 °C for 
20 min and purified using a 20 µg capacity Zymo-SpinTM clean up column. Digested vector was 
eluted in 30 µl sterile ddH2O and the concentration of the digested vector was determined. A 200 
ng sample was run on an agarose gel to ensure no degradation had occurred. The rest of the 
digestion was then aliquoted in 5 µl portions and stored at -20 °C until required.    
2.13.2 Assessment of vector quality 
It was important to assess vector quality before use in directed evolution library generation 
experiments. The entD gene was amplified using Phusion high fidelity polymerase and prepared 
for ligation as described in section 2.13.4. A ligation using a total of 500 ng DNA was set up as in 
section 2.13.5, using the Phusion amplified entD gene in place of the error prone PCR (epPCR) 
amplified entD. This ligation was then used to transform chemically competent BL21 ΔentD cells 
harbouring a pCDFDuet:bpsA plasmid. The transformation was plated onto LB agar plates 
containing 100 mM L-glutamine, 0.01% (w/v) L-arabinose, ampicillin and spectinomycin. Plates 
were incubated at 37 °C overnight and bpsA was induced as described in section 2.10.1. Plates 
were incubated at room temperature. Transformation and ligation efficiency were determined by 
comparing numbers of blue colonies vs. white colonies after 12-16 h. Blue colonies indicated a 
successful ligation, while white indicated a self-ligation or uncut vector. A successful ligation rate 
of 70% or higher was deemed sufficient for use in further experiments. 
2.13.3 Error prone PCR 
epPCR was carried out on entD using the GeneMorph® Mutazyme® II kit, according to the 
manufacturer’s instructions. Template was prepared by amplification of entD using Phusion 
polymerase. A high error rate was chosen, which was achieved through using 100 ng purified PCR 
product as template in a 50 µl reaction using 30 amplification cycles. Prior to thermocyling, 
reactions were divided into equal amounts (12.5 µl) across 4 tubes to reduce likelihood of clonal 
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mutations in the final library. The size and quality of the amplicons was determined by running a 
3 µl aliquot of total pooled reactions on an agarose gel.  
2.13.4 Insert preparation 
The 50 µl epPCR reactions were purified using 5 µg capacity Zymo-SpinTM columns, and eluted in 
20 µl sterile ddH2O. The concentration of each was determined by Nanodrop analysis of a 1 µl 
aliquot. The rest of the eluent was then digested using 30 U of each restriction enzyme, for 5 h, in 
a final volume of 50 µl. Buffer composition and temperature were as recommended by the 
manufacturer. The digest was then heat inactivated by incubation at 80 °C for 30 min. 
2.13.5 Ligation and transformation 
The total amount of DNA per ligation was 1- 1.5 µg, with a molar ratio of vector to insert of 1:6. 
Ligations were incubated at 22 °C for 1 h and then subsequently at 16 °C overnight. Following this, 
an additional 2 U of ligase was added and the reaction was incubated for a further 7 h. Ligations 
were purified using a 5 µg capacity Zymo-SpinTM column and eluted in 20 µl of ddH2O. Ligations 
were used to transform electrocompetent EcoBlue1 cells. Electrocompetent cells were prepared 
and transformed as in sections 2.6.6.3 and 2.6.6.4.   
2.13.6 First tier screening 
For screening, cells were thawed on ice and plated on iron limited pigment production plates as 
described in section 2.5.1.5.1, and incubated at 37 °C for 72 h. After this time, expression of bpsA 
was induced with the addition of IPTG as described for LB agar plates in section 2.10.1. Plates were 
incubated at 25 °C and monitored for colour development. After 24 h hits were selected, on the 
basis that the colonies appeared to be of comparably larger size and normal morphological shape 
as well as having less pigmentation than surrounding colonies. These were streaked on LB agar 
plates containing 100 mM L-glutamine, 0.01% (w/v) L-arabinose and appropriate antibiotics, 
incubated at 37 °C overnight and induced by addition of IPTG as described in section 2.10.1. Plates 
were incubated at room temperature, and potential hits were taken as those that appeared to 
have a loss of pigment production.   
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2.13.6.1 Conformation of ability to grow on iron restricted 
plates 
Due to confounding satellite colonies, clones picked as potential hits in section 2.13.6 were 
confirmed to have retained the ability to activate EntF (the native CP from E. coli that entD was 
evolved to retain the ability to activate) by being re-plated individually on iron limited plates at a 
density of approximately 100 colonies per plate. Plates were incubated at 37 °C for 72 owenh. 
Clones that were able to grow were selected as positive hits from the first stage of screening. 
2.13.6.2 Screening potential hits in EcoBlueE 
As an alternative method of confirming the retention of activity of potential hits with EntF, hits 
were tested for their ability to activate the EntF-CP substituted BpsA. The plasmids containing 
potential hits as identified in section 2.13.6 isolated via miniprep and then used to transform 
chemically competent EcoBlueE cells. These were plated on LB agar plates containing 100 mM L-
glutamine, 0.01% (w/v) L-arabinose and appropriate antibiotics, and incubated overnight at 37 °C. 
Plates were induced with IPTG as in section 2.10.1, and incubated at room temperature to monitor 
pigment production. Those that produced pigment within the first 24 h were selected as hits.    
2.13.7 Analysis of hits 
Each hit found in sections 2.13.6.1 and 2.13.6.2 was picked and grown in 3 ml LB cultures 
containing 0.2% (w/v) glucose, ampicillin and spectinomycin. Glycerol stocks were made using 500 
µl of the overnight culture and plasmid DNA was isolated from remaining cultures. The resulting 
DNA was transformed into chemically competent DH5α cells and in order to separate the variant 
entD-containing pBAD from the pCDFDuet1 plasmid containing the co-expressed bpsA reporter, 
with transformations plated onto LB agar plates containing ampicillin only. The resultant single 
plasmid containing cells were then grown overnight in 3 ml LB containing ampicillin, and plasmids 
were isolated. These were then used to transform both EcoBlue1 and EcoBlueE chemically 
competent cells. The ability of each of these to produce indigoidine was tested as in section 2.10.1, 
using LB agar plates containing 100 mM L-glutamine, 0.01% (w/v) L-arabinose and appropriate 
antibiotics. Evolved variants of entD that exhibited indigoidine production in EcoBlueE and less or 
none in EcoBlue1 were sent for sequence analysis. 
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2.13.7.1 Quantification of indigoidine production for evolved 
variants 
Variants of entD in each EcoBlue1 and EcoBlueE were assessed for ability to produce indigoidine 
as in section 2.10.2, with the amendment that the medium also contained 0.2% (w/v) L-arabinose. 
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Chapter 3: Using BpsA to probe Carrier Protein 
domain interactions  
3.1 Introduction 
Understanding the interactions between domains and modules within NRPS enzymes is a key 
requirement to understanding how these enzymes function. It is also an important first step in 
being able to swap modules or domains between different NRPS enzymes, with the ultimate goal 
of creating entirely new bioactive products. The work in this chapter builds on previous work that 
was performed in our lab by (then PhD student) Dr Jeremy Owen, and focuses on the interactions 
between CP domains and their downstream partner domains. CP domains are typically located 
upstream from either condensation (C) domains (in elongation modules) or thioesterase (TE) 
domains (in terminal modules). In this previous work, seven different CP domains were 
substituted into BpsA, then subsequently random mutagenesis was employed to improve the 
activity of certain swapped CP domains (Owen, 2010). One observation was that CP domains 
which are located upstream of a TE domain in their native context were more likely to result in a 
functional enzyme when swapped into BpsA. The native BpsA CP domain is itself located upstream 
of a TE domain, suggesting these CP domains may have evolved certain features that enable them 
to interact with TE domains preferentially as opposed to C domains or other downstream 
domains. Directed evolution to improve BpsA CP substitution constructs provided insight into 
which residues were particularly important, establishing a model of CP domain interaction. The 
work described in this chapter focuses on two of the key positions that were found to be 
important. These positions are the +4 and +24 residues, relative to the invariant serine residue 
found in every CP domain. This work, as well as aiding in our general understanding of NRPS 
interactions, led to the creation of evolved BpsA variants which themselves have various 
applications, including expanding the utility of a metagenomic screening system, the focus of 
chapter 4.  
3.1.1 CP interactions within NRPS enzymes 
Directly swapping one NRPS domain or module for another generally leads to enzymes with 
drastically reduced activity, if any activity at all (Calcott and Ackerley, 2014). The desire to reliably 
manipulate multi-modular biosynthetic enzymes such as NRPSs means much work has been done 
on understanding the interactions between different domains and modules, in order to improve 
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efficiency and activity of potential module or domain substitutions. The ultimate goal of these 
efforts is to selectively modify the existing peptide products made by these enzymes, or to create 
entirely new products. CP domains are important to the overall activity of the enzyme as they 
have to interact with a large number of other enzymes and domains. This includes upstream A 
domains and downstream C, E or TE domains as well as the PPTase enzymes that activate them. 
CP domains are required to be highly flexible, with the attached phosphopantetheinyl arm 
transporting the growing peptide product from one active site to the next (Mercer and Burkart, 
2007). The inherent flexibility of CPs has made structural studies difficult, with limited crystal and 
NMR structures solved (Lohman et al., 2014). One structural study of the type I PCP TycC3 (Koglin 
et al., 2006) suggested that the CP domain had three conformational states. Two states were 
exclusive to either the apo form (A state) or holo form (H state) of the CP domain. The third state 
(A/H) appeared to be shared by both the apo and holo forms. Further work however has shown 
that the A and H states are likely to have been artefacts (perhaps as a result of excising the domain 
from its native context) and the A/H state may be the only conformational state for a CP domain 
regardless of whether it is in the apo or holo form (Haslinger et al., 2015; Lohman et al., 2014; 
Tufar et al., 2014). It has recently been suggested that the flexibility of the CP domains comes from 
subtle rearrangements rather than larger conformational changes (Haslinger et al., 2015).  
Mutagenesis studies are an important alternative tool to elucidate key residues involved in 
domain interactions. Several studies have used alanine scanning mutagenesis to look at the 
interaction between the CP and neighbouring domains. This technique examines which residues 
can tolerate a sequence change to an alanine, while still allowing the original protein to retain 
activity. When a residue is resistant to change this implies that that particular position is important 
to the protein’s function. One study (Lai et al., 2006) used scanning alanine mutagenesis to 
examine the EntB CP domain within the enterobactin complex. The downstream interaction 
partner is the C domain of the EntF module (an in trans protein interaction). Helix II and helix III of 
the CP were mutated, as they had previously been shown to be generally important in these 
interdomain interactions (Lai et al., 2006). A selection was applied and surviving clones were 
sequenced. For each position, a ratio comparing how many times the WT residue was found as 
opposed to an Ala residue was determined. A higher ratio indicated Ala was not tolerated well at 
this position and the WT residue was said to be conserved. The most conserved WT residues were 
those at the +19 and +23 positions (in relation to the invariant serine residue), with the +4 and 
+24 positions being the next most conserved. These residues were considered to be important in 
protein function and interaction with the downstream EntF C domain. This same group next used 
scanning alanine mutagenesis to examine the EntF CP domain (Zhou et al., 2006), and found 
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substitutions to Ala at residues +21 and +24 to be the most detrimental to protein function, 
concluding that these residues were important in an interaction surface between the CP domain 
and the downstream TE domain. These two studies looked at downstream interaction of the CP 
domain with different domains (a C domain and a TE domain) and found residues in similar 
locations (all on helix III of the CP domain, with the +24 residue found in both cases), which may 
indicate that this region is particularly important for downstream interactions.  
3.1.2 BpsA as a probe for investigating CP interactions 
Previous work in our lab used BpsA as a tool for probing the interaction between the CP and other 
domains within the NRPS enzyme, in particular the TE domain (Owen, 2010). BpsA is an ideal NRPS 
for these experiments, given its relatively small size (for an NRPS) and its readily detectable 
product. The small size of BpsA means it can be relatively easily genetically manipulated, and 
addition of only one substrate (L-glutamine) is required to form the blue pigment indigoidine. Also, 
BpsA contains no C domain, which simplifies its use as a model NRPS as there are no confounding 
interactions with an upstream C domain. CP domains from seven foreign NRPS enzymes were 
substituted into BpsA, most of which initially had very low activity (if any), not unusual for NRPS 
domain substitution experiments (Calcott and Ackerley, 2014). A selection of these CP-substituted 
variants were improved via random mutagenesis, with superior variants recognised on the basis 
of improved indigoidine production. Although only a small sample size of seven CP domains was 
examined, the three CP domains that were directly upstream from TE domains in their native 
setting all retained some initial activity when substituted, while those four CP domains that were 
upstream from a C domain in their native setting did not. This led to the conclusion that CP 
domains that were upstream of TE domains in their native enzyme may have naturally evolved to 
preferentially interact with the TE domain over other possible downstream domains, and hence 
were better able to function when substituted immediately upstream of the TE domain in BpsA.  
Consistent with this, the CP domain from the first module of the PvdD NRPS from P. aeruginosa 
(PvdDCP1), which is located immediately upstream from a C domain in its native context, gave no 
activity when substituted into BpsA. The CP domain from the second module (PvdDCP2) on the 
other hand (upstream from a TE domain in its native context) did show activity (Figure 3.1). These 
two PvdD CP domains are of interest as the two PvdD modules have clearly risen from a gene 
duplication event, sharing a high sequence identity and both encoding for the same amino acid 
residue in the final NRPS product (Ackerley et al., 2003). While the A domains of PvdD share 99% 
amino acid identity and the C domains 80%, the CP domains of these two modules are more 
diverse at 72% identity. The divergence in sequence identity in the CP domains is almost entirely 
50 
 
downstream of the invariant serine, with 97% identity conserved upstream of this site and only 
20% identity downstream of this site. This likely reflects that these domains each have to interact 
with different downstream partners (the C domain for PvdDCP1 and the TE domain for PvdDCP2), 
and so any differences in sequence may reflect key residues involved in these interactions. In order 
to pinpoint residues which may be involved in the specialised downstream interaction, the BpsA 
PvdDCP1 substitution was the subject of a directed evolution effort to improve function via 
random mutagenesis. The sequence of the improved mutants highlighted residues that seemed 
to be important in restoring the interaction between the CP and TE domain.  The variant with the 
highest activity following the first round of evolution was “3kf0”, which had residue substitutions 
to Ile at both the +4 and +24 positions (in WT PvdDCP1 the wild type residues are Thr and Phe 
respectively). Based on modelling, it was hypothesised that these two positions were involved in 
the interaction with the hydrophobic TE interface (Owen, 2010). 
 
Figure 3.1 PvdD CP substitutions into BpsA. A) Module structure of BpsA. B) Module structure of PvdD. C) 
PvdDCP1 substitution results in a functional BpsA enzyme and indigoidine production. D) PvdDCP2 
substitution results in a non-functional BpsA enzyme with no indigoidine production. 
 
One conclusion from this previous work was that a hydrophobic amino acid at the +4 position was 
important for the interaction between the CP and TE domains, although due to lack of a solved 
structure for BpsA it was unclear exactly why. The +4 position was commonly mutated to a codon 
encoding a hydrophobic residue in evolved variants of the PvdDCP1 substitution, with the 
equivalent change frequently observed in a different CP domain substitution construct that was 
also evolved, DhbF. The third CP (EntF CP domain) substitution that was evolved already had a 
hydrophobic residue (Met) at the +4 position, and this residue was not altered in any of the 
evolved variants that were recovered (Owen, 2010).  
51 
 
The importance of a hydrophobic residue at the +4 position was also supported by CP domain 
alignments (Owen, 2010). Fifty four CP domains (with the corresponding downstream domains of 
each split between C, E or TE domains) from the NRPS of various Pseudomonas species were 
aligned. In the case of the 20 CP domains located upstream from TE domains, a hydrophobic 
residue was always present at the +4 position. For the 17 CP domains upstream from C domains, 
residues at this position were variable. For example PvdDCP1, upstream of a C domain in its native 
setting, contains a polar Thr at this position; whereas PvdDCP2, upstream of a TE domain, contains 
a hydrophobic Leu. It was hypothesised that one reason the initial PvdDCP1 substitution had failed 
to show any activity was because of the presence of the non-hydrophobic Thr (Owen, 2010). 
However, subsequent alignments (a total 103 CP domains sourced from 10 non-Pseudomonas 
bacterial species, including 15 CP domains upstream from TE domains) performed by Dr Mark 
Calcott identified four (out of 15) CP domains that were upstream from TE domains and yet had a 
Thr at the +4 position (Calcott, 2014).  The remaining 11 CP domains did all have hydrophobic 
residues at this position. This chapter addresses the question of whether these four CP domains 
might still be able to function within BpsA, to see if the +4 Thr would be prohibitive to effective 
function post-substitution, or whether they are still optimised for interaction with a downstream 
TE domain via some alternative evolutionary solution. 
From Dr Owen’s work it seemed clear that both the +4 and +24 positions were important, with 
hydrophobic residues being particularly key, however random mutagenesis via error prone PCR is 
limited in terms of the range of mutations it can reasonably access. Random changes can be 
introduced at any point in a gene but in practice it is unlikely that two or more changes will occur 
within the same codon, resulting in a limited number of amino acids are possible at each position 
(Hermes et al., 1990). In the case of PvdDCP1, this meant that the +4 position was effectively 
limited to just five possible amino acid changes (Ile, Asn, Pro, Ser and Ala) and the +24 position 
was limited to six possible changes (Leu, Ser, Tyr, Cys, Ile and Val). With these residues identified 
as being important, we wanted to take a closer look at which amino acid changes could be 
tolerated at this position and their relative effects on activity. The second aim of this chapter was 
to perform random codon mutagenesis of the +4 and +24 positions in PvdDCP1, both alone and 
in combination, to identify substitutions at these positions that substantially improved activity of 
the PvdDCP1 BpsA swap. 
3.1.3 Aims 
 Substitute into BpsA the four CP domains, found upstream of TE domains in their native 
context, which have a Thr at the +4 position and test for activity. 
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 Identify all amino acid residues at the +4 and +24 positions of PvdDCP1 that are able to 
promote effective function when substituted into BpsA. 
 Quantify the contributions of each of the tolerated +4 and/or +24 mutations, identifying 
any additive or synergistic effects between the two. 
 Kinetically characterise the top BpsA-PvdDCP1 substitution variants. 
3.2 Results 
3.2.1 Activity of CP domain BpsA substitutions having Thr at the 
+4 position 
The four CP domains identified in alignments by Dr Mark Calcott (Table 3.1), which were all 
immediately upstream of a TE domain in their native enzymes and yet contained a non-
hydrophobic Thr at their +4 positions, were investigated here. These four CP domains were 
selected to be substituted into BpsA to see which conclusion (stated in section 3.2.1) would hold 
true - whether these CPs located upstream of TE domains in their native context would function 
when substituted into BpsA, or whether CP domains with a Thr at the +4 position are not able to 
function when substituted into BpsA. Each of the four was cloned into bpsA using silent restriction 
sites. The ability of each to function was first assessed qualitatively using an agar plate based 
screen, followed up by a quantitative liquid assay for those that were shown to have activity. 
Table 3.1 Origin of carrier proteins immediately upstream of TE domains that also have a Thr at +4 position 
Gene name Species Accession number 
ACMSIII Streptomyces anulatus ADG27359.1 
GrsB Brevibacillus brevis CAA43838.1 
TycC Brevibacillus brevis AAC45930.1 
Pris3 Streptomyces pristinaespiralis O07944 
 
3.2.1.1 Solid media activity test 
Plasmids bearing bpsA variants containing each of the four CP domains were used to transform a 
sfp containing BL21 strain and the resulting transformants were plated out on L-glutamine 
containing agar plates. Due to the toxicity of indigoidine, expression of bpsA was delayed until 
after initial colony formation. After an overnight incubation, the agar slab was scooped out of the 
plate, set on a sterile lid and IPTG solution was spread evenly on the bottom of the plate. Agar 
slabs were then replaced on top and diffusion of the IPTG through the agar resulted in 
development of blue pigmentation in transformants that possessed an active BpsA variant. A 
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negative control of BpsA containing a deleted CP domain was included, as well as a control with 
the WT PvdDCP1 substituted in, which contained Thr at the +4 position and had already been 
shown not to function (Owen, 2010). Neither of the negative controls developed any blue colour. 
In contrast, each of the four substitutions showed at least minimal activity, with the number of 
days taken for colonies to turn blue listed in Table 3.2. Figure 3.2 shows a picture of each of the 
four plates after 7 days, with different degrees of blue pigmentation visible. Two of the CP domain 
substitute variants (ACMSIII and TycC) gave a stronger activity than the other two, with indigoidine 
production visible after two and three days respectively. The other two variants only developed a 
faint colour after six days, indicating extremely low levels of activity. All four of the CP-substitution 
variants tested were capable of producing indigoidine to some degree.  
Table 3.2 Time to develop blue pigmentation for different CP domains 
CP domain origin gene Time for colour to develop on solid 
media (days) 
ACMSIII 2  
GrsB 6  
TycC 3  
Pris3 6  
 
 
Figure 3.2. Initial assessment of BpsA CP-substitution activity on agar plates. The four CP-substitution 
strains were grown on L-glutamine containing plates and induced with IPTG. Photos taken after seven days 
of incubation at room temperature A) ACMS III B) GrsB C) TycC D) Pris3. 
A
C
B
D
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3.2.1.2 Liquid media activity tests   
The ability of strains expressing each of the four BpsA CP-substitution variants to produce 
indigoidine was tested quantitatively in liquid culture assays. The relative concentrations of 
indigoidine were determined using the method described by (Beer et al., 2014) and described in 
section 2.10.2. Cultures were measured at set time points at absorbance’s of both 590 and 800 
nm. In these assays, indigoidine is measured at an absorbance of 590 nm (Takahashi et al., 2007) 
while absorbance at 800 nm is used to normalise for cell density. This method was used in 
preference to a previous method where 96 well plates were spun down to remove cells and 
absorbance of indigoidine alone was measured at 590 nm (Owen, 2010). The dual absorbance 
reading method allowed for the same culture to be measured over multiple time points, as well 
as generally giving more consistent results in pilot studies (not shown). 
The results in Figure 3.3 show indigoidine production as measured after 30 h incubation at 18 °C. 
The ASMSIII substitution was the only CP-substituted BpsA displaying any activity, consistent with 
this substitution being the most active in the solid media activity test (Figure 3.2). The other three 
substitutions had no detectable activity above the level of a negative control in the liquid culture 
assay. This was not surprising as it was generally found that if a BpsA variant had poor enough 
activity that it did not turn its host colony blue on an agar plate assay after 48 h, it was unlikely to 
show any activity in the liquid culture assay over a measurable time period. 
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Figure 3.3. Quantitative assessment of the relative indigoidine synthesis activities of +4 Thr CP-
substitution strains. +4 Thr CP-substitution strains were set up in quadruplicate in a 96-well microplate and 
incubated at 18 °C. After 30 h, absorbance at 590 nm and 800 nm was measured using a microplate reader. 
Relative indigoidine concentration was calculated using these values, as described in section 2.10.2.1. WT 
BpsA is included as a positive control (dark blue bar) and BpsA with a deleted CP domain is included as a 
negative control (red bar (“neg”)). Error bars are +/- one standard deviation. 
 
Even though the activity of three of the four CP-substitutions tested was undetectable in the liquid 
based assay, the fact that each of the four CP-substitutions were all at least minimally functional 
in the agar plate assay (Table 3.2) supports the hypothesis that CP domains found upstream from 
TE domains (as opposed to upstream from C domains) in their native context are able to function 
more easily when substituted upstream from other TE domains. The fact non-hydrophobic Thr at 
the +4 position is not strictly necessary for the function of a CP-substitution with BpsA. However, 
the extremely low levels of activity of each of these substitutions implies that this +4 position may 
still be important, and this non-hydrophobic residue may be severely impairing the substitutions.     
3.2.2 Identification of amino acid residues at the +4 position of 
PvdDCP1 that result in partial restoration of indigoidine 
biosynthesis 
In previous work the +4 position in the CP domain was identified as being important in improving 
activity of CP substitutions within BpsA, with many evolved variants gaining a hydrophobic amino 
acid at this position (Owen, 2010). The work described in Section 3.2.1 showed that a hydrophobic 
residue at the +4 position was not strictly necessary for function, with four CP domains with +4 
Thr able to function when substituted into BpsA, albeit minimally in most cases. In contrast, when 
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PvdDCP1 had been substituted into BpsA it resulted in a completely non-functional enzyme. 
Directed evolution was previously employed to improve the activity of this enzyme, and various 
activity-enhancing mutations were found (Owen, 2010). All but one of the mutations at the +4 
position was Ile, with one Ala found in conjunction with another mutation. Given the practical 
limitations of error prone PCR (as discussed in section 3.1.2), these mutations found were two out 
of the five possible mutations that were practically available at this position, insufficient to confirm 
the pattern that hydrophobic residues were required. 
In order to determine which of the 20 amino acids at the +4 position of PvdDCP1 would yield a 
functional CP-domain substituted BpsA enzyme, a mutant library for the PvdDCP1 domain was 
generated, with an NNK codon at the +4 position. For the NNK codon, N stands for any base and 
K can be either a thymine or guanine. This combination results in 32 of the possible 64 codons 
being represented, collectively specifying all 20 possible amino acids. Primerless PCR was 
performed with Phusion® High-Fidelity polymerase using an ultramer (178 bp oligonucleotide) 
containing the degenerate codon NNK at the +4 position together with a reverse primer, thereby 
creating a double stranded product of the PvdDCP1 gene with the NNK codon at the +4 position. 
This was then amplified using BioMixTM Red and ligated into the BpsA substitution construct that 
had a deleted CP domain. This PvdDCP1 +4 NNK library was then transformed into BL21 ΔentD 
cells that contained an activating PPTase gene, sfp. To screen for active mutants the library was 
then plated on L-glutamine containing agar plates and bpsA expression was induced after initial 
overnight growth of colonies as in section 3.2.1.1. Plates were monitored over a period of four 
days and any blue hits were selected. The timing of discovery of each of the hits was recorded, 
ranging from a few hours to four days following induction. This gave the first indication of 
differences in activity levels between different mutants.  
Prior to selection, eight randomly selected clones from the library were sequenced to confirm that 
a reasonable diversity was present. With six out of the eight hits being unique clones, diversity 
was confirmed. In total 1-2 x 103 clones were screened, with approximately 47% of colonies giving 
a positive blue result.  As only one site was varied, there was likely a lot of redundancy and only 
165 hits were ultimately isolated for further analysis. From these, a total of 51 clones were 
sequenced (with varying activity levels based on time to turn blue in initial screen). Unexpectedly, 
sequencing revealed that 20 of these clones contained additional mutations, at locations other 
than the targeted +4 position. These additional mutations perhaps contributed to the unusually 
high rate (47%) of hits that were seen. Subsequent to this, the experiment was repeated only 
amplifying the PvdDCP1 +4 NNK gene with a high fidelity polymerase, PhusionTM, compared to the 
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previous PCR system Biomix RedTM. A further 1000 colonies were screened, this time yielding just 
a 15% blue hit rate. Seventeen of these were sequenced, and while there were still three found 
that had additional mutations present, the majority were mutated at the +4 position alone.  
Overall six unique clones were found which had mutations solely at the +4 position. These amino 
acids were Ile, Phe, Leu, Tyr, Met and Ala. The WT residue, Thr, was also found amongst the hits 
sequenced, but later found to have no activity when re-streaked on L-glutamine containing agar 
plates. It was noted during this process that false positives were more likely to be found after 
several days of incubation on an agar plate. After this amount of time some of the darker colonies 
leach indigoidine into the surrounding agar, making colonies producing their own indigoidine 
harder to identify. The time for each clone to produce indigoidine pigment was tested on agar 
plates, as in section 3.2.1.1.  This gave an indication of activity level of each clone, as well as 
allowing identification of any false positives. The time taken for each of the active +4 variant 
substitution strains to turn blue is summarised in Table 3.3.  
Table 3.3 Amino acid residues at the +4 position that resulted in improved BpsA activity 
Amino acid at +4 Time for colour to develop on solid media (days) 
Alanine 2 
Leucine 2 
Isoleucine 2 
Phenylalanine  3 
Tyrosine 3 
Methionine 4 
 
3.2.2.1 Quantitative assessment of hit activity 
In the previous section, six amino acid changes at the +4 position in PvdDCP1 were identified 
qualitatively as having the ability to generate functional BpsA variants, i.e. yielding blue coloured 
colonies on agar plates. To quantitatively assess the effect of the different mutations at this 
position, each unique clone capable of giving rise to the blue colouration on plates was then 
subjected to an assay in liquid media, where the amount of indigoidine was calculated through 
absorbance readings. The results for single mutations at the +4 position can be seen in Figure 3.4. 
The variant strains that displayed the greatest increase in indigoidine production were those with 
Ile and Phe at the +4 position, followed by Leu. All of the variants were much lower than wild type 
activity levels. The other three variants, with Tyr, Met and Ala at the +4 position, did not show any 
more activity than the negative control. The relative levels of activity do not correlate with those 
seen in the agar plate assays (Table 3.3), where the Ala substituted variant appeared to have equal 
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activity to Leu and Ile substituted variants, and the Phe substituted variant appeared to have the 
same level of activity  as the Tyr substituted variant. 
 
Figure 3.4. Quantitative assessment of the relative indigoidine synthesis activities of active PvdDCP1 +4 
mutation substitution strains. PvdDCP1 +4 variant strains were set up in quadruplicate technical replicates 
in a 96wp and incubated at 18 °C. After 48 h, absorbance at 590 nm and 800 nm was measured using a 
microplate reader. Relative indigoidine concentration was calculated using these values, as described in 
section 2.10.2.1. WT BpsA is included as a positive control (dark blue bar) and BpsA with a deleted CP domain 
is included as a negative control (red bar). Error bars are +/- one standard deviation.  
 
3.2.3 Identification of amino acid residues at the +24 position that 
result in partial restoration of indigoidine biosynthesis 
As described previously for the +4 position in section 3.2.2, a +24 NNK library for the pvdDCP1 
gene was generated and cloned into the CP domain substitution BpsA vector. This library was 
transformed into a strain containing the activating PPTase gene sfp, plated and screened for 
activity on L-glutamine containing agar plates. After induction with IPTG, plates were incubated at 
room temperature and blue colony “hits” were selected. Approximately 500 colonies were 
screened in total, with 17% of these being positive blue hits. Of these, 32 clones were sequenced, 
each of which only contained a change at the +24 site, with no additional mutations being found. 
Twelve unique clones were recovered, and each was plated on L-glutamine containing plates and 
induced with IPTG. The time taken for colonies to turn blue was recorded for each. The amino 
acids identified at this position together with the timing for blue colour to develop are summarised 
in Table 3.4. The time for colour to develop mostly corresponded with the day that hits were 
observed to appear in the original screen. 
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Table 3.4 Residues at +24 position resulting in improved BpsA activity 
+24 Time for colour to develop on solid media (days) 
L 1 
V 1 
M 1 
I 2 
S 2 
C 2 
Q 2 
T 2 
A 3 
G 3 
Y 4 
P 4 
 
3.2.3.1 Quantitative assessment of hit activity 
To quantitatively assess the effect of the different mutations at the +24 position, each unique hit 
was then subjected to an assay in liquid media, where the amount of indigoidine was calculated 
via absorbance readings. Only the top performing clones were tested, i.e. those that turned blue 
within 48 h on an agar plate (reasoning that anything beyond this was unlikely to show any activity 
in the liquid assay). Figure 3.5 illustrates the relative activity levels of these mutants. The apparent 
best clone had Ile at the +24 position, followed by Leu, Val and Met. All of these top residues are 
hydrophobic. Overall these results are in agreement with the conclusion drawn in the previous 
section, i.e. that changes at just one position, if it is the right position, can cause dramatic changes 
in overall activity. Based on these results it was next sought to determine whether changing two 
residues at the same time could achieve additive or even synergistic effects. 
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Figure 3.5. Quantitative assessment of the relative indigoidine synthesis activities of active PvdDCP1 +24 
mutation substitution strains.  PvdDCP1 +24 variant strains were set up in quadruplicate in a 96wp and 
incubated at 18 °C. After 48 h, absorbance at 590 nm and 800 nm was measured using a microplate reader. 
Relative indigoidine concentration was calculated using these values, as described in section 2.10.2.1. WT 
BpsA is included as a positive control (dark blue bar) and BpsA with no CP present is included as a negative 
control (red bar (“neg”)). Error bars are +/- one standard deviation. 
 
3.2.4 Identification of amino acid combinations at the +4 and +24 
positions that restore indigoidine biosynthesis 
Sections 3.2.2 and 3.2.3 show that changing either the +4 or +24 position can in isolation have a 
dramatic effect on the activity of a protein, in some cases transforming a completely inactive 
enzyme into a relatively active one. Next the effect of combining mutations at these positions was 
tested. A degenerate pvdDCP1 gene construct that contained NNK codons at both the +4 and +24 
sites was cloned into the CP-substitution BpsA vector. This library was then screened in the same 
manner as previously. Over 700 clones were screened, with 152 blue clones recovered, an 
approximately 21% hit rate (higher than observed for mutation of either the +4 or +24 residue in 
isolation). A total of 39 hits were sequenced. Interestingly several hits were found that contained 
the PvdDCP1 WT residue (Thr) at the +4 position, making them  equivalent to variants found in 
section 3.2.3 that had a mutation solely at the +24 position. In contrast, no hits were found with 
the PvdDCP1 WT residue, Phe, at the +24 position. The sequences of hits and the time taken for 
each to yield blue colonies when subsequently tested in E. coli on solid media is summarised in 
Table 3.5. 
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Table 3.5 Sequence and activity level of clones with mutations at +4 and +24 residues  
+4 +24 Time for colour to develop on solid media (days) 
M P 1 
V I 1 
M Y 1 
L T 1 
M L 1 
V A 1 
T L 1 
T V 1 
C M 1 
L P 1 
L M 1 
V L 1 
C V 1 
T M 1 
T A 2 
P M 2 
E L 2 
G I 2 
D L 2 
S A 2 
T C 2 
F P 2 
L N 2 
G L 2 
H A 2 
P C 2 
H S 2 
A S 2 
T N 3 
G T 4 
 
3.2.4.1 Quantitative assessment of hit activity 
To quantitatively assess the effect of the combined mutations at the +4 and +24 positions, each 
unique clone capable of giving rise to blue colony colouration on plates was then subjected to an 
assay in liquid media, with the amount of indigoidine calculated through absorbance readings. 
Again only the top activity mutants were chosen, in this case the clones that had turned blue 
within 24 h in the agar plate assay (restricting the time period to just one day due to the overall 
larger number of clones found). The results for this are illustrated in Figure 3.6. Due to the higher 
average activity of the clones, activity levels were able to be clearly distinguished after 24 h. The 
clones that displayed the highest activity levels were those with +4/+24 combinations of L/M, M/L 
and V/I. Each of these residues is strongly hydrophobic. Most of the top mutations, for instance 
L/M and M/L, had each of the combined mutations appearing individually in the +4 or +24 screens. 
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There is evidence to suggest some mutations may be synergistic, for example, the +4 L and +24 M 
variants individually were able to restore only a moderate degree of indigoidine synthesis after 48 
h, but when these two mutations were combined in the top performing variant in this assay (L/M, 
Figure 3.6), indigoidine synthesis approached WT levels after just 24 h. The degree to which the 
two positions interact is explored further in the next section. 
 
Figure 3.6 Quantitative assessment of the relative indigoidine synthesis activities of active PvdDCP1 
+4/+24 substitution strains. Top PvdDCP1 +4/+24 substitution variant strains were set up in quadruplicate 
in a 96wp and incubated at 18 °C. After 24 h, absorbance at 590 nm and 800 nm was measured using a 
microplate reader. Relative indigoidine concentration was calculated using these values, as described in 
section 2.10.2.1. WT BpsA is included as a positive control (dark blue bar) and BpsA with a deleted CP domain 
is included as a negative control (“neg”). Error bars are +/- one standard deviation. 
 
3.2.5 Combined effects of mutations 
Many of the amino acid changes that were found in the combined +4/+24 clones had also been 
found individually, allowing a comparison of the effects when a particular mutation was found 
either alone or in combination with another, and the identification of additive, synergistic or 
antagonistic mutations. In five separate cases the data were available to compare the +4 and +24 
mutations both together and for each in isolation (Figure 3.7). Clones analysed included +4/+24 
I/I, the top clone from Dr Owen’s first round of directed evolution, as each of the mutations (+4 
Ile and +24 Ile) was recovered individually during the course of this study. The relative activity 
level of each can be seen in Figure 3.7, with the effects from combining these particular mutations 
all appearing to be either additive or synergistic. In the case of the +4 Ala and +24 Ser substituted 
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variants the effect may have been additive, but overall the activity from these three clones was 
too small to draw a strong conclusion. The rest of the clones for which all +4/+24 combinations 
were available- +4/+24 L/T, M/L, L/M and I/I – each looked to be synergistic, with the activity of 
the +4/+24 clones being substantially greater than the activity of the individual clones combined. 
These included the two top mutants found in this screen, M/L and L/M as well as I/I, the top 
mutant found in previous first tier screening.  
 
Figure 3.7. Quantitative assessment of the relative indigoidine synthesis activities of PvdDCP1 
substitution strains for which the same +4 and +24 mutations had been found both alone and in 
combination. PvdDCP1 variant substitution strains were set up in quadruplicate in a 96wp and incubated at 
18 °C. After 48 h, absorbance at 590 nm and 800 nm was measured using a microplate reader. Relative 
indigoidine concentration was calculated using these values, as described in section 2.10.2.1. Error bars are 
+/- one standard deviation. 
 
Another example of synergy seen was when a mutation did not appear to have enough activity on 
its own to even be identified in the +4 screen, yet acted synergistically with a second mutation at 
+24. For example Val at the +4 position on its own appeared to have no effect (based on the fact 
it was never recovered from the NNK +4 library), but synergistic effects were seen in combination 
with Ala, Leu or Ile at the +24 position (Figure 3.8). In fact the +4/+24 V/I clone was the third top 
mutant overall. 
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Figure 3.8. Quantitative assessment of activity of PvdDCP1 substitutions that contained +24 mutations 
found alone or in combination with Valine at +4 position. PvdDCP1 variant substitution strains were set up 
in quadruplicate in a 96wp and incubated at 18 °C. After 48 h, absorbance at 590 nm and 800 nm was 
measured using a microplate reader. Relative indigoidine concentration was calculated using these values, 
as described in section 2.10.2.1.  Error bars are +/- one standard deviation. 
 
We can also compare cases where the +24 mutant was found on its own, and then recovered 
along with a variety of +4 mutations within the combined +4/+24 screen. In many cases it is clear 
that the +4 mutations found in the combined screening were passenger mutations, i.e. only there 
because another dominant substitution such as Leu was present at the +24 position. In some cases 
these may in fact be antagonistic mutations, where the +4/+24 variant had lower activity than the 
+24 alone. For example, Leu at +24 on its own had a greater activity than if Asp, Glu or Gly were 
present at the +4 position as well (+24 Leu yielded indigoidine after one day on an agar plate, 
while the +4/+24 variants D/L, E/L and G/L all yielded indigoidine after two days) (Table 3.5). This 
was not generally the case the other way around, i.e. no dominant mutations were observed at 
the +4 position that were able to support non-contributing mutations at the +24 position, 
indicating that the +24 position in this context was the more important mutation of the two for 
improving activity. 
3.2.6 Kinetic analysis of top mutants 
To verify trends that were seen at an in vivo level, the top performing PvdDCP1 substitution 
variants of BpsA from each library were selected for purification in order to enable kinetic 
analyses. The top variants chosen were the +4 Phe and +24 Ile substituted variants, as well as the 
top +4/+24 combination variant, L/M, and the most active variant from Dr Owen’s initial round of 
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evolution, +4/+24 I/I. Each of these mutants was already cloned into the pCDFDuet plasmid, which 
contains a His6 tag to allow for nickel affinity chromatography purification. Top mutants were 
each transformed into the E. coli BL21 ΔentD strain, i.e. an expression host lacking an activating 
PPTase to ensure the purification of un-activated apo BpsA. Enzymes were purified following the 
protocol for WT BpsA (Owen et al., 2011), with mutations having no noticeable effect on solubility 
or expression levels. Velocity values were derived at different L-glutamine concentrations and all 
variants were found to fit a Michaelis-Menten model (curves for each are shown in Figure 3.9). 
Kinetic parameters were derived for each of the top mutant enzymes as well as WT BpsA (Owen 
et al., 2011), and are given in Table 3.6. 
 
Figure 3.9. Michaelis-Menten curves for each substitution variant tested. Plots shown indicate the 
maximum velocity of indigoidine formation for each variant at different concentrations of L-glutamine. 
Curves were fitted using Graphpad Prism® and used to derive kinetic parameters for each BpsA variant with 
L-glutamine as substrate. Data points were generated from three repeats and error bars are +/- one SEM. 
 
Table 3.6 Kinetic parameters for BpsA and PvdDCP1 substituted improved variants 
BpsA variant Vmax (Δ A590 min-1 .µM-1) Km (mM) Vmax/Km (Δ A590 min-1 .µM-1.mM-1) 
WT 1.16 ± 0.023 0.67 ± .046 1.73 ± 0.12 
+4/+24 Ile/Ile  0.05 ± 0.002 0.012  ± 0.004 4.17 ± 1.40 
+4 Phe 0.015  ± 0.0003 0.038  ± 0.004 0.39 ± 0.42 
+24 Ile 0.028  ± 0.0007 0.017  ± 0.003 1.65 ± 0.29 
+4/+24 Leu/Met 0.076  ±0.002 0.056  ± 0.008 1.36 ± 0.20 
 
All variants were substantially impaired in maximal velocity relative to WT BpsA (being 1-2 orders 
of magnitude slower). However, in all cases the Km had also diminished. The Vmax/Km provides a 
measure of the relative catalytic efficiencies for each enzyme. Taking this into account, the +4/+24 
I/I variant (3kf0) has a higher efficiency than the WT BpsA enzyme. The +24 Ile substituted variant 
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and +4/+24 L/M combination variant both have similar efficiencies to the WT BpsA enzyme. The 
+4 Phe substituted variant has a lower activity than all the other tested variants, which is 
consistent with results seen in the liquid culture assays. 
3.3 Discussion 
The aim of this chapter was to investigate features of CP domains that were important for the 
creation of functional BpsA CP-substitution variants. This involved optimising the interactions 
between the foreign CP domains and the downstream TE domain of BpsA. The particular features 
studied were the location of the foreign CP to be substituted in its original enzyme, as well as two 
key residues, the +4 and +24 positions (relative to the invariant Serine). 
Four BpsA substitution variants having CP domains that were located upstream from TE domains 
in their native context were all found to be functional, with the most active variant producing 
indigoidine after two days in a solid media assay and all variants producing pigment within six 
days. The fact that they were all at least minimally functional is consistent with the previous 
observations that CP domains found upstream of TE domains in their native context are generally 
able to function when substituted into BpsA (Owen, 2010). However, the four CPs were specifically 
chosen because their sequences were inconsistent with a pattern previously noted; that is, they 
each contained a Thr residue at the +4 position instead of the hydrophobic residue that Dr Owen 
had found to be present in all of the CPs upstream from TE domains in his study. As each of these 
four CP-substitutions was functional, this implies that a hydrophobic residue at +4 is not necessary 
for a functional BpsA CP domain swap. These four CP domains must therefore contain other 
residues involved in optimising the interaction with the TE domain, which compensate in some 
manner for the +4 Thr. Nonetheless, activity for three out of the four substitutions was very low 
(not detectable in liquid culture assay), indicating further opportunity to evolve and improve these 
substitutions. It may be that targeted mutagenesis of the +4 site to a hydrophobic residue would 
be a good starting point. 
Next the substitution of PvdDCP1 into BpsA was examined. Located upstream from a C domain in 
its native context, and so unable to result in a functional variant when directly substituted into 
BpsA, this CP domain substitution had previously been improved using error prone PCR (Owen, 
2010). Mutations at the +4 and +24 positions had been found to restore activity to the 
substitution, in particular when these positions were changed to hydrophobic residues. This 
research confirmed that a mutation to a hydrophobic residue at the +4 position could restore 
activity to the substitution, revealing four other residues, Leu, Phe, Met and Tyr, in addition to Ile 
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and Ala (which were the only two residues found via error prone PCR) that resulted in a functional 
BpsA variant. The variants with the highest activity as measured by the liquid culture assay (Ile, 
Leu and Phe) are the more hydrophobic residues (Kyte and Doolittle, 1982). While the earlier 
substitutions of the four CP with the +4 Thr had shown that a hydrophobic residue at the +4 
position was not necessary for function, in the case of PvdDCP1 substitutions conversion of this 
threonine to a more hydrophobic residue was sufficient to restore a moderate level of activity. 
The results for the single mutations in PvdDCP1 at the +24 position were not so straightforward. 
Twice as many amino acids (12 in total) substituted at this position were found to result in 
functional variants. Previously Ile and Leu mutations had been identified via error prone PCR, so 
again assumed that hydrophobic residues were necessary for interaction with the TE interface. 
While the top variants identified in this chapter (Ile, Val, Leu and Met, as in the liquid culture assay) 
are all hydrophobic residues, there were other residues at this position also capable of giving rise 
to functional variants, including the hydrophilic Ser, Gln and Thr. Also, the PvdDCP1 WT residue at 
this position is hydrophobic (Phe), so if a hydrophobic residue at the +24 position was all that was 
required to yield a functional variant then the WT PvdDCP1 substitution should have been active. 
The main difference between Phe and the residues found in the improved mutants is that Phe is 
a bulky aromatic residue, while all the other residues are smaller and non-aromatic. In the WT 
BpsA CP, this position is occupied by a Leu, a smaller hydrophobic residue. We can conclude that 
a small, hydrophobic residue at the +24 position which is similar to the BpsA WT residue (Leu) is 
better able to interact with the BpsA TE domain. It appears that even a small, neutral residue that 
is hydrophilic, is still able to interact more successfully with the TE domain than the bulky aromatic 
residue Phe.  
While a single mutation at the +4 or +24 positions in PvdDCP1 was in some cases sufficient to 
convert a completely non-functional CP into a functional one, combining beneficial mutations at 
these positions showed an even greater effect. There were a larger number of +4/+24 substitution 
variants found, even though the library was not screened to saturation (a total of 30 unique active 
clones were found from a total of 39 improved variants sequenced). While many of these had 
relatively low activity and looked to have passenger or antagonistic mutations present, overall 
there was a much larger number of mutants with highly improved activity than was seen for 
mutations at each site alone (e.g., fourteen +4/+24 clones turned blue after 1 day agar, compared 
to three sole +24 site variants and none of the sole +4 site variants). Many of these top active 
variants had synergistic mutations at this position; mutations that showed marginal improvement 
on their own yet reached almost WT levels of activity in combination (as measured in a liquid 
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culture assay). When kinetics of the top variants were tested most were found to have similar 
efficiency levels to the WT BpsA enzyme, the two +4/+24 variants tested (I/I and L/M) had better 
or close to the efficiency of the WT enzyme. 
The +24 site of the CP domain had also been identified as being involved in domain interactions 
via scanning alanine mutagenesis studies, in both the EntB and EntF CP domains, where a mutation 
to Ala at the +24 position was found to be detrimental to activity (Lai et al. 2006; Zhou, Lai, and 
Walsh 2006). One of the limitations of the scanning alanine mutagenesis approach is that alanine 
may be tolerated in a position, even if that position is important for function. In this case we have 
shown that small hydrophobic residues at the +24 position may improve the function of a CP-
substitution, indeed Ala was one of the mutations found in this study that gave rise to a functional 
variant. This may be why Lai et al. (2006) found the +24 site to only be of intermediate importance 
compared to the other sites identified in that study.  
In another CP substitution study (where the CP of the NRPS VibB, required for vibriobactin 
synthesis in Vibrio cholera, was substituted into the E. coli enterobactin synthase EntB) (Zhou et 
al., 2007b)), a mutation at the +24 position was also identified as being able to restore function to 
CP-substituted protein. In this case the improved variant contained the charged, hydrophilic 
residue Lys at +24. The downstream domain of the CP here was a C domain. It may be that the 
+24 position is a key residue for the interactions between CP and their downstream domains, and 
that the type of residue required may be dependent on what the downstream domain is.  If this is 
the case, then site directed mutagenesis may be able to be used instead of a completely random 
approach to optimise the activity of future CP domain substitutions. This would have the 
advantage of generating a much lower number of possible clones to screen.  
Some inconsistencies were seen in the way indigoidine production activity levels were measured, 
both when comparing solid media vs. liquid media of E. coli expressing the BpsA variants, and 
when comparing the kinetics of the purified enzymes. Some variants that were slower to turn blue 
on an agar plate were faster in liquid assay. For example, the +24 Ile-substituted variant was faster 
than the Leu, Val and Met-substituted variants in the liquid culture assay but a day slower on the 
solid media assay. Each of these methods of measuring indigoidine production is appropriate for 
different objectives. The solid media plate assay is simple and gives a quick and easy estimation 
of activity. This is excellent for screening as it has a high capacity, and it is easy to spot active 
mutants. This assay gives a rough estimation of activity, with variants that show activity within the 
first 48 h usually sensitive enough to then test in a liquid assay. However, the liquid assay is more 
appropriate for second tier screening of hits, as it is a lot more sensitive and quantitative. It is 
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more of a medium throughput approach so is best used when the most active hits have already 
been identified on agar plates. One limitation of the liquid culture assay is the comparison with 
the WT enzyme. The WT reaches peak levels of 590 nm absorbance faster than the mutants tested, 
and when measurements are taken at either 24 or 48 h (depending on activity of variants) the WT 
absorbance has likely already tapered off. This means a variant may look to have a similar activity 
to WT at one time point, but if measured earlier it would have appeared far less active 
comparatively. This assay is effective however for comparing mutants with similar levels of 
activity. Finally, measurement of Michaelis-Menten enzyme kinetics provided a much more 
detailed analysis of enzyme activity, however is much more time consuming so was only used for 
top mutants. Results were found to be mostly consistent with liquid assay results, in that when 
looking at enzyme efficiencies the top mutants were comparable to the WT. It is important to note 
however that the WT BpsA enzyme had the highest Vmax of any of the variants tested, which is 
consistent with this enzyme performing most effectively in the liquid assays, where the glutamine 
concentration was not limiting. Thus, even though the +4/+24 I/I clone had a higher efficiency 
than the WT, it did not appear to be more active in the liquid culture assay, where its substantially 
lower Km for L-glutamine would not have provided a discernible rate advantage.  
As this work was being performed, a CP substitution study was published using the BpsA 
homologue from Photorhabdus luminescens, IndC. Beer et al. (2014) substituted eight natural and 
seven synthetic CP domains into IndC. Five of the eight natural CP domains were located upstream 
from TE domains in their native contexts, yet only one of these substitutions was functional. This 
was inconsistent with the results seen in our study, but these other substitutions may have failed 
due to incorrectly defined domain boundaries. As CP domains are part of larger enzyme 
complexes, the boundaries of domains need to be carefully defined. Beer et al. (2014) only 
optimised their boundary positions after their initial substitutions were completed, going on to 
show that once these had been optimised a previously non-functional substitution (the CP from 
BpsA) was now functional. As the other CPs were not retested with the new boundaries, it is not 
possible to determine whether the other CP substitutions would have been functional had the 
correct boundaries been selected. In contrast, the boundaries for the BpsA CP substitutions 
described in this chapter had previously been optimised (Owen, 2010), and are similar to the final 
optimised boundaries selected by Beer et al. Of note, Beer et al. did not highlight any residues as 
being particularly important. All of the substitutions that were functional had Val at the +4 position 
and Phe at the +24 position, and were identical to the WT IndC residues. 
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The implications of the work described in this chapter are that there are several options for 
engineering CP-substituted variants in order to improve the activity of the substituted enzymes. 
Firstly, if you take into account the location of the CP domain in its original enzyme (e.g., upstream 
of a C domain vs. upstream of a TE domain) and transport it into an equivalent location, it seems 
that this would increase the likelihood of it being functional. This has been a consistent result seen 
with the BpsA enzyme and may translate to other NRPS enzymes as well. It has also been shown 
that targeted mutagenesis of just one or two important residues can be successful in improving 
the activity of a substituted variant to almost WT levels. In particular the +24 position has shown 
to be important for function both in BpsA substitutions as well as substitutions into another NRPS 
enzyme (EntB), implying that this might be a general rule that could be applied to improve CP 
domain activity within recombinant NRPS constructs.
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Chapter 4: Metagenomic screening for PPTases and 
secondary metabolite genes 
4.1 Introduction 
The previous chapter describes how BpsA can be used to investigate interactions between CP 
domains and their neighbouring domains. As part of this collaborative research, Dr Jeremy Owen 
had earlier evolved several CP-substituted variants of BpsA. These contained CP domains from 
foreign NRPS enzymes whose activity was improved via directed evolution to maximise their 
activity within BpsA. The research described in this chapter utilised some of these alternative BpsA 
enzymes in a different screening process, the discovery of novel PPTase and secondary metabolite 
genes from metagenomic DNA samples. BpsA is inactive when expressed in E. coli due to the lack 
of any activating endogenous PPTase (Owen et al., 2011); co-expressing the bpsA gene with a 
length of DNA that includes an activating PPTase gene results in production of indigoidine. Thus, 
we reasoned that we would be able to use this BpsA based screen as a means to discover novel 
PPTases and, by association, the secondary metabolite genes that are often found adjacent them. 
This research focused on the further development of this screen, both by improving the E. coli 
screening strain by reducing background activation of BpsA and also by using the previously 
engineered CP-substituted BpsA variants to broaden the screen.  
In the current work, the screening strain was first improved via deletion of the native E. coli 
PPTase, entD. This reduced background activation of BpsA, which had previously resulted in a 
small level of blue pigmentation seen in the centre of all colonies after two days. This was 
particularly important for utility of one of the evolved BpsA variants, which contained a native CP 
recognised by EntD. Expanding the screening method to include use of the evolved BpsA variants 
was found to broaden the range of PPTase-containing hits recovered. Subsequently a detailed 
proof of principle was performed, including the complete screening of two separate metagenomic 
libraries with three different bpsA variants (including WT bpsA). The results demonstrated that 
alternative CP domains integrated into bpsA can recover PPTase enzymes that have differing 
specificities. It was also shown that this screen can serve as a very effective enrichment method 
for discovering secondary metabolite biosynthesis genes (NRPSs and PKSs), with nearly 50% of the 
hits discovered containing evidence of these biosynthetic gene clusters. The majority of results 
presented in this chapter were published in the peer-reviewed journal Environmental 
Microbiology (Owen et al., 2012), a publication for which I was co-first author.  
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4.1.1 Metagenomic screening to discover previously inaccessible 
enzymes and natural products 
Microorganisms have always been a rich source of enzymes and natural products, and historically 
discoveries of such products have come from microorganisms which are able to be cultured under 
standard laboratory conditions. Recent metagenomic analyses of various microbial environments 
has shown that they contain much more variety than previously thought, with over 99% of these 
microorganisms seemingly unable to be grown in the lab (Keller and Zengler, 2004; Rappé and 
Giovannoni, 2003; Torsvik et al., 2002). The field of metagenomics has been expanding and many 
methods for tapping into this diversity have been developed (Banik and Brady, 2010). Such 
methods involve isolating the DNA directly from environmental samples known to be rich in 
microbial DNA, such as soil or sponges, and then screening these via various methods to uncover 
new genes of interest. These screening methods are traditionally split into either sequence or 
function based screening, both of which have advantages and disadvantages. Sequence based 
screening relies on knowing what you are looking for and isolating genes whose sequence or 
conserved sequence regions are already known; this can be a powerful technique generating huge 
amounts of data, however you will not find anything unless you know what to look for. The basis 
for our screen is function based, which has the advantages of being able to screen for something 
truly novel, as long as you have the right activity screen to find it. This approach also ensures that 
the genes found will be able to be expressed as functional proteins in E. coli – an important 
consideration for downstream applications of the recovered genes. Function based screens can 
also be cheaper than large scale sequence based efforts, however are dependent on being able to 
clearly detect an activity of interest. 
4.1.2 Use of PPTases in metagenome screening 
PPTases have been utilised before in a metagenomic screening context to discover new secondary 
metabolite genes, albeit in quite a different context. In an early instance of this Sfp, a broad range 
PPTase, was used to identify CP domains within a metagenomic sample (Zhang et al., 2009).  This 
study used a phage display method to display expressed proteins from a metagenome sample on 
the phage’s surface, and subsequently any carrier proteins present were labelled with CoA-
attached biotin using Sfp (Yin et al., 2007). Any biotin labelled CPs were then isolated through 
streptavidin binding and then identified, with the goal being to recover the natural product 
biosynthetic gene clusters that expressed the labelled CPs. This was initially shown to be effective 
in a proof of principle study that used a library created from B. subtilis DNA (Yin et al., 2007), with 
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almost half of the known CPs in B. subtilis recovered in this screen. Another group developed a 
similar method which also involved using Sfp to label CPs, this time in a proteomic sample instead 
of a phage display (Meier et al., 2009). This research again employed a CoA-biotin derivative, and 
isolation of labelled proteins through binding with streptavidin. Proteins were then identified 
through mass spectroscopy methods. These approaches both used one PPTase (Sfp) to identify 
many CPs from a genome. This has the advantage of finding NRPS or PKS genes directly, although 
many false positives were also recovered in both cases. The concept of targeting PPTases as a 
means of identifying unknown antibiotic biosynthesis clusters was first suggested by Mootz et al 
(2002b), by using complementation of a lys5 mutation in Saccaromyces cerevisiae. The lys5 gene 
encodes an essential PPTase in the lysine biosynthesis pathway. Foreign PPTases expressed in a 
lys5 mutation strain allow for growth on media lacking lysine. However, there is no evidence of 
proof of principle for their idea having been demonstrated. Our aim was to screen for PPTase 
enzymes using the CP domain of BpsA as a target. As the genes for PPTases and the secondary 
metabolite enzymes they activate appear to often be found nearby to each other, it was hoped 
that the discovery of these PPTases would lead to the discovery of new secondary metabolite gene 
clusters. 
4.1.3 BpsA as a tool in metagenome screening 
Many of the properties that made BpsA an ideal candidate for screening of improved CP domain 
swaps in the previous chapter also lend themselves to this metagenomic screening strategy. Still 
a key property is its ability to produce a coloured product when activated, with any blue colonies 
easily visualised on relatively high density agar plates that contain L-glutamine. Another property 
of BpsA that makes it particularly useful for metagenome screening is the fact that it is expressed 
in its inactive form when expressed in E. coli. This is due to the fact that the native PPTases of E. 
coli do not recognise the CP domain of BpsA. When BpsA is expressed alongside environmental 
DNA (eDNA) fragments, the presence of any expressed PPTases that recognise BpsA will cause the 
enzyme to be activated. This idea was first tested using a small insert (2-6 kb) soil library, kindly 
provided by Nadia Parachin of Lund University (hereafter known as the “Swedish soil library”) 
(Owen, 2010). A total of nine hits were found, representing three unique sequences, all containing 
genes coding for PPTases (Figure 4.1). One of these hits also had fragments of natural product 
biosynthetic genes clustered with it. The annotations for all genes found are in Table 4.1. These 
promising results led to the further development of this screen, in the research that will be 
described in the remainder of this chapter. 
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Figure 4.1 eDNA fragments isolated from preliminary work. Adapted from Fig 7.10 (Owen, 2010). Three 
hits found from the Swedish soil library in an initial screen. Number of PPTase corresponds to number of 
the clone. Red indicates a PPTase; blue indicates biosynthetic associated genes and green indicates all other 
genes. Table 4.1 gives a description of the genes. 
 
Table 4.1 Top BlastX matches for ORFs discovered in eDNA fragments 
Clone Gene Top described match from 
BLAST search 
Species within which top 
match was found 
Percentage 
identity 
1 TE  microcystin synthetase associated 
thioesterase 
Planktothrix agardhii 46% 
 PPTase 1  4'-phosphopantetheinyl 
transferase 
Beijerinckia indica subsp. 
indica 
43% 
 KS  polyketide synthase Streptomyces coelicolor 59% 
     
2 NTR  Nitroreductase  Nitrococcus mobilis  50% 
 PPTase 2  4'-phosphopantetheinyl 
transferase 
Micromonospora aurantiaca 39% 
 DUS  Dihydrouridine synthase  Amycolatopsis mediterranei 63% 
     
3 PPTase 3  4'-phosphopantetheinyl 
transferase 
Bradyrhizobium japonicum 43% 
 Mg  Magnesium Transporter Marichromatium purpuratum 55% 
 
4.1.3.1 Demonstration that bpsA constructs containing 
alternative carrier protein domains expand the screening 
capabilities  
One of the limitations of only using WT BpsA is that it can only pick up those PPTases that would 
recognise and activate the CP domain of BpsA. We reasoned that there may be many PPTases that 
are incapable of such recognition (e.g., as is in the case with the native PPTases of E. coli). If so, 
then it should be possible to improve upon the initial screen by introducing different CPs from 
foreign NRPS enzymes into BpsA and using these to access a wider variety of PPTase and therefore 
secondary metabolite genes. As discussed in the previous chapter, the evolution of CP domain 
substitutions within BpsA had previously been performed in the context of gaining better 
understanding of interactions between different NRPS domains. As a result of this work, several 
different BpsA CP-substitutions were created, having been evolved for increased activity (Owen, 
2010). In this chapter we aimed to take advantage of this unique resource, and use these evolved 
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forms of bpsA as alternative reporter genes for PPTase activity - thereby expanding number of 
potential PPTase recognition sites and thus hits found in this metagenomic screen. The first 
alternative CP domain that was used in this study was the terminal CP domain from pvdD, a 
pyoverdine producing NRPS of P. aeruginosa PAO1. The second alternative CP domain used was 
from the entF NRPS from the enterobactin synthesis cluster in E. coli. Firstly the native PPTase of 
E. coli, entD, was knocked out of the BL21 E. coli strain used for screening, in order to eliminate 
background activation by EntD.  The strains of E. coli with the entD gene deletion which carried 
the improved BpsA CP domain substitution constructs were called EcoBlueP (BpsA with PvdD CP 
substitution) and EcoBlueE (BpsA with EntF CP substitution), with the WT BpsA enzyme containing 
strain referred to as EcoBlue1.  
4.1.4 Metagenomic libraries used in this study 
The two metagenomic libraries used in this study were both previously synthesised small insert 
plasmid libraries, limiting the size of any genes found. This is not a limiting factor for finding PPTase 
genes, the largest known being around 700 bp long. It did however mean that while this screen 
could find fragments of secondary metabolite genes, it would likely not recover any complete gene 
clusters (which are frequently as big as 100 kb) and so would only be used as a proof of principle 
screen in this regard. The Swedish soil library used in the preliminary screening (Owen, 2010) was 
also used here, both in order to screen it to saturation with the WT bpsA and to test it with the 
two new alternative CP-substituted bpsA constructs. This library contained inserts ranging from 2 
to 6 kb in size. Another metagenomic library was also used - a larger library created, but not 
screened by, Dr Owen. This was created using soil from Wellington, New Zealand, and will be 
referred to as the “New Zealand soil library”. This second library had inserts ranging from 1 to 3 
kb in size. 
4.1.5 Aims 
 Improve screening strains via knock out of the native E. coli  PPTase, entD 
 Rescreen Swedish soil library to saturation using EcoBlue1, EcoBlueP and EcoBlueE 
 Screen a newly created NZ soil library using EcoBlue1, EcoBlueP and EcoBlueE 
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4.2 Results 
4.2.1 Creation of optimised ΔentD screening strain 
The first small scale proof of principle screen described in section 4.1.3 was performed in BL21, an 
E. coli strain that contains all native E. coli PPTases. However a level of background activity was 
seen as a result of BpsA being activated to a small degree by the native E. coli PPTases. This and 
the fact that EcoBlueE contains an entF-substituted bpsA variant, entF being a native substrate for 
the E. coli PPTase entD, motivated us to knock out entD, to eliminate any background activation. 
This PPTase is non-essential, involved in secondary metabolism including the production of 
enterobactin (Lambalot et al., 1996).  The knockout of entD was performed using the method of 
Datsenko and Wanner (Datsenko and Wanner, 2000), as described in more detail in section 2.7. 
The successful removal of the entD gene eliminated the background activation of BpsA, as can be 
seen in Figure 4.2. Without the knockout, after two days small levels of background activity are 
seen with WT BpsA (small blue dots in the centre of colonies, Figure 4.2, upper left corner). Much 
darker blue can be seen in the strains with the two CP-substituted BpsA reporters expressed, 
showing that it was indeed necessary to knock out entD in order to screen with these alternative 
reporters. After entD knock out (lower panels) no blue pigmentation can be seen with any of the 
BpsA variants. 
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Figure 4.2 BpsA variant activation in WT strain vs entD knock out. A) WT bpsA, B) pvdD substituted bpsA 
and C) entF substituted bpsA, were each expressed in either BL21 (top panels) or BL21 ΔentD (bottom 
panels). All strains were grown on identical pigment producing media Photos taken after two days 
incubation at room temperature. 
   
4.2.2 Screening the Swedish soil eDNA library with three 
alternative bpsA reporter strains 
In previous work the Swedish soil eDNA library was screened for PPTase activity using WT BpsA. 
This resulted in the discovery of three unique clones, each containing one PPTase gene as shown 
in Figure 4.1. Here this same library was screened again, first using the WT BpsA reporter to ensure 
the library was screened to saturation. Approximately 3 x 106 clones were screened (an 
approximate 20 fold coverage given the estimated library size of 1.3 x 105 unique clones (Parachin 
and Gorwa-Grauslund, 2011)), with approximately 5-10 x 103 clones per plate. It was found that 
this cell density was high enough to enable genuinely high throughput screening while still 
allowing for selection of individual colonies from a plate, though occasionally hits had to be re-
streaked onto a second plate in order to obtain single colonies. Plates were incubated at 21 °C for 
a total of seven days to ensure all PPTases, even slow acting ones, were found. Individual blue 
colonies were easily identified on even relatively high density plates due to the clear dark blue 
colour, e.g. Figure 4.3. Both plasmids (bpsA containing and eDNA insert containing) were then 
isolated in a mixed miniprep and transformed into another E. coli strain, enabling the eDNA 
containing plasmid (pRSETB) to be selected in isolation via ampicillin selection, in order to isolate 
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the single eDNA containing plasmid. Transformants were tested to confirm the loss of 
spectinomycin resistance and therefore elimination of the bpsA containing plasmid (pCDFDuet). 
The eDNA inserts were then sent for sequence analysis. A total of 61 clones were identified from 
the Swedish soil library when screened in EcoBlue1. These 61 clones comprised only four unique 
inserts, the three that had been previously found (Owen, 2010) and a fourth previously 
undiscovered insert. This indicated that this library had not previously been screened to saturation 
with the WT BpsA enzyme, but likely now was. Given the relatively large size of the soil library and 
the fact that most microorganisms should contain at least one PPTase, it seemed unlikely that 
there would be only four PPTase genes present. We concluded that this screen was only picking 
up PPTases that recognise the BpsA CP domain, which led us to conduct additional screens using 
our evolved bpsA variants, as described in section 4.1.3.1. Screening the library in EcoBlueP and 
EcoBlueE resulted in three additional clones being recovered, as well as the first four that had 
been recovered using the EcoBlue1 strain. For EcoBlueP, screening approximately the same 
number of colonies as with EcoBlue1 we recovered 51 blue colonies. When the inserts from these 
were sequenced these were identified as the four previous clones, along with one new clone 
(clone 5, Figure 4.4). Screening the library with EcoBlueE yielded 60 blue colonies. Sequencing 
revealed these to be each of the previously discovered five clones together with two additional 
clones (clones 6 and 7, Figure 4.4). In this case the evolved versions of bpsA were necessary to find 
other PPTases present in the eDNA library, which may not activate the WT BpsA as well. Figure 
4.4 gives a summary of the hits found in this library, as well as the strain they were found in. Table 
4.2 gives the full annotations for each ORF found in each of the eDNA inserts.   
 
Figure 4.3 Identification of a blue PPTase containing colony through eDNA screening. Blue colony 
containing a PPTase ‘hit’ easily visible on an eDNA screening plate. 
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Figure 4.4 Summary of all eDNA hits in Swedish soil library found with EcoBlue1, EcoBlueE, and EcoBlueP. 
A) Summary of all the hits found in the Swedish soil library. Number of PPTase corresponds to number of 
clone. Red indicates a PPTase, blue indicates genes associated with biosynthetic gene clusters and green 
indicates all other genes. Grey indicates hypothetical gene or proteins with unknown function. B) Table 
indicates which of the three reporter strains each hit was found with, with a Y indicating it was found using 
that strain and an N indicating it was not found using that strain. * indicates that sequencing reactions from 
either direction were unable to proceed past that point. The full annotation details for each of the ORFs is 
given in Table 4.2 
 
Out of the seven PPTase-containing clones found, three were found alongside genes that indicated 
the likely presence of a secondary metabolite gene cluster. Insert one contained partial ORFs 
whose top BLAST matches were a thioesterase domain (from a PKS) and a polyketide synthase 
gene (Table 4.2).  Insert seven contained two genes where the top BLAST matches were to NRPS 
genes, as well as one ORF where the top match was for drug efflux transporter, also commonly 
associated with these types of biosynthesis genes, for exporting products from the producing cell. 
Insert six contained an ORF whose top BLAST match was for a methyltransferase. These are a class 
of common secondary metabolite tailoring domains, which add methyl groups to their associated 
products. Overall the BLAST scores for each of these genes was relatively low, with the highest 
being 59% but all the rest being under 50%, indicating that the biosynthesis genes found in such 
metagenomic libraries may be substantially different from other known biosynthesis genes. This 
highlights the advantage of functional based screening, as given the low similarity of sequences 
that were found it is unlikely these genes could have been found with sequence based screening 
(which relies on searching for conserved sequences).  
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Table 4.2 Top BLASTX matches for ORFs within the Swedish eDNA library clones 
Clone Gene Top described match from BLAST search Species from which top match 
was found 
Percentage 
identity 
1 TE  microcystin synthetase associated 
thioesterase 
Planktothrix agardhii 46% 
 PPTase 1  4'-phosphopantetheinyl transferase Beijerinckia indica subsp. indica 43% 
 KS  polyketide synthase Streptomyces coelicolor 59% 
     
2 NTR  Nitroreductase  Nitrococcus mobilis  50% 
 PPTase 2  4'-phosphopantetheinyl transferase Micromonospora aurantiaca 39% 
 DUS  Dihydrouridine synthase  Amycolatopsis mediterranei 63% 
     
3 PPTase 3  4'-phosphopantetheinyl transferase Bradyrhizobium japonicum 43% 
 Mg  Magnesium Transporter Marichromatium purpuratum 55% 
     
4 Pep* peptidase m14 carboxypeptidase a Micromonospora sp. L5 37% 
 PPTase 4  4'-phosphopantetheinyl transferase Agrobacterium vitus  40% 
 SuHy  Putative secreted sugar hydrolase  Stigmatella aurantiaca  26% 
 PHOS  type I phosphodiesterase/nucleotide 
pyrophosphatase 
Candidatus Solibacter usitatus 
Ellin6076 
39% 
     
5 Ac  adenylyl cyclase class-3/4/guanylyl 
cyclase  
Ralstonia eutropha JMP134  46%  
 PPTase 5  4'-phosphopantetheinyl transferase Microcoleus vaginatus FGP-2  39%  
 ICD  putative integrase core domain protein  uncultured marine 
microorganism  
45%  
     
6 PPTase 6 phosphopantetheinyltransferase family 
protein 
Gloeobacter violaceus 40%  
 GJ12277 GJ12277 Drosophila virilis 28% 
 Meth* type 11 methyltransferase Desmospora sp. 8437 34% 
 HYP hypothetical protein gamma proteobacterium 
IMCC1989 
27% 
 USP* similar to universal stress protein Candidatus Kuenenia 
stuttgartiensis 
65% 
 ABC ABC Transporter 
 
Syntrophobotulus glycolicus 
DSM 8271  
 
45% 
     
7 DEF* drug efflux transporter  Pseudomonas aeruginosa 
PAO1 
26% 
 PPTase 7 4'-phosphopantetheinyl transferase  Hyphomicrobium denitrificans 
ATCC 51888 
51% 
 OciA OciA (an NRPS) 
 
Planktothrix agardhii NIVA-CYA 
116 
47% 
 A amino acid adenylation domain protein bacterium Ellin514 38% 
ORF names are given on the basis of top previously characterised match (lowest e value) as identified in 
BLASTX alignments. *Indicates ORFs where the top match was a hypothetical protein. 
 
4.2.2.1 PPTase activity of hits from Swedish library within 
EcoBlue1, EcoBlueP, and EcoBlueE 
As some clones were only recovered using CP-substituted BpsA variants we wanted to check 
explicitly whether the PPTase in that particular clone was only able to recognise that particular CP 
domain. To test this each of the seven unique clones was transformed into EcoBlue1, EcoBlueP, 
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and EcoBlueE. These were then all plated out onto auto-induction agar plates so that the density 
of cells on each plate was approximately 100 colonies. After initial overnight growth at 37 °C plates 
were then incubated at room temperature for seven days and the time for blue colour to develop 
was observed. The results of this are summarised in Table 4.3. The number of ticks indicates the 
time taken for blue colour to develop. Three ticks indicates the blue colour developed on the first 
day, two ticks indicates blue colour development after two days, and one tick indicates a faint blue 
colour developed within three to seven days. A cross indicates no blue developed within the seven 
days. Figure 4.5 shows an example of representative plates, for hit seven. No blue colour was seen 
in EcoBlue1, and a darker blue was seen within EcoBlueP rather than EcoBlueE.   
Table 4.3 Cross reactivity of all Swedish clones in each reporter strain 
Clone Found in Level of activity in 
EcoBlue1 EcoBlueP EcoBlueE EcoBlue1 EcoBlueP EcoBlueE 
1 Y Y Y    
2 Y Y Y    
3 Y Y Y    
4 Y Y Y    
5 N Y Y    
6 N N Y x x  
7 N N Y x   
 
 
Figure 4.5 Clone 7 expressed EcoBlue1, EcoBlueP, and EcoBlueE three days after plating on auto-induction 
media with incubation at 37 °C. Clone 7 from the Swedish soil library in A) EcoBlue1 B) EcoBlueP and C) 
EcoBlueE. After three days incubation at room temperature, the darkest colour was seen in EcoBlueP, 
followed by EcoBlueE, with no blue colour seen in EcoBlue1. The colour of colonies on each of these plates 
did not alter substantially after an additional four days of incubation.  
 
Table 4.3 shows that when activity was directly tested in this manner, results were generally 
consistent with the strain each PPTase bearing clone had been recovered in. There were however 
two discrepancies. Clone 5 was only found using the EcoBlueP and EcoBlueE reporter strains, yet 
this clone showed low level activity in each reporter strain (including EcoBlue1). Clone 7 was only 
A CB
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found using EcoBlueE yet showed a higher activity in EcoBlueP when transformed into each 
reporter strain. These discrepancies could be due to the frequencies with which each of these 
clones were found. Both clones were found at a low abundance within the library, clone 5 twice 
and clone 7 once. They would both have been easy to miss because they were found in such low 
abundance. The generally low activity of clone 5 in each of the reporter strains may have also been 
a contributing factor. It is still clear however that screening with the alternative strains EcoBlueP 
and EcoBlueE was necessary to recover all of the seven clones that were found, as if the library 
had only been screened with EcoBlue1 then we could never have recovered clones 6 and 7, which 
showed no activity at all in this strain. Nonetheless, every hit found activated the EntF-substituted 
BpsA variant, suggesting that all hits could have been found using the EcoBlueE strain alone. 
This result supports the fact that as well as discovering new secondary metabolite biosynthetic 
genes, this screen is also capable of finding PPTase genes with different CP specificities, which may 
also have useful biotechnological applications (indeed, development of more specific PPTase 
enzymes became a primary focus of research that is described later in this thesis). In terms of 
generating dark blue colonies, the evolved variants of bpsA were generally less active overall then 
the WT enzyme. Nevertheless, some PPTases still showed more activity with these “impaired” 
variants (e.g. PPTases 4 and 7, both showing greater activity with EcoBlueP) perhaps indicating a 
much greater affinity for that particular CP as a substrate. 
4.2.3 Screening the New Zealand soil library with EcoBlue1, 
EcoBlueP, and EcoBlueE   
In addition to the Swedish soil library, Dr Owen also created a library made from soil collected 
from a residential property in Wellington, New Zealand (New Zealand soil library or NZ soil library). 
In the current work this was also screened for PPTase activity, using EcoBlue1, EcoBlueP and 
EcoBlueE. The size of this library was not quantified, but it was assumed to be a much larger and 
more diverse library as double the number of unique hits were found, even though it did not 
appear to yet be screened to saturation. For this library, 2.5-3 x 106 colonies were screened using 
each reporter strain. For EcoBlue1, 40 blue colonies were found, which when sequenced proved 
to be nine unique clones. When the library was screened in EcoBlueP 34 blue colonies were found, 
which when sequenced proved to be ten unique clones. In EcoBlueE only five blue colonies were 
found, which when sequenced proved to be three unique clones. Figure 4.6 gives a graphical 
summary of all hits found in the NZ soil library, as well as in which strain each hit was found. Table 
4.4 gives the full annotations for each ORF found in each of the eDNA inserts.  Again the two 
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alternative reporters were required to find every hit, with some being only found in either 
EcoBlueP (clones 1, 6, 7) or EcoBlueE (clone 13).  
 
Figure 4.6 Summary of hits found in NZ soil library. A) Summary of all the hits found in the NZ soil library. 
Number of PPTase corresponds to number of clone. Red indicates a PPTase, blue indicates biosynthetic 
associated genes and green indicates all other genes. B) Table indicates which of the three reporter strains 
each hit was found with, with a Y indicating it was found in that strain and an N indicating it was not found 
using that strain. The full annotation details for each of the ORFs is given in Table 4.4. 
 
Within the NZ soil library, five out of the 13 clones were found to also contain genes that are 
indicative of natural product gene clusters. Insert one contained a gene that matched to a 
simocyclinone biosynthesis gene, a PKS whose product has anti-tumour properties (Schirmer et 
al., 2005). Insert two contained a match to another PKS, Aufl, involved in the production of the 
secondary metabolite aurafuron (Frank et al., 2007). Insert four contains a cyclic peptide 
transporter, commonly found in these gene clusters for use in the export of biosynthetic products 
(von Döhren, 2009). Insert six was a match to an NRPS A domain. Insert seven contains a 
glycosyltransferase, which is associated with post-translational modification of both PKS and NRPS 
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enzymes, for example in vancomycin production (Baltz, 2002). The gene isopropylmalate 
isomerase from insert ten has also been found in a gene cluster containing NRPS and PKS genes 
(Zhu et al., 2009). 
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Table 4.4 Top BLASTX matches for NZ library clones 
Clone Gene Top described match from BLAST search Species from which top match was 
found 
%  
identity 
1 SimX4*  SimX4-like protein  Streptomyces sviceus 79%  
 PPTase 1  Phosphopantetheinyl transferase  Streptomyces avermitilis  67%  
     
2 PPTase 2  4'-phosphopantetheinyl transferase Nostoc punctiforme  39% 
 Ox oxidoreductase Sorangium cellulosum 33% 
     
3 PPTase 3  4'-phosphopantetheinyl transferase Hyphomicrobium denitrificans  45% 
 AufI* Polyketide Synthase AufI Stigmatella aurantiaca  37% 
     
4 CPT cyclic peptide transporter subfamily Synechococcus sp.  64% 
 PPTase 4  4'-phosphopantetheinyl transferase bacterium Ellin  58% 
 IRBP interphotoreceptor retinoid-binding protein Citromicrobium sp. JLT1363 45% 
     
5 PPTase 5  4'-phosphopantetheinyl transferase Verrucosispora maris 41% 
 UPGD undecaprenyl-phosphate glucose 
phosphotransferase  
Lautropia mirabilis  61% 
     
6 NAG 
  
Nacetylglucosaminyldiphosphoundecapreno
lN-acety l-beta-D-mannosaminyltransferase  
Streptosporangium roseum  55% 
 PPTase 6 4'-phosphopantetheinyl transferase Thiomonas intermedia K12 41% 
 A amino acid adenylation domain protein bacterium Ellin  50% 
     
7 GLYC glycosyltransferase  Paenibacillus vortex 58% 
 PPTase 7 4'-phosphopantetheinyl transferase Sorangium cellulosum  41% 
     
8 PPTase 8 4'-phosphopantetheinyl transferase Microcoleus vaginatus 47% 
     
9 PilT  twitching motility protein PilT  Heliobacterium modesticaldum 51% 
 PPTase 9 4'-phosphopantetheinyl transferase Stigmatella aurantiaca  40%  
     
10 PPTase 10 4'-phosphopantetheinyl transferase MtaA  Acidobacterium capsulatum  41% 
 Iso* isopropylmalate isomerase large subunit Roseovarius sp. 217 41% 
 Mem membrane protein  Ramlibacter tataouinensis  27% 
     
11 PPTase 11 4'-phosphopantetheinyl transferase  
 
Nostoc punctiforme PCC 73102 46% 
 Amp  AMP-dependent synthetase and ligase  Bacillus tusciae  47%  
     
12 MDB*  molybdopterin binding aldehyde oxidase 
and xanthine dehydrogenase  
Desulfotomaculum reducens 44%  
 DNA replicative DNA helicase domain protein 
 
Borrelia afzelii PKo 33% 
 PPTase 12 phosphopantetheine-protein transferase  Microcoleus vaginatus  37%  
     
13 PBP polysaccharide biosynthesis protein  Rhodoferax ferrireducens T118 43% 
 PPTase 13 putative 4'-phosphopantetheinyl transferase  Candidatus Nitrospira defluvii 36% 
     
14 PPTase 14 phosphopantetheinyl transferase uncultured gamma 
proteobacterium 
HF4000_48E10 
40% 
ORF names are given on the basis of top previously characterised match (lowest e value) as identified in 
BLASTX alignments. *Indicates ORFs where the top match was a hypothetical protein. 
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4.2.3.1 PPTase activity of hits from NZ library within the 
EcoBlue1, EcoBlueP and EcoBlueE 
As with the Swedish library, we wanted to see whether certain clones could only have been 
recovered using specific bpsA reporter strains. The NZ soil library was not thought to be screened 
to saturation (the NZ library was a larger size than the Swedish library, with fewer redundant hits 
found overall), and it was reasoned that testing the activity of each PPTase in each strain might 
provide an estimate of how close to being screened to saturation the NZ library was. For instance 
only three unique hits were found in EcoBlueE, so this was a way of testing how many more of the 
14 total hits could be recovered using EcoBlueE.  
To test this, each of the 14 unique clones found in the NZ soil library were used to transform into 
each of EcoBlue1, EcoBlueP, and EcoBlueE. These were then plated out onto identical auto-
induction plates so that the density of cells on each plate was approximately 100 colonies. After 
initial overnight growth at 37 °C, plates were incubated at room temperature for seven days and 
the time for blue colour to develop was observed. Results are summarised in Table 4.5. The 
number of ticks indicates time for blue colour to develop. Three ticks indicates the blue colour 
developed on the first day, two ticks indicates blue colour development after two days, and one 
tick indicates a faint blue colour developed within three to seven days. A cross indicates no blue 
developed within the seven days.   
Table 4.5 Cross reactivity of all NZ clones in each reporter strain 
Hit Found in Level of activity 
EcoBlue1 EcoBlueP EcoBlueE EcoBlue1 EcoBlueP EcoBlueE 
1 N Y N    
2 Y Y Y    
3 Y Y N    
4 Y Y Y    
5 Y Y Y    
6 N Y N x  x 
7 N Y N x   
8 Y Y N   x 
9 Y Y N   x 
10 Y N N   x 
11 Y N N    
12 Y N N    
13 N N Y    
14 Y Y N    
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The results seen here (Table 4.5), indicating which clones are capable of giving rise to indigoidine 
production when expressed in each of the bpsA variant containing strains, were not consistent 
with which strains these clones were actually found in (Figure 4.6). While there were two instances 
of such inconsistencies when the same experiment was run for the Swedish soil library, there were 
many more such instances here, where a clone was not found in a particular strain yet was still 
able to activate the bpsA variant within that strain. It was suspected that this library had not been 
screened to saturation, and these results confirmed that.  Nonetheless, it was demonstrated that 
(similar to the Swedish library) the complete set of hits could not be found with EcoBlue1 alone, 
with two out of 14 clones showing no activity in this strain. Interestingly, all clones in this instance 
had activity in the EcoBlueP strain, meaning we could have screened with this reporter alone and 
still have recovered all of the hits. As this library was not screened to saturation however, we 
cannot state that this is the case within the whole library.  
4.3 Discussion 
The discovery that the vast majority of bacteria cannot be cultured effectively in the lab has 
prompted widespread efforts to find other ways of accessing the natural product biosynthetic 
genes of uncultivable microorganisms, as bacteria have been such a rich source for drug discovery 
from natural products in the past. Here we describe a novel method, a relatively simple screen 
based on the function of PPTase enzymes. PPTases activate both NRPSs and PKSs - secondary 
metabolite genes responsible for many bioactive natural products. We hypothesised that PPTase 
genes would co-localise with their biosynthetic counterparts, and that by finding PPTase genes we 
could then pull out associated NRPS or PKS genes. The functional screening approach described 
here has several advantages, including the relative ease and high throughput nature of the screen 
which means a large number of potential hits can be screened quickly and easily. Another 
advantage of a function based screen over a sequence based screen is that it doesn’t require prior 
knowledge of exact sequences or a specific product. As long as a biosynthetic gene cluster is found 
alongside a PPTase then the gene cluster itself could code for anything, making it more likely to 
discover clusters that encode entirely new structures. Indeed, many of the secondary metabolite 
genes we did find shared very low sequence identity with any known genes. 
This novel metagenome screening method was successful in finding 21 previously undiscovered 
PPTase genes, including several that were associated with NRPS and/or PKS biosynthetic gene 
clusters. As PPTases are not always found directly near the genes for their substrates we did not 
expect to find evidence of these secondary metabolite genes in every hit.  Still, this method has 
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proved to be a powerful enrichment tool, with a minimum of eight out of the total 21 clones found 
from both libraries containing evidence of these secondary metabolite genes, around 40% of the 
hits If we take in to account that these are small inserts, where we can’t always see sufficient 
genes present upstream or downstream of the PPTase gene to be confident that they are not 
within a biosynthetic cluster, the actual hit rate is likely even higher.    
The types of biosynthetic genes recovered included not only core NRPS and PKS genes (for 
example the A domain of an NRPS (Clone 7 from the Swedish soil library) or the “polyketide 
synthase” gene (Clone 1 from the Swedish soil library) found in the Swedish soil library), but also 
NRPS or PKS tailoring domains or other associated genes. Examples of these tailoring domains 
include glycosyl transferase (Clone 7 from the NZ soil library) or methyltransferase (Clone 6 from 
the Swedish soil library) domains. 
While this experiment has shown this approach to be a successful one on the small scale, we were 
only using very small insert DNA libraries, the largest insert recovered being approximately 5 kb 
(Clone 7 in the Swedish soil library) whereas most were much smaller (1-2 kb). Secondary 
metabolite gene clusters can be up to 100 kb or larger. In order to find whole secondary 
metabolite gene clusters, libraries with a much larger insert size need to be screened. For this, 
specialised plasmids such as cosmids, fosmids and bacterial artificial chromosomes (BACs) could 
be used. These allow much larger lengths of DNA to be screened, around 40 kb for fosmids and 
cosmids or 150-350 kb for BACs. These types of libraries tend to be much harder to make and 
might lead to lower hit rates, e.g. due to potential problems with expression of genes (if a PPTase 
gene was in the in middle of a large insert and not near any promoters that E. coli can recognise). 
However, with these larger insert libraries there is the potential to discover entire secondary 
metabolite gene clusters. An advantage of this would be that if the PPTase is expressed well and 
functional in E. coli (as it must be, to be found in the screen) then this may increase the likelihood 
of any secondary metabolite genes being expressed in a functional form also.  
As well as a method for discovering new natural product biosynthetic genes, this screen is also 
able to uncover new PPTase enzymes. There has been no direct screen for these enzymes in the 
past. This is of interest because of the many biotechnological applications of PPTases. The further 
characterisation of the PPTases, initiated in this chapter, was expanded in research described in 
the next chapter of this thesis. As well as allowing the discovery of totally new PPTases, the nature 
of the screen whereby we use different evolved variants of bpsA that contain alternative carrier 
protein domains means that we may also be able to pre-select for PPTases that have different 
carrier protein specificities. Table 4.3 and Table 4.4 suggest that each PPTase has a range of 
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activities with the different reporter strains. This is of interest for several applications of PPTases, 
for example site specific protein labelling, where more specific PPTase CP pairs may broaden the 
applications of the current technology. This property will be explored further in chapter Five. 
An unusual and unexplained result is the small number of blue colony hits found in EcoBlueE 
compared with the other two strains using the NZ soil library, where only five blue colony hits 
were found in EcoBlueE, compared to 40 in EcoBlue1 and 34 in EcoBlueP. When screening the 
Swedish soil library, a similar number of hits (50-60) were found in all three strains. This suggests 
that we can rule out the entF-substituted bpsA being less active in general. 
Screening both of the eDNA libraries with CP-substituted bpsA variants in addition to the WT bpsA 
gene proved to be a valuable strategy for uncovering an even greater range of PPTases and thus 
biosynthetic gene clusters. A total of five of the hits found from both libraries would not have been 
discovered with WT bpsA alone, due to the apparent inability of the PPTase enzyme to recognise 
and activate the native CP from bpsA. It seemed likely that there were many more PPTases present 
in the eDNA sample than the screen with WT bpsA was picking up. Indeed, it is probably still the 
case that there are even more PPTase containing inserts in both libraries that remain 
undiscovered. Possible reasons for this include that the three CPs used may not be sufficiently 
diverse, and screening with even more still may increase the numbers of hits recovered. The 
PPTase enzymes may also have had trouble being expressed in E. coli.. This however can also 
potentially be an advantage, as we may be selecting for enzymes that express easily in E. coli and 
so by not finding any poorly expressing enzymes we will avoid downstream expression and 
solubility issues. Another potential reason for not finding hits is that a relatively large proportion 
of eDNA may have contained incomplete PPTase genes.  
Since publication of our screen (Owen et al., 2012) , other labs have adopted a similar approach. 
One screen for PPTase activity inspired by our research involves using a PPTase knock out strain 
of a bacterium that employs NRPS enzymes to make a siderophore; i.e., a secondary metabolite 
used to scavenge iron from iron restricted environments (Charlop-Powers et al., 2013). Here, 
libraries were screened on iron-restricted agar plates (to which a chelating agent had been added), 
and the presence of a PPTase within the eDNA meant siderophore production pathways could be 
activated and bacteria were able to grow. eDNA from these colonies was then isolated and 
PPTases were identified along with genes for potential secondary metabolite products. Proof of 
principle for this was demonstrated in two systems, E. coli with entD knocked out and 
Pseudomonas aeruginosa with pcpS knocked out. This screen can only find PPTases capable of 
activating both entF and entB (E. coli enterobactin CPs) in E. coli or all the PCP domains of the P. 
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aeruginosa pyoverdine synthetases. The P. aeruginosa pcpS gene is essential and for this screen 
to work a special strain needs to be used which has pcpS knocked out and replaced with acpS 
(Barekzi et al., 2004). This knockout is still viable, as acpS activates primary metabolism pathways, 
but is unable to activate the pathways of secondary metabolism. Overall this knock out screen 
proved to be a powerful enrichment tool, resulting in 20-50 fold enrichment for NRPS and PKS 
genes (Charlop-Powers et al., 2013). It should be noted however that this screen is dependent on 
having a PPTase knockout strain available, and will only find PPTases capable of activating all CP 
domains of the strain used.  
While all of the PPTase enzymes discovered in this screen had homology to other known PPTases, 
this method could theoretically be used to find other genes with PPTase activity that may not 
share homology with known PPTases, i.e. a presently unknown class of PPTase. There has never 
been in the past a method to screen directly for and discover new PPTase activity like this. One of 
the big advantages of function based screens when compared to sequence based is that as long 
as a gene expresses a certain function, it does not matter if the sequence is known or not. During 
the course of this project it was thought that this screening method had uncovered a new type of 
PPTase, with a clone that was recovered three times and had a very small insert size (only 942 bp 
long), the top BLASTX match for which was a hypothetical protein (which contained a “domain of 
unknown function 1257”), this hit was not pictured in Figure 4.6. It appeared that this plasmid was 
conferring a PPTase activity and being such a small ORF it seemed obvious (at the time) that this 
must encode a PPTase enzyme. Extensive time and effort was spent on analysing this clone. Firstly 
it was attempted to clone any possible ORFs present in the insert (two small ORFs were 400-450 
bp each), but when this was unsuccessful in producing a functioning PPTase product, progressively 
smaller sections of the ORF were also cloned, to try and determine minimum sequence which 
would give PPTase activity. This eDNA plasmid was then tested for its ability to complement a 
ΔentD strain, when grown on iron restricted (i.e. to show a different measure of PPTase activity- 
not just the activation of BpsA). It did not show the ability to complement entD. Two 
cyanobacterial genes with the same “domain of unknown function 1257” were also cloned and 
tested for the ability to activate BpsA, but they were also unable to. Nonetheless, when this hit 
was tested for activity from the original glycerol stock, indigoidine production was still seen. These 
cells were then passaged in order to lose the eDNA containing plasmid to test whether there was 
something strange about the strain that had caused auto-activation of BpsA. Eventually after 
multiple time resequencing the eDNA insert, it became apparent that there had been two eDNA 
insert containing clones present in the cell of the original hit strain- in two of the hits this was 
Clone 2 and in one Clone 4 (from the NZ soil library). It appears that the plasmid containing the 
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gene for the hypothetical protein must have been transformed into the same cell as each other 
originally in a double transformation event. Upon further research it was discovered that this kind 
of double transformation event can actually be quite common, with one test showing double 
transformants present when as little as 5 ng total DNA was used (Goldsmith et al., 2007). In the 
transformation of libraries for this study, between 50 and 100 ng of DNA was used, so this explains 
the presence of these double transformants. In the future this is something that needs to be taken 
into account when preparing such libraries, and much smaller concentrations of DNA should 
perhaps be used.  
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Chapter 5: BpsA as a tool to characterise PPTase 
enzymes 
5.1 Introduction 
As a consequence of the metagenomic screening method employed in Chapter 4 for the discovery 
of new biosynthetic gene clusters, a number of novel PPTase genes were also discovered. These 
are referred to here as the “eDNA PPTases”, with the PPTases from Clones 1-7 of the Swedish soil 
library referred to as PPTases Sw 1-7 and the PPTases from Clones 1-14 of the NZ soil library 
referred to as PPTases NZ 1-14. PPTases themselves are of interest for a number of different 
biotechnological applications, e.g. for use in the site specific labelling of proteins. In particular, 
PPTases that have a high degree of specificity for a CP domain substrate hold potential for many 
applications. The 21 eDNA PPTases discovered in Chapter 4 were of particular interest as it 
appeared that they intrinsically possessed a relatively high degree of specificity for the CP domains 
with which they were discovered. To further test this, in the research described in Chapter 4 each 
PPTase-containing eDNA insert was tested for the ability to activate the three different BpsA 
variants (Tables 4.3 and 4.6). Some of the PPTases appeared to be highly specific, having the ability 
to activate one or two of the BpsA substitution variants but not all of them (for example, for 
PPTase Sw 6 indigoidine production was only seen in the EcoBlueE strain; while for NZ 6 
indigoidine production was only seen in the EcoBlueP strain).  
In order to further examine the activity of these eDNA PPTases, the individual genes for each of 
the PPTases were cloned as part of work presented in this chapter, and further characterised using 
BpsA-coupled assays. Historically, methods for characterising PPTases have been both time 
consuming and laborious, which has meant very few of the PPTases described in published 
literature have been characterised in vitro at a kinetic level. As of the recent review by Beld et al 
(2014), only seven PPTases had been described kinetically. Methods more recently developed in 
our lab which involve the monitoring of the PPTase reaction by coupling it to the BpsA indigoidine 
synthesis reaction provide a less cumbersome means of measuring PPTase activity. These BpsA 
based assays were used here to further characterise the 21 eDNA PPTases described in Chapter 4. 
Under this closer examination, it appeared that many of the eDNA PPTases had relatively low 
activities overall. They were also far less specific (in terms of their preferences for certain CP 
domains) than had been anticipated based on the work described in Chapter 4. The scope of the 
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current chapter was therefore broadened to include other, already known PPTase enzymes. These 
had been characterised before to varying extents, and the BpsA based assays were used here to 
expand on the existing knowledge of these enzymes.    
5.1.1 Traditional methods of PPTase characterisation  
Traditionally, methods for measuring the kinetic activity of PPTases have been technically 
challenging and time consuming. The formation of the activated holo-CP product by a given 
PPTase could be monitored in one of two ways, either through the incorporation of radiolabelled 
[H3-pantetheine]-CoA onto the activated holo-CP, followed by quantification using liquid 
scintillation counting (Gehring et al., 1997; Quadri et al., 1998; Sanchez et al., 2001), or through 
HPLC analysis of the CP domains to quantify the relative levels of apo and holo CP domain based 
on their difference in size (Finking et al., 2002; Huang et al., 2006). Both methods have also been 
used to determine simply whether or not a PPTase is capable of activating a particular CP domain. 
Where a range of substrate concentrations are tested these methods can be used to determine 
kinetic parameters. However, these assays are all end point assays, and the PPTase reaction 
cannot be monitored in real time.   
5.1.2 BpsA as a method for determining PPTase kinetic 
parameters 
In our lab a new method of measuring PPTase kinetics, based on the enzyme BpsA, was previously 
developed (Owen et al., 2011). This assay is based on the fact that the rate of indigoidine synthesis 
is directly proportional to the amount of holo-BpsA present. The rate at which indigoidine 
synthesis increases over time is therefore proportional to the rate at which a PPTase activates 
BpsA. This can be measured in a simple assay by measuring the absorbance at OD590 (i.e., levels of 
indigoidine synthesis) over time. The data for the reaction velocity was found to fit a Michaels-
Menten model, allowing kinetic parameters to be determined. This method was used to 
determine the kinetic parameters for three PPTases: Sfp, PcpS, and PP1183 (Owen et al., 2011). 
The data obtained for Sfp and PcpS (with respect to CoA as the variable substrate), was in 
reasonable agreement with previously determined values. This method has since been used in the 
characterisation of several other PPTases (Vickery et al., 2014; Zimhony et al., 2015). 
5.1.3 Competition assay with BpsA 
While measuring kinetic parameters in a BpsA coupled assay gives data for a PPTase in relation to 
its ability to activate BpsA (in particular the CP domain of BpsA), it does not provide any 
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information about the ability of a PPTase to activate other CP domains. For this an additional assay 
also developed in our lab, the BpsA competition assay, can be performed (Owen et al., 2011). In 
this assay a PPTase is incubated with BpsA, a limiting amount of CoA, and varying amounts of the 
target CP domain, which then “compete” with BpsA for the limited pool of CoA. The amount of 
holo-BpsA at each concentration of competing CP is determined via analysis of the indigoidine 
synthesis rate (Figure 5.1). An IC50 can be calculated, which represents the CP domain 
concentration at which the CP is able to compete for 50% of the available CoA, i.e. where the rate 
of activation of both BpsA and the competing CP by the PPTase is equal. Where a PPTase has a 
greater preference for the competing CP domain over BpsA, then the IC50 value will be lower. If a 
PPTase was unable to activate the competing CP domain then this would manifest as the velocity 
of the indigoidine synthesis reaction remaining constant, independent of the concentration of 
competing CP domain.  
 
Figure 5.1 BpsA competition assay scheme. (1) A solution containing a mixture of BpsA (Blue) and a foreign 
CP (Green) is incubated with a PPTase and a limiting amount of CoA. (2) The PPTase transfers all available 
phosphopantetheine from the limited CoA to the BpsA enzyme and/or free CP, the amounts of each depend 
on the CP specificity preference of the particular PPTase (e.g. a preference for BpsA (left), or for the free CP 
(right)). (3) Amount of activated BpsA present is determined via the rate of indigoidine synthesis, from which 
the preference of the PPTase for any CP in comparison to BpsA is derived. 
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5.1.3.1 Candidate CP domain section for competition assays 
The competition assay allows assessment of PPTase activity with different CP substrates. For the 
work described in this chapter, a range of CP domains were selected for use in these assays: both 
type I and type II ACPs and PCPs.  CP domains were also selected on the basis of having been 
purified before, and found to remain primarily in the apo-form when expressed in E. coli. Already 
available as cloned individual CPs in the lab were the individual CP domain from BpsA (BpsA_CP) 
and the first CP domain from PvdD (PvdDCP1), both type I PCPs. Additionally, the CP from EntF 
(type I PCP) was cloned as well. As these were all type I PCPs, two type II PCPs were also selected; 
BlmI, a type II PCP from the bleomycin synthetase NRPS (Du and Shen, 1999) and SgcC2,a type II 
PCP from PKS responsible for the synthesis of the enediyne C-1027 (Van Lanen et al., 2005). Two 
ACP domains (a type I and a type II) were also chosen. MtaF is a type I ACP from a hybrid NRPS/PKS 
involved in myxothiazol synthesis (Gaitatzis et al., 2001) and TcmM is a type I ACP from the PKS 
responsible for tetracenomycin synthesis (Shen et al., 1992). BlmI and TcmM had been used as 
substrates for PPTase kinetic analyses before (Huang et al., 2006; Sanchez et al., 2001) whereas 
SgcC2 and MtaF had not. All CP domains used in this study are summarised in Table 5.1.    
Table 5.1 Carrier protein domains used in this study 
Carrier protein Type Species of origin 
BlmI Type II PCP Streptomyces verticillus 
SgcC2 Type II PCP Streptomyces globisporus 
MtaF Type I ACP Stigmatella aurantiaca 
TcmM Type II ACP Streptomyces glaucescens 
EntF Type I PCP E. coli   
PvdDCP1 Type I PCP P. aeruginosa  
BpsA_CP Type I PCP S. lavendulae 
 
5.1.4 Additional PPTases selected for characterisation 
A number of additional PPTases were selected for characterisation using the BpsA based assays 
once it became apparent that the majority of the eDNA PPTases had very low activity (too low to 
perform the competition assay with). Sfp was chosen as an internal control, as the most 
comprehensively analysed of the previously studied PPTases. Sfp has a broad CP substrate 
specificity, and has been shown to be active with ACPs, PCPs, and ArCPs from a number of different 
species. It is the PPTase for which the most kinetic studies have been performed (Finking et al., 
2002; Mootz et al., 2001; Quadri et al., 1998; Sanchez et al., 2001). The next PPTase chosen for 
further characterisation was Svp, from Streptomyces verticillus. This has been shown to be another 
broad acting enzyme that has activity with both PCP and ACP domains, and is also one of the few 
97 
 
PPTases for which a comprehensive kinetic analysis has been performed (Huang et al., 2006; 
Sanchez et al., 2001), which found it to have 346 fold greater activity than Sfp with a particular 
ACP substrate (Sanchez et al., 2001). Svp has since become more widely used for homologous 
expression of NRPS and PKS enzymes, and was used for the original homologous expression of 
BpsA (Takahashi et al., 2007). MtaA, from Stigmatella aurantiaca is also a broad specificity 
candidate, activating the NRPS/PKS hybrid (which contains both ACP and PCP domains) 
responsible for the production of the antibiotic myxothiazol. It has been shown to be able to 
activate both ACP, ArCP and PCP domains, although it has not been kinetically characterised 
before (Gaitatzis et al., 2001). Its broad range of activity has also led to its use in heterologous 
expression applications, including recently for the heterologous expression of the BpsA 
homologue, IndC, in E. coli (Brachmann et al., 2012). Gsp, from Bacillus brevis was discovered 
around the same time as Sfp, and has been found to complement Sfp (Borchert et al., 1994), as 
well as Lys5 (Mootz et al., 2002b) and AcpS (Mootz et al., 2001). The fact that it can complement 
type I and type II PPTases means it is regarded as having a broad substrate specificity, though it 
has never been tested directly for activity with a range of CP domain substrates, or kinetically 
characterised. It has however been used for the heterologous expression of NRPSs in E. coli (Ku et 
al., 1997).  The final PPTase selected for characterisation in the present work was EntD, the PPTase 
involved in enterobactin synthesis in E. coli, and which was also one of the first classified PPTases 
(Lambalot et al., 1996). Lambalot et al. showed that in vitro EntD activated the PCP from EntF, and 
had a very low activity level with ACP, despite being unable to complement an AcpS deletion 
(Barekzi et al., 2004; Flugel et al., 2000). However, EntD has not previously been tested directly 
for activity with a wide range of CP substrates nor characterised kinetically. Additionally we 
examined the PPTase from Pseudomonas syringae pv. phaseolicola 1448A (PPT1448a), which had 
not been characterised before at all. The PPTases selected for study in this chapter are listed in 
Table 5.2. 
Table 5.2 PPTases used in this study 
PPTase Species of origin Reference 
Sfp B. subtilis (Quadri et al., 1998) 
Svp S. verticillus (Sanchez et al., 2001) 
Gsp B. brevis (Borchert et al., 1994) 
MtaA S. aurantiaca (Gaitatzis et al., 2001) 
EntD E. coli (Lambalot et al., 1996) 
PPT1448a P. syringae  This study 
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5.1.5 Aims 
 Clone each of the eDNA PPTases that was described in Chapter 4 into pET28a(+) and 
evaluate activity levels with available CP-substituted BpsA variants. 
 Establish conditions for the purification of eDNA PPTases and characterise them in vitro 
using the BpsA-coupled kinetic assay and competition assay.  
 Use BpsA based assays to further characterise the activity of a selection of other known 
PPTase enzymes with a range of CP domain substrates. 
5.2 Results I: Characterisation of the activity and 
specificity of the eDNA PPTases 
5.2.1 Activity of eDNA PPTases with three BpsA variants, as tested 
on solid media 
In the research described in Chapter 4, the specificity of each of the eDNA PPTases was assessed 
by expressing the plasmids containing the entire eDNA insert (which had been identified as 
containing a PPTase gene) in each of the EcoBlue1, EcoBlueP and EcoBlueE strains. To objectively 
test the activity of each of the PPTases, the individual PPTase genes (hits Sw 1-7 and NZ 1-14) were 
isolated and cloned from their respective eDNA inserts into the pET28a(+) expression vector. For 
three of the PPTases (Sw 4 and 7, and NZ 3), it was unclear where the exact ORF for the gene 
started, with each of these three hits having two potential start codons. These PPTases were 
cloned twice, with each potential start codon, resulting in a full length gene and either a 
potentially truncated or extended version (with the longer ORF referred to as “a” and the shorter 
as “b”). 
The pET28(+) constructs containing each of the eDNA PPTase genes were then used to transform 
each BpsA variant strain (EcoBlue1, EcoBlueP, and EcoBlueE). Each of the resulting strains was 
then plated on auto-induction plates at a density of approximately 100 colonies per plate, and the 
amount of time taken for pigment production was recorded. The results for this experiment are 
shown in Figure 5.2, with the shade of blue indicating the activity levels of each PPTase within 
each BpsA variant strain, with darker blue indicating faster indigoidine production and therefore 
greater activity of a particular PPTase with the corresponding CP domain substrate. 
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PPTase Relative level of activity in 
EcoBlue1 EcoBlueP EcoBlueE 
Sw     1       
2    
3    
4a         
4b    
5    
6    
7a    
7b    
 
NZ     1    
2    
3a    
3b    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
Figure 5.2 Analysis of relative activities for cloned eDNA PPTases in the three CP-substituted BpsA 
reporter strains EcoBlue1, EcoBlueP and EcoBlueE. Each strain (EcoBlue1, EcoBlueP and EcoBlueE) 
containing each of the cloned eDNA PPTases was plated out at a density of approximately 100 colonies per 
plate on auto-induction pigment producing plates and incubated at room temperature after overnight 
growth. Dark blue shading indicates indigoidine synthesis was seen within the first 24 h, mid blue indicated 
it was seen at 24-48 h and for light blue indigoidine synthesis was seen after 48 h. White indicates no 
pigment production after four days of observation. 
 
The levels of activity recorded here for each PPTase with the three different CP domain substrates 
were different from the levels of activity that were described in Chapter 4 when plasmids 
containing the entire eDNA insert were tested in a similar fashion. In most cases the activity level 
seen here for the cloned PPTases was either the same or improved when compared to the whole 
eDNA inserts. In some cases activity was seen here where none was observed for the 
corresponding construct previously. For example, when tested in the work described in Chapter 
4, hits NZ 6 and 7 were completely inactive when expressed in EcoBlue1 and hits NZ 8, 9, and 10 
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were all completely inactive when expressed in EcoBlueE. Here, all of those combinations resulted 
in indigoidine synthesis. In fact, PPTase NZ 6 was so active with WT BpsA that indigoidine was 
produced in the EcoBlue1 strain within the first 24 h. The differences seen may reflect that some 
of the PPTases did not express well when present in the middle of a larger eDNA insert (perhaps 
due to inability of E. coli to effectively recognise the native gene promoter in the eDNA construct). 
However, possibly as a consequence of the increased levels of expression leading to heightened 
activity, none of the eDNA PPTases exhibited the same degree of specificity here that they had 
appeared to possess in the research presented in Chapter 4, with every eDNA PPTase clearly 
demonstrating at least some activity with every CP-substituted BpsA variant tested.  
For each of the PPTases where two possible ORFs had been cloned, the shorter one in every case 
had less activity, indicating that the longer ORF was likely the correct gene sequence. For NZ 3 the 
truncated version (NZ 3b) did show a degree of specificity, having a small amount of activity when 
expressed in EcoBlueP alone; however this activity was so small overall it is unlikely to be of use 
in any downstream applications. For the other two PPTases (Sw 4 and 7), the longer (likely full 
length genes) did have more activity, but there was not a substantial difference between the two 
versions. The difference in lengths was greater for these two sets of genes than for the NZ 3 
constructs (Sw 4a and 7a were 38 and 28 residues longer respectively, compared to NZ 3a being 
only 20 residues longer than NZ 3b). 
5.2.2 Expression of eDNA PPTases 
The eDNA PPTase pET28(a)+ constructs were used to transform BL21 (DE3) cells in order to enable 
purification of the PPTases for in vitro tests. PPTases are generally difficult enzymes to purify, with 
most expressed as insoluble proteins under standard protein expression conditions in E. coli 
(Huang et al., 2006; Rottier et al., 2013). Most PPTases require expression at low temperatures in 
order to obtain enough soluble protein. For each of the 21 eDNA PPTases (24 if including the 
truncated versions of Sw 4 and 7, and NZ 3) discovered in Chapter 4, multiple expression 
conditions were tested, in order to find a subset of PPTases that could be purified and studied in 
vitro. Initially several different chaperone strains were tested with three of the PPTases, however 
this approach did not result in greatly increased solubility compared to expression in BL21(DE3) at 
low temperatures and was not investigated further. Instead a variety of media conditions were 
tested for their ability to improve solubility at the standard low expression temperature of 18 °C. 
The first media condition investigated was the use of the media supplements glycine-betaine and 
sorbitol. High concentrations of sorbitol increase osmotic stress and promote uptake of glycine-
betaine which acts as a chemical chaperone (Blackwell and Horgan, 1991; Oganesyan et al., 2007). 
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The use of auto-induction media was also tested; this method has been shown to greatly increase 
protein yields and can greatly increase the amount of soluble protein expressed (Studier, 2005).  
Each of the eDNA PPTases was tested for expression levels on a small scale (in 10 ml cultures) with 
the following four expression conditions: LB media at 37 °C, LB media at 18 °C, LB media with 1 M 
sorbitol and 2.5 mM glycine-betaine at 18 °C (each using IPTG induction at a final concentration 
0.5 mM), and auto-induction media at 18 °C. After expression, cultures were lysed by French-press 
and soluble and insoluble fractions were separated by centrifugation. The insoluble fractions were 
subsequently re-solubilised in 6 M urea and samples were analysed on SDS-PAGE gels. The media 
conditions that resulted in the highest amounts of soluble protein varied for each PPTase, though 
18 °C was clearly the best temperature for expression with none of the proteins soluble at 37 °C. 
Figure 5.3 shows a representative example of the SDS-PAGE gels for three PPTases (Sw 3, NZ 1, 
and NZ 7) expressed under each of the four conditions. Sw 3 (Fig 5.3 A) was insoluble under all 
conditions, and was never able to be purified. Both NZ 1 and NZ 7 (Fig 5.3 B and C) were able to 
be expressed as soluble proteins in all media conditions at 18 °C, and were both later expressed 
on a large scale (in 400 ml) in LB at 18 °C for purification.  
Ultimately, of the 24 eDNA PPTases tested (which included the three truncated genes), sufficient 
levels of soluble protein to continue with large scale expression and purification were observed 
for 13. 
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Figure 5.3 SDS-PAGE gels showing relative soluble and insoluble protein expression levels for eDNA 
PPTases Sw 3, NZ 1 and NZ 7 under four different expression conditions. The eDNA PPTases A) Sw 3, B) 
NZ 1 and C) NZ 7 were expressed in 10 ml cultures under four different conditions: in LB media at either 37 
°C or 18 °C (LB37 and LB18), auto-induction media at 18 °C (AI18), and in LB media with glycine-betaine 
and sorbitol as supplements at 18 °C (BS18). With the exception of the auto-induction media, expression 
was induced by addition of IPTG to a final concentration of 0.5 mM. Cells were lysed via French press and 
soluble (S) and insoluble (I) fractions were separated via centrifugation. Resultant fractions were run on an 
SDS-PAGE gel. The predicted molecular weights (based on gene sequence) of each protein is: Sw 3- 30.4 
kDa; NZ 1- 28.5 kDa and NZ 7- 30.4 kDa. Asterisks indicate the size of each protein.  
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5.2.3 Purification of PPTases 
Where adequate levels of soluble protein were seen during small scale expression tests, the 
corresponding conditions were employed for the large scale (400 ml culture) expression of the 
protein, which was then purified using nickel affinity chromatography. Cells were lysed using the 
French press, as detergent methods for lysis were found to result in non-functional protein. 
Amendments to the standard nickel affinity chromatography method for the purification of 
PPTases are as described in section 2.8.5.2. The thirteen PPTases that were purified are displayed 
on an SDS-PAGE gel (Figure 5.4). Only one hit from the Swedish soil library (Sw 4 in both its full-
length and truncated forms) could be purified. There were eleven hits from the NZ soil library that 
were purified. For all PPTases, relatively low amounts of protein were purified, with 
concentrations of final 4 ml protein preparations ranging from approximately 5 µM to 30 µM. 
 
Figure 5.4 SDS-PAGE analysis of purified eDNA PPTases. SDS-PAGE analysis of eDNA PPTases immediately 
following purification and buffer exchange. NZ 1, 6, 7 and 14 were purified using LB18; NZ 2 was purified 
with BS 18, the rest were purified using AI18. The predicted molecular weights based on gene sequences 
are as follows: Sw 4a, 32.7; Sw 4b, 28.5; NZ1, 28.5; NZ 2, 28.4; NZ 3a, 27.8; NZ 4, 30.5; NZ 5, 27.6; NZ 6, 
30.9; NZ 7, 30.4; NZ 8, 29.8; NZ 9, 33.9; NZ 10, 33.0; NZ 14, 29.7. Asterisks indicate the size of each protein. 
 
5.2.4 Preliminary activity of purified PPTases 
Before PPTases were evaluated in kinetic experiments, they were first tested for preliminary 
activity to ensure they were active enough for these further tests. In order to accurately measure 
kinetics for a PPTase using BpsA, there needs to be a change in indigoidine synthesis over time, 
i.e. an acceleration in the reaction (Owen et al., 2011). If the activity of a PPTase was too low, then 
the rate of indigoidine synthesis appeared to be steady (i.e. the OD590 values as measured over 
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time appear as a straight line, with no acceleration increase towards a peak value) and accurate 
kinetics could not be determined.  
Preliminary tests were carried out as described in section 2.11.3, with purified PPTase enzymes 
set up as a serial dilution series, mixed with BpsA and the reagents required for the indigoidine 
synthesis reaction, and then the OD590 values were measured over time. An example of the results 
for three separate enzymes is shown in Figure 5.5. The decrease in absorbance values once a peak 
is reached is characteristic of the indigoidine synthesis curve, and may be due to a precipitation 
of indigoidine. Only the absorbance values before this peak is reached are used in any analysis. 
PPTase NZ 9 appears to be very active with the BpsA CP domain, resulting in a quick increase to a 
high maximum OD590 value. The other two PPTases appear to be less active, resulting in much 
slower reactions. The results cannot be compared directly due to the enzyme concentrations 
being different (the highest concentration possible was used for each purified PPTase, to maximise 
the often low enzyme activities). For instance the concentration for NZ 10 was almost twice that 
of the other two PPTases, indicating that it may be an even weaker enzyme than it appears in 
Figure 5.5.  
 
Figure 5.5 Example of the preliminary activity assay for three eDNA PPTases (NZ 9, NZ 3a and NZ 10). 
Preliminary activity assays were performed as described in section 2.11.3. The raw absorbance values at 
OD590 as measured every min are displayed for three PPTases (NZ 9, NZ 3a and NZ 10). Data is shown for 
one replicate of a triplicate data set. The concentration of NZ 9 used was 1.8 µM, NZ 3a was 1.6 µM and NZ 
10 was 3.5 µM. 
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There are several possible ways to quantify the activity of each enzyme in order to identify those 
with enough activity to perform a kinetic analysis (for example the peak OD590 value, the slope of 
the curve, or the time taken to reach the peak OD590 value). When each of these measures was 
compared they were found to give fairly consistent rankings from most active to least active 
PPTase for the tested enzymes (data not shown). As a simple measure for relative overall activity 
of the PPTase the “time to reach peak OD590” was recorded. The time for each of the purified 
PPTases to reach their peak OD590 as measured in the preliminary activity assay is listed in Table 
5.3, ranked for activity from most active to least active. NZ 9 was the fastest of all the enzymes 
measured, with the times varying from 7.5 min (NZ 9) to 65 min (NZ 14). NZ 6, 7, and 8 are not 
displayed in this table as they displayed no activity over the time period measured even at the 
highest PPTase concentration.   
Table 5.3 Time for PPTase to reach peak OD590 in preliminary activity assay 
PPTase Time at which peak was reached (min) 
NZ 9 7.5 
NZ 1 9 
Sw 4a 19 
NZ 2 24 
NZ 5 26 
NZ 3a 28 
NZ 10 45 
Sw 4b 59 
NZ 4 62 
NZ 14 65 
 
5.2.5 Kinetics for the most active eDNA PPTases via BpsA assay 
The top six hits as determined in section 5.2.4 were characterised further, using the BpsA assay, 
to derive kinetic parameters as described in section 2.11.4.  The PPTase Sw 4b was also tested, in 
order to compare it to Sw 4a. The Michaelis-Menten curves for each of the top three enzymes are 
given in Figure 5.6, with separate graphs shown for the most active hit (NZ 9, Fig 5.6 A) and the 
next two most active hits (NZ 1 and 2, Fig 5.6 B), due to the large difference in velocity values. The 
remaining four enzymes tested had substantially lower velocities and are not illustrated here. The 
kinetic parameters for all seven enzymes (as measured with CoA as the variable substrate), are 
given in Table 5.4.  
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Figure 5.6 Michaelis-Menten curves for the eDNA PPTases NZ 9 and NZ 1 and 2. Plots indicate the 
maximum velocity of indigoidine production at different concentration of CoA for A) NZ 9 and B) NZ 1 and 
NZ 2. Curves were fitted using Graphpad Prism® and used to derive kinetic parameters for each PPTase. 
Data points were generated from three repeats and error bars are +/- SEM.   
  
Table 5.4 Kinetic parameters of the most active eDNA PPTases with CoA as variable substrate 
PPTase Vmax (ΔA590.min-2.mM-1)  Km (µM) Vmax/Km (ΔA590.min-2.µM-1.mM-1)  
NZ 9 30.6 ± 1.14 0.56 ± 0.11 54.5 ± 10.4 
NZ 1 0.11 ± 0.033 0.63 ± 0.11 1.5 ± 0.26 
NZ 2 2.40 ± 0.088 2.5 ± 0.40 0.96 ± 0.16 
Sw 4a 0.045 ± 0.0027 1.28 ± 0.36 0.037 ± 0.010 
Sw 4b 0.026 ± 0.0013 1.13 ± 0.28 0.024 ± 0.0060 
NZ 5 0.11 ± 0.015 21.89 ± 7.72 0.0052 ± 0.0020 
NZ 3a 0.017 ± 0.00087 4.59 ± 0.91 0.0037 ± 0.00076 
 
PPTase NZ 9, identified in the preliminary tests as potentially the most active of the eDNA PPTases, 
did have the highest Vmax/Km (i.e., catalytic efficiency) compared to the other PPTases tested, and 
by this measure was 36 fold more active than the next most active PPTase (NZ 1) and more than 
10,000 fold more active than the least active PPTase that was tested (NZ 5). In general relative 
comparisons of the catalytic efficiency to the initial method of ranking the most active enzymes 
(the time to reach a peak OD590 value) were very consistent, and it appears that using this measure 
as an approximation of activity was justified. The main discrepancy is that Sw 4b had a higher 
catalytic efficiency than both NZ 5 and NZ 3a, when they had both reached the peak OD590 value 
in half the time that Sw 4a did. This may be explained by the fact that NZ 5 and NZ 3a had relatively 
high Km values, and in the preliminary tests the CoA concentration used was well above both of 
these Km values. Somewhat surprisingly Sw 4a and 4b had very similar catalytic efficiencies, despite 
4b being a truncated product and showing less activity with WT BpsA in the in vivo assay (section 
5.2.1), taking an extra 24 h for indigoidine production when expressed in EcoBlue1.  
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5.2.6 Assessment of NZ 9 activity with additional CP domains via 
the competition assay 
The eDNA PPTase that displayed the highest level of activity with BpsA, NZ 9, was examined 
further using the competition assay in order to identify which other CP substrates it could activate. 
NZ 9 was tested against the CPs from PvdD and EntF, and also four other CP substrates (see section 
5.1.3.1). IC50 values with each CP are given in Table 5.5. IC50 values were derived for every CP 
except for TcmM, as the data for this assay did not fit an IC50 curve.  
The curve generated with TcmM is shown alongside the curve for the CP domain that gave the 
lowest IC50 value (MtaF), in Figure 5.7 (the low IC50 indicates that NZ 9 has a preference for the 
MtaF domain (which is an ACP domain) as a substrate as compared to the BpsA CP domain). This 
preference for the MtaF CP domain does not appear to be a general preference for ACP domains 
as substrates, as the ACP TcmM was the CP domain with which NZ 9 had the least activity (too low 
for an IC50 value to even be calculated). Perhaps if higher still concentrations of TcmM had been 
available then the IC50 could have been calculated. Nonetheless, every CP domain tested in 
competition with BpsA for NZ 9 resulted in a decrease of indigoidine synthesis velocity, indicating 
that NZ 9 is a PPTase that has a broad substrate range.   
Table 5.5 IC50 values for NZ 9 with various CP domains 
CP domain IC50 (µM) 
BlmI 5.7 (5.4-6.2) 
SgcC2 1.2 (1.1-1.3) 
MtaF 0.34 (0.32-0.36) 
TcmM Undefined* 
EntF CP 4.8 (4.3-5.3) 
PvdDCP1 1.4 (1.3-1.5) 
*Too low for accurate measurement 
Parentheses indicate 95% confidence intervals 
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Figure 5.7 IC50 curves for NZ 9 with TcmM and MtaF as the competitive CP domains. Plots shown indicate 
indigoidine synthesis velocity values as a percentage of the maximum velocity for each PPTase/CP pair, at 
varying concentrations of the competing CP domain (either TcmM or MtaF) for the PPTase NZ 9. Data points 
were generated from three repeats and error bars are +/- one SEM. Four-parameter dose-response curves 
were generated using Graphpad Prism®, and used to derive IC50 values for each CP domain. 
 
5.3 Results II: Characterisation of the activity and 
specificity of additional PPTases 
Due to the inability to purify many of the eDNA PPTases and the generally poor activity levels of 
those that were purified, it was decided use the BpsA based PPTase characterisation assays on a 
selection of additional PPTases. The PPTases were mostly previously described enzymes that had 
had some degree of characterisation performed, as described in section 5.1.4. Four of the PPTases 
(Sfp, Gsp, Svp and MtaA) were ordered as codon optimised genes to minimise any problems with 
soluble protein expression. The other two genes (EntD and PPT1448a) were cloned from gDNA 
and so were not codon optimised. 
5.3.1 Solid media activity test with three BpsA variants 
Although most of the PPTases tested here (with the exception of EntD and PPT1448a) were known 
from previous work to have a broad substrate specificity, all were subjected to a rapid initial test 
for the substrate specificity by expressing each in the EcoBlue1, EcoBlueP and EcoBlueE strains 
and assessing indigoidine production on auto-induction agar plates as described in section 5.2.1. 
The results for this are seen in Figure 5.8. Most of the PPTases had high activity in all strains, with 
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PPT1448a (the only previously uncharacterised PPTase here) having the lowest activity, despite 
still showing some degree of activity across all strains.  
PPTase Relative level of activity in 
EcoBlue1 EcoBlueP EcoBlueE 
Sfp    
Svp    
Gsp    
MtaA    
EntD    
PPT1448a    
Figure 5.8 Cross reactivity of PPTases in the three BpsA variant strains, EcoBlue1, EcoBlueP and EcoBlueE. 
Each strain (EcoBlue1, EcoBlueP and EcoBlueE) containing each PPTase was plated out at a density of 
approximately 100 colonies per plate on auto-induction pigment producing plates. The level of activity for 
each cloned PPTase is represented by the shade of blue presented. Dark blue indicates indigoidine synthesis 
was seen within the first 24 h, for mid blue indigoidine synthesis was seen at 24-48 h and for light blue 
indigoidine synthesis was seen after 48 h. 
 
5.3.2 Purification and preliminary activity of PPTases 
Purification of the additional PPTases was more straightforward than was encountered with the 
eDNA PPTases, with all successfully expressed in large scale cultures (400 ml) in LB media at 18 °C. 
Proteins were purified via nickel affinity chromatography as in section 2.8.5.2. and analysed by 
SDS-PAGE (Figure 5.9). PPT1448a is the one exception that did not appear to have purified very 
well; the concentration of this protein was relatively low, which may in part be due to the fact that 
the gene encoding this PPTase was not codon optimised for expression in E. coli.  
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Figure 5.9 SDS-PAGE analysis of purified PPTases. SDS-PAGE analysis of PPTase proteins immediately 
following purification and buffer exchange. The predicted molecular weights based on gene sequences are 
as follows: Sfp, 28.3; Svp, 27.8; Gsp, 30.0; MtaA, 33.7; EntD, 25.8; PPT1448a, 25.6. Asterisks indicate the 
size of each protein. 
 
For each of the purified PPTases, preliminary activity was tested as in section 5.2.4, and the time 
taken to reach a peak OD590 value for each is given in Table 5.6. Three of the PPTases (MtaA, Sfp, 
Gsp) stand out as being substantially more active with the WT BpsA CP domain as substrate than 
the other three PPTases, reaching their peak OD590 in under 10 min. Both EntD and PPT1448a were 
less active with WT BpsA in the in vivo test in section 5.3.1, so it is not unexpected that these were 
two of the less active enzymes. The seemingly low activity for Svp however was unexpected; Svp 
was the PPTase originally used in the heterologous expression of BpsA (Takahashi et al., 2007) and 
so has been shown to have activity with BpsA.   
Table 5.6 Time for PPTase to reach peak OD590 value in preliminary activity assay 
PPTase Time at which peak was reached (min) 
MtaA 2 
Sfp 3.5 
Gsp 7.5 
EntD 44 
Svp 59 
PPT1448a 89 
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5.3.3 PPTase kinetics measured via BpsA assay 
Each of the PPTases was kinetically characterised for activity with WT BpsA, using CoA as a variable 
substrate. As expected the top three PPTases identified in the previous section had much higher 
activity levels than the remainder, and the Michaelis-Menten curves for these enzymes are 
presented in Figure 5.10. The corresponding kinetic parameters derived for each of the enzymes 
are listed in Table 5.7. For the enzyme PPT1448a, while activity was detected (i.e., slight increase 
in OD590 values over a period of 90 min) the reaction was not fast enough to enable kinetic 
parameters to be calculated.  
Sfp appeared to be the most active enzyme, with nearly four times the catalytic efficiency of the 
next most active enzyme, MtaA. The inability to derive kinetic parameters for PPT1448a was not 
surprising given the relatively low activity (Table 5.6) and the low amount of enzyme purified. This 
previously uncharacterised PPTase did however display the ability to activate BpsA, and perhaps 
if it had been possible to purify a greater amount of the protein then kinetics could have been 
measured. 
 
Figure 5.10 Michaelis-Menten curves for Sfp, MtaA and Gsp. Plots indicate the maximum velocity of 
indigoidine production at different concentrations of CoA for Sfp, MtaA and Gsp. Curves were fitted using 
Graphpad Prism® and used to derive kinetic parameters for each PPTase. Data points were generated from 
three repeats and error bars are +/- SEM. 
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Table 5.7 Kinetic parameters for various PPTases with CoA as the variable substrate 
PPTase Vmax (ΔA590.min-2.mM-1)  Km (µM) Vmax/Km (ΔA590.min-2.µM-1.mM-1)  
Sfp 1275 ± 17.3 0.161 ± 0.013 7919 ± 660 
Svp 0.021 ± 0.0006 0.23 ± 0.053 0.094 ± 0.022 
Gsp 150.4 ± 3.8 0.51 ± 0.069 292.7 ± 40.1 
MtaA 870 ± 15.88 0.435 ± 0.043 2003 ± 200 
EntD 5.3 ± 3 1.24 ± 0.28 4.3 ± 0.99 
PPT1448a n.a n.a n.a 
 
5.3.4 Assessment of activity levels for Sfp, Gsp, MtaA and EntD with 
various CP domains via a competition assay 
The four most active PPTases (having the highest catalytic efficiencies as described in Table 5.7) 
were each subjected to the CP domain competition assay to assess their activity with other foreign 
CP domains. Seven CP domains were tested for each PPTase, following the protocol in section 
2.11.5. The IC50 values for all possible PPTase/CP combinations are given in Table 5.8.  
Table 5.8 IC50 values (µM) for PPTases as determined in the CP domain competition assay 
CP Sfp Gsp MtaA EntD 
BlmI 2.3 (2.2-2.6) 14.7 (10.9-20.0) 6.5 (0.96-43.3) 20.0 (6.6-60.1) 
SgcC2 0.68 (0.65-0.71) 0.55 (0.52-0.59) 1.3 (1.1-1.4) 2.0 (1.2-3.3) 
MtaF 0.40** 0.76 (0.71-0.81) 1.5 (1.3-1.7) 18.8 (2.5-139.2) 
TcmM 39.4 (30.6-50.7) 22.4 (19.6-25.6) Undefined* 10.2 (3.4-16.5) 
EntF 6.0 (5.5-6.7) 5.2 (3.4-7.9) Undefined* 2.1 (1.5-3.1) 
PvdDCP1 1.8 (1.6-2.0) 0.92 (0.87-0.97) 0.86 (0.69-1.08) 1.9 (1.0-3.3) 
BpsA CP 0.51 (0.49-0.54) 0.48 (0.44-0.52) 0.68 (0.64-0.71) 7.3 (3.6-15.0) 
* Too low for accurate measurement  
**Confidence interval unable to be calculated 
Parentheses indicate 95% confidence intervals 
 
All of the PPTases tested were active to some degree with each of the CP domains, although the 
degree to which they were active with each did vary. In Figure 5.11, for each PPTase IC50 curves 
are displayed for three representative competing CP domains to demonstrate the range of 
activities that were seen with different CP domain substrates.  An unusual result was seen for Sfp 
and the CP domain MtaF (Fig 5.11 A). At low MtaF concentrations, BpsA activation was mostly 
complete, represented by 100% maximum velocity. Above the IC50 value (at the increased CP 
concentration), the velocity of the reaction dropped to 0%. This indicates that above a certain 
concentration of the MtaF CP there was no activation of BpsA at all, indicating Sfp had a powerful 
preference for MtaF over BpsA. Overall Sfp gave relatively low IC50s with most CP domains, 
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indicating an ability to activate all of the competing CP domains, as would be expected for this 
PPTase which has been widely described as having broad substrate specificity (Quadri et al., 1998). 
Gsp and MtaA also displayed relatively low IC50 values with most competing CP domains indicating 
that they also had broad specificities, on a comparable level with Sfp. EntD had higher IC50 values 
indicating it was less effective at activating this range of CP domain substrates. For EntD, the assay 
was also hindered by the fact that the activity of EntD with BpsA was so low (the catalytic efficiency 
differed from the other enzymes measured here by 2-3 orders of magnitude as measured in 
section 5.3.3), which is the reason for the large confidence intervals seen for the EntD IC50 values 
in Table 5.8. Interestingly EntD had a larger IC50 for the free BpsA CP domain compared to the 
other three PPTases, indicating that it may have a preference for activating CP domains (or at least 
the BpsA CP domain) when it is part of  a complete NRPS enzyme, compared to the CP domain 
alone. 
 
Figure 5.11 Representative IC50 curves for each PPTase with a range of competing CP domains. Plots shown 
indicate indigoidine synthesis velocity values at different concentrations of a competing CP domain, 
presented as a percentage of the maximum velocity value for a given PPTase/CP pair, for the PPTases A) 
Sfp, B) Gsp, C) MtaA, and D) EntD. Data points were generated from three repeats and error bars are +/- 
one SEM. Four-parameter dose-response curves were generated using Graphpad Prism® and used to derive 
IC50 values. 
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5.4 Discussion 
In this chapter the eDNA PPTases discovered in the metagenomics bioprospecting study described 
in chapter 4 were characterised further based on their activity and specificity in a series of BpsA 
based assays. All of these eDNA PPTases were found to have a broad ranging activity with a 
number of different CP domain substrates. Only a subset of these PPTases were characterised in 
vitro due to issues with soluble protein expression, and the majority of those that were able to be 
purified had low activity in in vitro tests. Due to the inability to characterise all of the eDNA 
PPTases, the scope of the chapter was broadened and the same BpsA based assays were also used 
to characterise the activity of several other previously identified PPTases. The simplicity of these 
assays allowed for a greater examination of the activity and specificity of some of these enzymes 
than had previously been described. Some of these selected PPTases had been characterised 
before in vitro, to varying extents (ranging from the well-studied Sfp to the PPTase PPT1448a, 
which had not before been characterised as a PPTase). This research provided confirmation that 
PPT1448a displays PPTase activity in vivo and in vitro (though activity with BpsA was too low for 
full kinetic or competition assays to be performed).  
The eDNA PPTases identified in Chapter 4 were tested here and found to be a lot less specific for 
certain CP domain substrates than they had first appeared to be, with expression of the individual 
cloned genes resulting in increased indigoidine synthesis in all three of the BpsA variant strains 
(EcoBlue1, EcoBlueP, and EcoBlueE) as compared to the expression of whole eDNA inserts. A 
contributing factor was likely that some of the PPTase genes may not have expressed well in their 
heterologous E. coli host when they were present in the middle of a larger eDNA insert, a factor 
in any functional metagenomic screening method (Gabor et al., 2004). The fact that activity was 
seen in at least one strain for each of the eDNA insert-containing plasmids indicated there was at 
least a minimal amount of PPTase expression from the eDNA plasmids. It was likely that this level 
of expression was the same across each of EcoBlue1, EcoBlueP, and EcoBlueE. The low expression 
levels of some of these eDNA inserts may have over-emphasised the extent of CP domain 
substrate specificity possessed by any individual PPTase. For example, in the present chapter it 
was shown that NZ 9 had a relatively low amount of activity with the EntF CP domain, both in vivo 
and in vitro, however this PPTase originally appeared to have no activity as an eDNA insert in the 
BpsA reporter strain EcoBlueE.  
An important part of the metagenomic screening strategy presented in the previous chapter was 
having multiple CP-substituted BpsA variants, which led to the discovery of a wider range of 
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PPTases and thereby associated natural product biosynthetic genes. Here however it has been 
shown that that the inability to recover all of the eDNA PPTases using WT BpsA alone was not 
because some of these PPTases were entirely incapable of activating WT BpsA. In fact, all of the 
discovered eDNA PPTases were able to activate WT BpsA quite effectively when expressed at 
higher levels in E. coli. From the work described in the present chapter it now seems that some of 
these PPTases had only appeared unable to activate WT BpsA because their eDNA expression 
levels were too low (yet still sufficient for them to activate alternative CP-substituted variants, 
enabling their discovery in either EcoBlueP or EcoBlueE instead). This suggests that another 
approach for improving the BpsA metagenome screening method, rather than attempting to 
create and then screen eDNA libraries with multiple CP-substituted versions of BpsA, would be to 
increase the expression levels of the eDNA inserts, for example by using alternative hosts instead 
of E. coli (Gabor et al., 2004; Troeschel et al., 2010). 
During the course of cloning the eDNA PPTases, three PPTases were cloned which had two 
different possible start codons, these were Sw 4 (construct 4a being 38 residues longer than 4b), 
Sw 7 (7a being 28 residues longer than 7b) and NZ 3 (3a being 20 residues longer than N3b).  The 
fact that the longer genes all gave greater levels of activity (as tested in vivo for Sw 4a and 4b, Sw 
7a and 7b, and NZ 3a and 3b (Fig 5.2), as well as in vitro for Sw 4a and 4b (the only pair able to be 
purified; Table 5.4)) suggested that the shorter versions were in fact truncated versions of the full-
length genes. In two previous studies looking at N-terminal truncations of PPTases, the truncated 
proteins have been completely inactive (Huang et al., 2006; Jiang et al., 2013), suggesting this 
region is important for protein function. This was consistent with the results seen for NZ 3, where 
the truncated protein was almost completely inactive (displaying only a small amount of activity 
when expressed in EcoBlueP and no activity in the other two strains). It was not however 
consistent with the other two truncations, which had much longer sections of the N-terminus 
removed yet still retained some activity (including almost equal in vitro activity in the case of Sw 
4a and 4b). This indicates that the N-terminus may not be strictly essential for PPTase function. It 
would be interesting to see if a compromise could be achieved whereby a portion of the N-
terminus is removed to generate a loss of activity with one substrate but not another, thereby 
increasing the specificity of a target PPTase. 
Overall the eDNA PPTases were generally difficult enzymes to purify and work with, though based 
on previous literature this is not entirely unexpected for PPTases. While a little over half were able 
to be purified, most of these had very low activity which made them difficult to characterise via 
the BpsA assays. One unusual result was the fact that three of the purified PPTases (NZ 6, 7 and 
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8) displayed no activity at all in vitro, even though all displayed a moderate level of activity with 
WT BpsA when expressed in EcoBlue1. For NZ 8 it may have been the case that not enough protein 
was purified, as only small amounts were detected. However for NZ 6 and 7 relatively large 
amount of protein were purified and yet absolutely no activation of BpsA was seen, even when 
assays were incubated for an extended time. This could indicate that these enzymes were highly 
unstable under the in vitro conditions that were employed.  
Of the eDNA PPTases that were characterised in vitro, NZ 9 was substantially more active than all 
of the other eDNA PPTases (although PPTases NZ 1 and 2 did have reasonable activity levels as 
well). NZ 9 was also shown in the competition assay to be active with all CPs tested, with similar 
IC50 values to the previously known broad specificity PPTases Sfp, Gsp and MtaA. This suggests 
that while none of the eDNA PPTases found may be particularly useful in applications that require 
highly specific PPTases, NZ 9 may be a good candidate for applications that require a PPTase with 
a broad range of activity, such as in the heterologous expression of NRPS or PKS genes.  
Of the additional non-eDNA PPTases that were examined, the activities of most were consistent 
with their previously described abilities to activate a wide range of substrates. Sfp, the standard 
broad range PPTase had activity with every CP tested in the competition assay. This was not 
unique however and Gsp and MtaA also showed the ability to activate a wide range of other CP 
domains. Each of the PPTases showed a different pattern for the CP domains they were 
preferentially able to activate. For example, Gsp had the greatest preference for the CP domain 
SgcC2, compared to its ability to activate BpsA and the other CP domains it was tested with, 
whereas Sfp had the greatest preference for MtaF compared to the other CP domains it was tested 
with. EntD exhibited some unusual results, for instance having a relatively high IC50 for the BpsA 
CP domain. A limitation of the results given for EntD is the low activity that EntD displayed with 
BpsA means these reactions were extremely slow, and as a result have a lot higher margin of error 
than all the other PPTases tested.  Unfortunately with the data presented in this chapter it is not 
possible to compare between the PPTase enzymes directly, as they all have different baseline 
levels of activity with BpsA. To measure kcat/Km for each PPTase/CP pair we would need to calculate 
the kinetic parameters for the PPTases with respect to the concentration of BpsA, not CoA as was 
performed here. This work will be performed in the future.  
An unusual exception for the additional PPTases tested in the in vitro assays was Svp. This has 
previously been shown to be a reasonably active PPTase (when tested kinetically alongside Sfp, a 
similar or better amount of activity was seen with several CP substrates, notably far greater 
activity with the CP TcmM as a substrate (Sanchez et al., 2001)). Particularly relevant here, Svp 
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was the PPTase to be used in the first heterologous expression with BpsA, and was shown to have 
the ability to activate BpsA in vitro (Takahashi et al., 2007). Yet in the present study Svp did not 
show enough activity with BpsA to even be tested in the competition assay with a wider range of 
CP domain substrates. It would have been interesting to see if Svp had a low IC50 value for the CP 
TcmM if we had been able to measure Svp in the competition assay, as all of the other PPTases 
tested with TcmM had a low degree of activity with it, compared to BpsA as measured in the 
competition assay. Svp did appear to be very active (with all CP-substituted variants) of BpsA when 
tested in vivo, which suggests that the purified protein may have been less stable under the 
conditions that were employed than the other proteins tested here. 
Overall every purified PPTase tested in this chapter could activate every CP domain substrate 
tested to at least some degree, indicating it is difficult to find PPTases that are specific towards a 
particular CP domain (which is a property desired in many applications). The research described 
in next chapter therefore adopted a directed evolution approach in order to alter the CP substrate 
specificity of the PPTase, EntD. 
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Chapter 6: Engineering the PPTase EntD for altered 
substrate specificity 
6.1 Introduction 
PPTases vary in the degree to which they are able to recognise and activate different CP domain 
substrates. Some have a narrow range of specificity for their native CP substrate, while others (for 
example the broad range PPTase Sfp) are active with a large number of different CP substrates. 
Generally  type II PPTases have a relatively broad substrate range, often showing substantial 
activity with non-cognate CP domains (Beld et al., 2013), which was also consistent with the results 
presented in Chapter 5. There are certain applications for PPTases, such as site-specific protein 
labelling, where it would be advantageous to have PPTases that exhibit a narrower substrate 
specificity. Earlier in this work it was thought that such PPTases may have been found in Chapter 
4, by virtue of the metagenomic screening method used (i.e. certain PPTases were only recovered 
when screening with BpsA variants containing a specific CP domain substitution). However, when 
these PPTases were examined in more detail in Chapter 5, all of them were found to be 
substantially less specific for individual CP substrates than preliminary results had suggested.  
An alternative approach to obtaining more specific PPTases is to engineer an existing PPTase 
enzyme to modify its specificity. This chapter describes the development of a screen to alter 
PPTase substrate specificity, retaining activity with one CP substrate and losing activity with 
another. The E. coli type II PPTase EntD was chosen for this proof-of-principle study. One 
advantage of using EntD was that the WT enzyme expressed well and was easily purified (as 
opposed to many other PPTases, including many of the eDNA PPTases examined in Chapter 5). 
Another advantage was the availability of a ΔentD E. coli strain which was created during the 
course of this thesis (Section 4.2.1). Here, this was used to screen for variants that were able to 
complement the ΔentD deletion. Evolved EntD variants that retained activity with the endogenous 
E. coli enterobactin synthetase NRPS enzymes were selected under iron restricted conditions, on 
the basis that only host cells able to produce enterobactin siderophore would be able to grow. 
These variants were simultaneously counter-selected for a loss of activity with the BpsA CP 
domain, measured by a loss of pigment production at a colony level. It was hypothesised that this 
dual positive and negative selection would enable identification of PPTase variants that had 
evolved greater specificity for the native enterobactin NRPS CP domains. 
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6.1.1 PPTases for site specific protein labelling 
Site-specific protein labelling is an approach that has a range of applications including the study 
of protein structure, dynamics and interactions (Foley and Burkart, 2007; Rashidian et al., 2013). 
One method for the site-specific modification of proteins is to use PPTases to add CoA-derived 
labels to CP-derived tags. In this method, a target protein is tagged with a CP domain or a smaller 
peptide tag that is also able to serve as a PPTase substrate, enabling the PPTase to attach a label 
derived from a modified CoA analogue. The types of CoA analogues that can potentially be used 
for this are varied, with many small molecules (e.g. fluorophores, biotin, quantum dots) able to be 
conjugated onto the thiol group of CoA (La Clair et al., 2004; Meier et al., 2006; Sunbul et al., 
2008). The tethered small molecules are then transferred onto the tag by the PPTase. Many of the 
PPTases previously studied in this regard (including Sfp and EntD) have been found to be relatively 
flexible in the CoA analogues that they can accept (Chen et al., 2009; La Clair et al., 2004). In 
structural studies of Sfp bound to CoA, the 3’-phospho-5’-ADP moiety was shown to be important 
in CoA binding, while the Ppant moiety did not play a significant role, an observation thought to 
explain this promiscuity towards CoA analogues with Ppant modifications (Reuter et al., 1999). 
The CP domains themselves are relatively small (80-90 amino acids), and so their presence may 
be less likely to disturb protein function than many other common labelling proteins which are 
much bigger (for example GFP is 238 amino acids long) (Rashidian et al., 2013; Yin et al., 2004). 
More recent developments evolving the CP domain substrate have led to even smaller, less 
obtrusive peptide tags, just 10-12 amino acids in length (Yin et al. 2005; Zhou et al. 2007; Zhou et 
al. 2008). Another recent development of this technology has been the ability to reverse the 
labelling process, i.e. to remove labels by treatment with acyl carrier protein hydrolase (AcpH) 
(Kosa et al., 2012). 
Currently the site specific labelling of proteins by PPTases is limited to at most a dual labelling 
system, employing two PPTases and two CP-derived tags (Figure 6.1). In the original version of this 
technology the more specific PPTase AcpS is used first to label an ACP substrate, followed by Sfp 
which has a broader substrate range and labels any remaining CP domains present in the reaction 
mix (primarily its own PCP targets but possibly also any ACP domains left unlabelled by AcpS) 
(Vivero-Pol et al., 2005). This technology has since been improved via development of smaller 
peptide tags, these being evolved so that their activating PPTase would have greater specificity 
with them, which resulted in the Sfp labelled S6 tag and the AcpS labelled A1 tag (Zhou et al. 2007; 
Zhou et al. 2008). Despite an increase in specificity there are still limitations with this technique, 
and some background non-specific labelling is still seen (Marchetti et al., 2014). The current 
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system is also limited to just two PPTase/tag pairs, only allowing the labelling of two protein 
substrates.  
 
Figure 6.1 Use of PPTases in site-specific protein labelling. A) Two potential PPTases with non-overlapping 
CP-substrate specificities can label different CP tags with different fluorescent CoA analogues. B) Given two 
specific PPTase CP pairs, two proteins of interest (P.O.I) can be differentially labelled. Adapted from (Vivero-
Pol et al., 2005). 
 
It would be useful to have additional PPTases that exhibit a narrow substrate specificity, i.e. that 
also exhibit very little cross reactivity with other CP substrates. Past attempts to improve the 
specificity of the PPTase/tag pair have always evolved the CP substrate, with no attempt to evolve 
the PPTases themselves. The aim of this chapter was to develop a screen to evolve a target PPTase 
to have highly specific activity for a given CP substrate.  
6.1.2 Engineering PPTases for altered substrate specificity 
There has been one previous published study to engineer PPTase substrate specificity, evolving 
Sfp to alter its substrate specificity with CoA (Sunbul et al., 2009). Though Sfp had been shown to 
be promiscuous with many CoA analogues, 3’-dephospho CoA (dpCoA) was shown to be a poor 
substrate for Sfp (Quadri et al., 1998). In this evolutionary scheme Sfp was co-displayed on a phage 
surface alongside the small peptide tag ybbr. The addition of biotin-conjugated dpCoA meant 
mutant enzymes that were able to catalyse the reaction with dpCoA could be subsequently 
recovered via a streptavidin selection (with the gene encoding these enzyme variants also 
recovered within the phage particles). Sfp variants were created via site directed mutagenesis, 
with four sites rationally selected (residues 28, 31, 44 and 90) based on the crystal structure of Sfp 
(Reuter et al., 1999). The top mutant recovered (R4-4) exhibited 329 fold higher activity with 
dpCoA over CoA. However, this selectivity was only observed when labelling the ybbr tag, and no 
difference in selectivity was seen when labelling a full CP substrate. By chance during the course 
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of the experiment additional mutations (due to PCR errors) were recovered at two sites where the 
sequence had not been randomised, one of which proved to be beneficial. Beyond this, there have 
been no published attempts to engineer the CP substrate specificity of a PPTase. 
6.1.2.1 Proof-of-principle engineering of the EntD PPTase 
For the development of a dual selection/screen that would serve as a proof-of-principle for being 
able to evolve PPTases to have altered CP substrate activity, the type II PPTase EntD from E. coli 
was chosen. It was reasoned that the ΔentD E. coli strain (created in Chapter 4) would allow for a 
powerful selection, resulting in the ability to interrogate larger variant libraries. The WT EntD 
enzyme is also able to be expressed as a soluble protein and purified, characteristics important 
for verifying activity via in vitro tests, as well as for enabling downstream site specific labelling 
applications.  
The native role for EntD in E. coli is activation of the NRPS enzymes of the enterobactin synthesis 
pathway (specifically the EntB and EntF enzymes). Enterobactin is a siderophore that is involved 
with iron uptake, making it essential for E. coli growth under conditions of iron starvation, and 
non-essential under normal growth conditions. EntD is already regarded as a narrowly specific 
PPTase, having much greater activity for its own substrates rather than foreign CPs. For example, 
entD was not able to complement an acpS mutant in E. coli (Flugel et al., 2000). Also, the 
heterologous expression of many NRPS and PKS enzymes within E. coli usually requires the co-
expression of a more broadly-acting PPTase (for example Sfp) for the production of an active 
NRPS/PKS enzyme (Kealey et al., 1998; Ku et al., 1997).  
The aim of the research described in this chapter was to decrease or abolish the activity of EntD 
with the CP domain of BpsA, while retaining activity with its native E. coli CP domains, those of 
EntB and EntF. The WT EntD enzyme already exhibited a preference for the latter substrates; for 
example, it was shown earlier that EntD has a greater activity with its own native substrate EntF 
than that of WT BpsA (Chapter 5). The ΔentD strain of E. coli that was created in Chapter 4 was 
used to select EntD variants able to complement this mutation under iron restricted selection, by 
activating the native E. coli CP domains involved in enterobactin synthesis. Only variants that were 
still functional as PPTases able to activate the CP domains of the enterobactin synthesis pathway 
were able to grow, eliminating non-functional variants. An immediate selection step that 
eliminates non-viable PPTase enzymes is a huge advantage and means a larger number of variants 
can be screened more easily. This allowed the creation of a totally random variant library via error 
prone PCR. As there is no structural information available for EntD, a more targeted approach 
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would have been difficult. At the same time, to screen for mutants with improved selectivity the 
entD variant library was expressed in the EcoBlue1 strain and those that were able to grow under 
iron restricted selection were counter-screened for a loss of activity with the CP of BpsA, by 
selecting for reduction (or ideally, elimination) of indigoidine production. The directed evolution 
scheme is illustrated in Figure 6.2. 
 
Figure 6.2 Directed evolution scheme for EntD evolution. A) Selection of entD variants that are able to 
activate the native CP domains of the enterobactin synthesis NRPS. (1) entD is amplified by error prone PCR 
to create a library of random variants. (2) entD variant library is used to transform cells harbouring BpsA. 
(3) Transformed cells are plated on iron restricted media, where only host cells expressing EntD variants 
that can still activate the CP of the enterobactin NRPS are viable. B) Selection for loss of EntD activity for 
BpsA. (4) Induction of BpsA via addition of IPTG. (5) Screening for white colonies (those that have lost the 
ability to activate BpsA and therefore cannot produce indigoidine). 
 
6.1.3 Aims 
 Develop a screen to select for EntD variants that retain activity with the EntF CP domain 
and lose activity with the BpsA CP domain. 
 Verify that the EntD variants recovered have altered activity levels with these CP 
substrates. 
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6.2 Results 
6.2.1 Optimisation of EntD and BpsA expression under iron 
restricted conditions 
6.2.1.1 Development of a co-expression system for EntD and 
BpsA 
Previously in this research, the expression of bpsA and the activating PPTase genes was 
simultaneous, from different plasmids that were each under IPTG inducible control (i.e., the pET 
plasmid for the PPTase genes and the pCDFDuet plasmid for bpsA). Both genes were expressed 
using a delayed induction method to address the limitation that if activated BpsA is expressed and 
indigoidine is produced before colonies can form, then the mildly toxic effects of indigoidine 
prevents colonies from forming after transformation (Owen, 2010). For this screen however, 
constitutive expression of a functional EntD variant was required for growth. In order for a BL21 
ΔentD transformant to grow on iron restricted media, the enterobactin biosynthesis genes would 
need to be activated by an EntD variant capable of recognising its cognate substrates, i.e. the CP 
domains of EntF and EntB, to enable production of enterobactin and thus survival under iron 
restricted selection.  At the same time, delayed induction of BpsA was still required to avoid the 
indigoidine toxicity problem, so plasmids with separately inducible controls for entD and bpsA 
genes were required. As delayed expression systems for BpsA (either autoinduction or late 
addition of IPTG under scooped agar plates (section 2.10.1)) had already been optimised, entD 
was cloned into a different expression system. The entD gene was also the smaller of the two and 
easier to clone. Due to availability and its ability to be maintained together with pCDFDuet in the 
same host cell, the pBAD plasmid (which induces genes via an arabinose promoter) was chosen 
for EntD expression.  
Expression of pBAD:entD in both EcoBlue1 and EcoBlueE was tested at different concentrations of 
arabinose (0.001%, 0.01% and 0.5%, w/v) in LB plates with  BpsA induced via IPTG addition using 
the scoop method as described in section 2.10.1. At the lower concentration (0.001%) there was 
low indigoidine production overall, but with much more being produced in the EcoBlueE strain 
(compared to EcoBlue1). At the two higher concentrations (0.01% and 0.5%) similar levels of 
indigoidine production were seen in both the EcoBlue1 and EcoBlueE strains, with a faster reaction 
time seen at the higher concentration. At 0.001% (w/v) arabinose EntD was clearly better able to 
activate the EntF CP-substituted BpsA, exaggerating the preference that EntD already had for the 
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EntF CP-substituted BpsA compared to the WT BpsA. Based on these results, the higher 
concentration of 0.01% was chosen for final screening plates to more easily see changes in activity 
in the EcoBlue1 background. 
6.2.1.2 Optimisation of solid media for iron restricted growth 
and indigoidine production 
Iron restricted plates consist of minimal media to which has been added the iron chelator 2,2’-
dipyridyl (Roche and Walsh, 2003). For this work the usual carbon source for minimal media plates, 
glucose, was replaced with glycerol, as glucose represses pBAD expression. The optimal 
concentration of 2,2’-dipyridyl for distinguishing functional EntD variants was then tested. The E. 
coli strains BL21, BL21 ΔentD, and BL21 ΔentD pBAD:entD were each plated out at a density of 
approximately 100 colonies/plate at three concentrations of 2,2’-dipyridyl (100 µM, 50 µM and 
10 µM) on minimal media agar plates containing 0.01% (w/v) arabinose, and growth seen at 48 h 
was recorded (Table 6.1). There was no growth at all on any of the plates after just 24 h. After 48 
h, a concentration of 10 µM 2,2’-dipyridyl was not enough to see any growth difference between 
the three strains. A difference was seen at 50 µM, with normal growth for BL21 WT and reduced 
growth for both the ΔentD strains, but the presence of pBAD:entD did not make a difference. At 
100 µM 2,2’-dipyridyl there was no growth at all in the knock out strain, and this was rescued by 
overexpressing entD in pBAD, at similar levels as the WT strain. It was subsequently decided to 
incubate plates for 72 h, at which point larger colonies were seen on the BL21 and BL21 ΔentD 
pBAD:entD plates, while the ΔentD strain still had no growth. This made it easier to see any 
difference in indigoidine levels between the larger colonies. 
Table 6.1 Growth of BL21 strains at three different concentrations of 2,2'-dipyridyl in minimal media agar 
plates containing 0.01% (w/v) arabinose after 48 h 
E. coli strain 
2,2’-Dipyridyl concentration (µM) 
10 50 100 
BL21 Normal  Normal  slow 
BL21  ΔentD Normal  slow none 
BL21  ΔentD pBAD:entD Normal  slow slow 
 
Next the expression and detection of indigoidine on iron restricted minimal media plates was 
optimised, using the strain EcoBlue1 pBAD:entD. L-glutamine at the previously optimised 
concentration of 100 mM was sufficient in these plates to enable indigoidine expression and 
caused no problems with growth. Some pigmentation was visible before induction, which may 
have been due to leaky expression of BpsA from the pCDFDuet plasmid. This may have been 
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caused by the absence of glucose from the media, which would normally counteract IPTG 
induction. This leaky expression was presumed to be minimal, given that the cells were still able 
to grow, and that induction was still required to get substantial indigoidine production. An issue 
that arose with induction was that due to the 72 h incubation of the plates, scooping the agar out 
to add the ITPG became very difficult due to the degree to which the agar had dried out. To solve 
this problem plates were made with a higher percentage of agar (1.7% compared to the usual 
1.5%) and each plate was made from 25 ml of media rather than the usual 20 ml. Plates were also 
sealed with parafilm during the 37 °C incubation. Another problem encountered was that after 
induction, the degree of indigoidine production was non-uniform across the plate (e.g., Figure 
6.3). All colonies are identical and should theoretically be producing the same level of indigoidine, 
yet the representative colonies in Figure 6.3 appear to be much darker in the middle of the plate 
and lighter around the sides. It was reasoned that this could be due to non-equal amounts of 
induction resulting from uneven spreading of the IPTG under the agar. These uneven pigment 
levels had been seen before in other screening methods (for example the eDNA screening in 
Chapter 4). This was not considered a huge problem at the time as in that screen any level of blue 
pigmentation was considered a hit. In the current screen however the level of pigmentation is 
important, as the desired phenotype is that of impaired pigment production. It was necessary to 
ensure any white or light blue hits found were a result of the EntD variant losing activity for the 
BpsA CP domain, and not because of the location of the colony being in an area of poor induction 
on the plate. I was unable to resolve the uneven pigment production levels, so each potential hit 
had to be evaluated relative to the pigmentation of other immediately neighbouring colonies as 
opposed to the entire plate. 
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Figure 6.3. Assessment of pigment production on low-iron agar plates. EcoBlue1 pBAD:entD was plated on 
low-iron agar plates containing 100 mM L-glutamine. After 72 h incubation at 37 °C the plate was induced 
with 100 µl 2.5% (w/v) IPTG spread under the agar, and incubated at room temperature for a further 24 h 
before the photo was taken. 
 
6.2.2 Creation of EntD variant libraries for screening 
An entD variant library was created via error prone PCR, using the GeneMorph® Mutazyme® II 
polymerase and the WT entD as a template, with a high error rate applied. The gene library was 
cloned into the pBAD plasmid vector via compatible restriction sites (XhoI and HindIII), and used 
to transform electro-competent EcoBlue1. In order to estimate cloning efficiency, the WT entD 
gene was cloned into the same vector and also used to simultaneously transform electro-
competent EcoBlue1. This transformation was plated onto LB plates containing 100 mM L-
glutamine and 0.01% (w/v) arabinose, and induced with IPTG after initial growth as described in 
section 2.10.1. The percentage of blue colonies observed here was 87%, this was taken as an 
appropriate estimate for the cloning efficiency of the entD variant library. To check sequence 
diversity ten clones were sequenced. A high error rate had been chosen with the Mutazyme® II 
polymerase, as experience in our lab has shown that in practice the error rate is less than stated 
by the manufacturer. This seemed to be the case here as well, with two clones out of ten still being 
WT entD and five clones having just one mutation in the 630 bp entD gene. The remaining three 
clones had either two or three mutations. 
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To initially assess the percentage of variants encoding functional PPTases within the library, 
transformants were plated out onto both LB and low-iron agar pigment production plates. LB 
plates were incubated at 37 °C for 16 h prior to induction with IPTG, whereas low-iron plates were 
incubated at 37 °C for 72 h prior to induction. A survival percentage (corresponding to the 
percentage of functional PPTases in the library) was calculated by comparing the number of 
colonies growing on LB plates with those that grew on low-iron plates. The survival rate was 
estimated at 80% (taking into account the previously estimated insert ratio). This estimation was 
confounded by the fact that the plates appeared to have a lot of satellite colonies. This can be 
seen in Figure 6.4, which illustrates a number of larger colonies (which have blue centres indicative 
of leaky bpsA expression resulting in a small amount indigoidine production before induction) 
surrounded by a few smaller satellite colonies. Satellite colonies grow by scavenging enterobactin 
from the surrounding larger colonies as opposed to having a functional PPTase of their own. This 
problem has been seen before in iron-limited screens (Charlop-Powers et al., 2013).  
 
Figure 6.4 Satellite colonies on low-iron agar plates. EcoBlue1 expressing the entD library was plated on a 
low-iron plate and incubated for 72 h at 37 °C. Photo was taken prior to IPTG induction. 
 
Another way to estimate the number of functional PPTases was to look at the number of blue 
colonies on LB plates for the EntD variant library vs. WT EntD. When estimated in this way, it 
seemed that closer to 50-60% of PPTases in the EntD variant library were still able to activate 
BpsA. The difference in these numbers is likely due to the survival rate being an over-estimate 
owing to the satellite colonies; alternatively, it may be that it is easier for the EntD variants to lose 
activity with the BpsA CP domain than with the enterobactin CP domains. The former explanation 
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being more likely to explain the discrepancy in estimates, it was assumed the number of functional 
EntD variants was closer to 50-60%.  
6.2.2.1 Library screening and further optimisation 
Initial library cloning efforts were relatively inefficient for reasons that are unknown; in total 
approximately 5 × 103 clones were screened on low-iron pigment (indigoidine) production plates. 
This was however sufficient to identify several promising hits. Hits were selected as being those 
colonies that were white or had reduced pigment production in comparison to the surrounding 
colonies in the immediate vicinity. To cater for false positives resulting from the uneven 
pigmentation distribution or the presence of the satellite colonies on the low-iron plates, 
additional downstream screening steps were introduced. After the initial low-iron plate screening, 
colonies that looked promising (i.e., white or light blue, and ideally large and far away from other 
colonies) were streaked onto LB pigment production plates. This second step of streaking hits onto 
an LB plate allowed a better qualitative differentiation of pigment production levels. The whitest 
of these variants were cultured and plated out individually onto both LB and low-iron pigment 
production plates at a density of ~100 colonies/plate. This confirmed their ability to grow under 
iron limiting conditions (implying they were still able to activate their native CP substrates), as well 
as examining whether they were truly unable to activate WT BpsA. In total approximately 250 hits 
were chosen from iron restricted screening plates for streaking on LB. Twenty five of these hits 
were then plated on both LB and low-iron agar, and from this eight promising hits which had low 
to no indigoidine production as well as the ability to grow under low-iron selection were identified. 
These eight hits were subjected to further testing in the work described in section 6.2.3. 
6.2.2.2 Investigation of an alternative indigoidine-based 
screening strategy using EcoBlueE 
Streaking out potential hits onto LB pigment production plates was a quick and easy step to 
overcome the problem of uneven pigment production leading to uncertainty about which EntD 
variants had lost the ability to activate BpsA. The extra step of growing colonies on low-iron media 
to overcome the problem of satellite colonies was a much more laborious strategy, with individual 
plates required to re-streak each potential hit. An alternative approach for confirming that the 
EntD variants still had activity with the EntF CP domain was explored. Instead of looking at the 
ability of EntD variants to complement the ΔentD strain under iron limitation, their ability to 
activate an EntF-substituted BpsA was tested (using the EcoBlueE strain). From the 250 initial hits 
recovered in the screening in section 6.2.2.1, 80 of the whitest hits on secondary screening LB 
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pigment production plates were selected (i.e., those hits that had been confirmed for a loss of 
activity with BpsA). Cultures for these hits were pooled and plasmids were isolated via miniprep. 
This new enriched library of EntD variants that had lost activity with the BpsA CP was then 
transformed into EcoBlueE and plated on LB pigment production plates. Cells were induced in the 
usual manner after overnight growth and this time colonies with the strongest pigment 
production were chosen as hits (i.e. those that retained activity with the EntF CP domain). This 
resulted in seven more hits being recovered and subjected to further verification. 
6.2.3 Verification of potential hits on solid media   
The fifteen hits found via the screening methods described in sections 6.2.2.1 and 6.2.2.2 were 
subjected to additional verification to confirm they had the desired activities with the appropriate 
substrates. First plasmids carrying each PPTase variant were separated from the BpsA-containing 
plasmid by transforming the mixed plasmids into DH5α, and selecting for the pBAD plasmid using 
ampicillin. The pBAD plasmid for each EntD variant hit was then used to transform both EcoBlue1 
and EcoBlueE, and each was tested for pigment production on LB agar containing L-glutamine and 
arabinose. After initial colony growth, BpsA was induced with IPTG as described in section 2.10.1. 
Eight out of the 15 hits tested appeared to have gained the specificity that was selected for, i.e. 
appeared to have lost the ability to activate the WT BpsA (loss of indigoidine production when 
expressed in EcoBlue1), while retaining activity with the EntF CP domain (indigoidine was 
produced when expressed in EcoBlueE). Of these eight hits, four each were recovered by the two 
different screening methods described in sections 6.2.2.1 and 6.2.2.2. As an example, the results 
for Clone 1 are displayed in Figure 6.5, compared to WT EntD. The time taken for indigoidine to 
be produced was similar for most hits, except for Clone 4 which was much slower. This indicated 
that this clone may have also lost some activity with the EntF CP domain as a substrate. 
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Figure 6.5. Verification of CP specificity for Clone 1. Clone 1 was expressed in both A) EcoBlue1 and B) 
EcoBlueE. WT EntD is shown for comparison in C) EcoBlue1 and D) EcoBlueE. Each strain was plated on LB 
agar with 0.01 % (w/v) arabinose and 100 mM L-glutamine and induced with 100 µl 2.5 % (w/v) IPTG before 
being incubated at room temperature. Photos were taken 48 h post induction. 
 
The other seven of the 15 hits tested proved to be false positives. Most of these still had at least 
limited activity with both substrates, resulting in indigoidine production in both EcoBlue1 and 
EcoBlueE. This was surprising given each of the potential hits had already been double checked 
for loss of ability to activate BpsA. It may be relevant that here that each of the EntD variants was 
re-transformed into EcoBlue1 - possibly individual bpsA genes in the previous screening strains 
had acquired deleterious mutations, with the mild toxicity of indigoidine providing some selective 
pressure for these mutations. There was also one false positive for which there was no indigoidine 
production in either EcoBlue1 or EcoBlueE. This may have been a satellite colony, a completely 
non-functional PPTase that appeared white so was recovered as a hit yet was unable to produce 
its own enterobactin and was just scavenging some from a nearby colony. Another possibility is 
that the EntD variant could still activate its native substrate EntF CP in E. coli (so it could produce 
enterobactin and grow on iron restricted plates), but it could not activate the EntF CP-substituted 
BpsA. 
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6.2.4 Sequence analysis of verified hits 
Hits that were verified in section 6.2.3 were sequenced, and a list of all clones and their mutations 
is given in Table 6.2. The mutation rate among the hits was relatively high, with 2-3 amino acid 
mutations per gene (the size of entD is 630 bp). Though only a small library was screened, the hits 
recovered were diverse, with seven out of eight hits sequenced being unique (Clone 7 was 
recovered twice). 
Table 6.2. Mutations present in improved entD variants 
Clone Mutations present 
1 A45T, Y88N 
2 L33S, R47H, Y88N 
3 P25Q, F151L 
4 P12T, Y88N, E112G 
5 W35L, A45T, Y88N 
6 L42Q, Y88N 
7 G76D, P81S, Y88N 
 
All but one of the hits contained a shared mutation, Y88N. That this mutation was recovered 
together with so many alternative mutations is strong evidence that it had arisen several times 
during the epPCR reaction and was actively selected for. However, it was not found on its own so 
it was unclear what the effects of any of the other mutations that were found alongside it might 
be. Clone 3 was the only variant that did not contain this mutation, thought it did contain the 
mutation F151L. This Phe residue is highly conserved within PPTases, with all known PPTases 
having either a Phe or a Trp residue at this location.  
6.2.5 Quantification of EntD variant activity with different CP 
substrates 
6.2.5.1 Optimisation of arabinose concentration for liquid 
culture assay 
In order to obtain quantitative data on the activity of the EntD variants with different CP 
substrates, a liquid culture assay was performed to compare activity in EcoBlue1 versus EcoBlueE. 
It was first necessary to optimise the arabinose concentration, as previously this assay had been 
run when both the genes were under IPTG control. The previously optimised conditions of 0.5 mM 
IPTG, 100 mM L-glutamine at 18 °C were kept constant and the concentration of arabinose was 
varied from 2% to 0.00002% (w/v) in six 10-fold serial dilution steps. The pBAD:entD plasmid was 
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expressed in both EcoBlue1  and EcoBlueE. The levels of pigment production observed at both 24 
and 48 h are displayed in Figure 6.6. At the higher concentrations of arabinose (2% and 0.2%), 
both strains produced similar levels of indigoidine at 24 h, with no noticeable difference between 
EcoBue1 and EcoBlueE (Figure 6.6 A). After 48 h a greater differentiation in pigment production 
between the two strains was seen (Figure 6.6 B). At the lower concentrations of arabinose, 
EcoBlueE pBAD:entD had much higher levels of indigoidine production than EcoBlue1 pBAD:entD, 
with the two lowest arabinose concentrations showing no visible pigment production in EcoBlue1 
(Fig 6.6 B). These results indicate that when there is a lower amount of EntD present (i.e., at lower 
arabinose concentrations), then this small amount of enzyme is sufficient to activate the EntF CP-
substituted BpsA, but a larger concentration of EntD enzyme is required to activate WT BpsA. So 
that any potential changes in the substrate specificity of the evolved EntD variants were not 
exaggerated due to the lower concentration of EntD enzyme, the second highest arabinose 
concentration (0.2%) was chosen for use in the final assay.  
 
 
Figure 6.6. Evaluation of optimal arabinose concentration for indigoidine synthesis. Columns contain a 10-
fold serial dilution series from 2% to 0.00002% of arabinose, The top four rows contain EcoBlue1 pBAD:entD 
and the bottom four rows contain EcoBlueE pBAD:entD. Each well contains a final volume of 150 µl with 0.5 
mM IPTG and 100 mM L-glutamine, as well as 100 µg/ml of ampicillin and spectinomycin. The plate was 
incubated at 18 °C with shaking at 200 rpm and photographed at A) 24 h and B) 48 h.  
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6.2.5.2 Quantitative assessment of hits 
Each of the seven sequence verified hits was quantitatively assessed by measurement of 
indigoidine production in liquid culture, which had previously proven to be a more sensitive and 
quantitative measure of PPTase activity (Chapter 3). Each EntD variant was evaluated both in 
EcoBlue1 and EcoBlueE, and Figure 6.7 displays the pigment production for each variant at 24 and 
48 h. After 24 h incubation, most of the variants tested showed very little activity in EcoBlue1, and 
were all much less active than WT EntD in this strain. Clones 4 and 7 seemed to have lost activity 
with both substrates but all others had retained their activity with the EntF CP domain, still able 
to activate the EntF-substituted BpsA variant in EcoBlueE. More activity was seen with all clones 
after 48 h, and the quantification of this indigoidine production at both time points is displayed in 
Figure 6.8. This shows that at 24 h, all EntD variants generated substantially less indigoidine 
production than the WT EntD, with Clones 4, 6, and 7 resulting in no visible indigoidine production 
at this stage. After 48 h, increased indigoidine production was seen across all the strains (except 
for Clone 4 in EcoBlue1, which still appeared inactive with WT BpsA). For every variant tested, 
there was a greater level of indigoidine production in EcoBlueE than EcoBlue1. Most variants did 
however have lower activity in EcoBlueE than the WT EntD enzyme, indicating that in reducing 
activity with the WT BpsA, overall activity with the EntF CP seemed to have decreased as well. The 
exception to this is Clone 1 which, compared to WT EntD, both lost activity in EcoBlue1 and gained 
activity in EcoBlueE. 
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Figure 6.7 Indigoidine production of the seven EntD variants in liquid media. Each of the seven clones was 
measured for indigoidine production in EcoBlue1 and EcoBlueE.  Wells each contained 130 µl of pigment 
production media (LB with 0.2% (w/v) arabinose, 100 mM L-glutamine, 0.5 mM IPTG, 100 µg/ml ampicillin 
and spectinomycin) inoculated with 20 µl of overnight culture. Plates were incubated at 18 °C with shaking 
at 200 rpm and photographs were taken after A) 24 h and B) 48 h. 
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Figure 6.8 Quantitative assessment of indigoidine production resulting from the seven EntD variants 
being co-expressed with two BpsA variants that contain different CP domains. Quantification of 
indigoidine production resulting from the seven EntD variants (compared with WT EntD) being expressed 
in EcoBlue1 or EcoBlueE. Each was set up in quadruplicate in a 96-well microplate in pigment production 
media and incubated at 18 °C. After A) 24 h and B) 48 h absorbance at 590 nm and 800 nm was measured 
using a microplate reader. Absorbance at 590 nm was normalised for cell density as measured at 800 nm 
to give a relative measure of indigoidine, as described in section 3.2.1.2. Error bars are +/- one standard 
deviation. 
The results of this liquid assay were somewhat inconsistent with the agar plate assay in section 
6.2.3. Previously (in Chapter 3) it was observed that the liquid assay is more sensitive and hits that 
are slow to turn blue on agar (with no pigment produced within the first 48 h), will not produce 
any indigoidine in the liquid assay. However here Clones 2, 3 and 5 all had no activity at all on the 
agar plate assay in section 6.2.3 when expressed in EcoBlue1, yet were able to produce indigoidine 
in the liquid culture assay here. This could be due to the fact that here the expression of the EntD 
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variants were under arabinose control, and it may be that the concentration of arabinose in the 
agar was not high enough for substantial levels of induction. 
6.2.6 Kinetic analysis of selected EntD variants 
Several EntD variants spanning a range of activity levels as measured in section 6.2.5.2 were 
selected to be purified and characterised kinetically, for activity with WT BpsA and the EntF-
substituted BpsA. The EntD variants were already in the pBAD plasmid, which adds a His6 tag to 
enable nickel affinity purification, but sufficient levels of soluble protein could not be obtained 
following arabinose induction. As expression of EntD via IPTG induction had already been 
optimised for expression in pET, it was decided to clone four of the entD variants (1, 3, 4 and 6) 
into pET. The encoded EntD enzyme variants were then purified following the protocol for the 
purification of PPTases described in section 2.8.5.2, with expression carried out in LB at 18 °C as 
for WT EntD. Initial tests for activity were performed to establish whether each variant possessed 
enough activity for full enzyme kinetic assays to be performed. Overall, all the variants tested had 
very low activity when compared to WT EntD, and because of this kinetics for most EntD variants 
were unable to be determined. An exception was Clone 1, for which kinetic analysis was 
performed (using purified EntF CP substituted BpsA as substrate) in two independent biological 
replicates (two independently expressed and purified protein preparations, with an assay 
performed in triplicate for each protein preparation). The Michaelis-Menten curve for varying CoA 
concentration for each of the replicates is shown in Figure 6.9. The two replicates were consistent, 
and the kinetic parameters derived from each were averaged and given in Table 6.3, along with 
the kinetic parameters for WT EntD. Note that Clone 1 did not exhibit sufficient activity with WT 
BpsA to measure any activity in this assay.  
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Figure 6.9 Michaelis-Menten curves for two biological replicates of the EntD variant “Clone 1” with the 
EntF CP-substituted BpsA as substrate. Plots indicate the maximum velocity of indigoidine production at 
different concentrations of CoA. Curves were fitted using Graphpad Prism® and used to derive kinetic 
parameters for each replicate of Clone 1. Data points were generated from three repeats and error bars are 
+/- SEM.  
Table 6.3 Kinetic parameters of EntD Clone 1 and EntD WT 
EntD 
variant 
BpsA substrate Vmax 
(ΔA590.min-2.mM-1)  
Km (µM) Vmax/Km 
(ΔA590.min-2.µM-1.mM-1)  
Clone 1 BpsA (EntF CP)  0.33 ± 0.014 3.39 ± 0.59 0.098 ± 0.018 
Clone 1 BpsA n.d n.d n.d 
WT EntD BpsA (EntF CP)  18.8  ± 0.91 0.96 ± 0.23 19.6  ± 4.8 
WT EntD BpsA 5.3 ± 0.26 1.24 ± 0.28 4.28 ± 0.99 
n.d. = not detected 
While the Clone 1 variant had lost a lot of activity (around a 200-fold drop in catalytic efficiency 
(i.e., Vmax/Km) when compared to WT EntD) the specificity of the enzyme was greatly improved, 
with this variant having no detectable activity at all with the WT BpsA enzyme. The three other 
variants that were purified (Clones 3, 4, and 6) had also lost a lot of activity, to such an extent that 
it was not possible to measure their kinetic activity. However, it was possible to see that they had 
also gained the desired specificity and were able to activate the EntF-substituted BpsA 
preferentially over WT BpsA (data not shown). 
6.3 Discussion 
The aim of this chapter was to conduct proof-of-principle directed evolution studies to modify the 
PPTase EntD in order to narrow its CP domain substrate specificity. EntD was evolved to be more 
selective for a native CP substrate (the CP of EntF), while losing activity with a second CP substrate, 
the native BpsA CP domain. Despite the small size of the EntD variant library screened, I was 
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successful in recovering several variant EntD enzymes which displayed this altered substrate 
specificity. While there was a loss in overall catalytic efficiency, the top variant recovered had 
retained enough activity with EntF in order to derive kinetics with the EntF CP-substituted BpsA, 
while displaying no measurable activity with WT BpsA in the same assays. The screen developed 
here will be able to be adapted for evolution of other PPTases with other CP substrates. 
In total seven clones were identified that had low activity with the WT BpsA CP domain, and higher 
relative levels of activity with the EntF CP domain. The top performing EntD variant recovered was 
Clone 1. An in vivo liquid assay was performed to quantify the activity of the EntD variants with 
the CP domains of BpsA and EntF, as measured by indigoidine production in both EcoBlue1 and 
EcoBlueE. Clone 1 appeared to be substantially more selective than WT EntD, with a greater 
difference in the activity between EcoBlue1 and EcoBlueE (Figure 6.8). Clone 1 appeared in vivo to 
have even more activity with the EntF CP-substituted BpsA than WT EntD did (all other variants 
were less active in EcoBlueE as compared to WT EntD) when tested in the liquid culture assay. 
However when purified enzyme for Clone 1 was tested kinetically with BpsA (section 6.2.6), it was 
found to be much less active than WT EntD with the EntF CP substituted-BpsA, with an 
approximate 200-fold drop in catalytic efficiency under the in vitro conditions tested. Even though 
there was this large loss of activity with EntF as the CP substrate, there was no detectable level of 
activity with WT BpsA, showing that the screen had been successful in recovering an EntD variant 
with narrowed CP substrate specificity. A possible reason for the difference between the in vivo 
and in vitro activity levels seen is that the purified enzyme may be a lot less stable then the purified 
WT EntD, due to the mutations it contained. Future work could examine this, for instance running 
a thermostability assay to compare the stability of the EntD variants against the WT enzyme 
(Niesen et al., 2007).  
The remaining EntD variants were all less active than Clone 1, as measured via indigoidine 
production in the in vivo liquid culture assay. This also appeared to be the case at the purified 
protein level as there was not enough activity seen with any of the other purified enzyme variants 
to run kinetic assays. Despite this low overall activity, all of these clones did appear to display 
improved selectivity, having a greater level of activity with the EntF CP domain over the BpsA CP 
domain, in both solid and liquid media assays. However, for the reasons noted above it was 
difficult to accurately judge the extent of improvement, as the timing of measurement influenced 
relative activity levels, and it is unclear whether fold-improvement in activities is the most 
appropriate measure for comparing different enzymes. While it would be preferable to lose 
activity with the BpsA CP substrate without any concomitant loss in catalytic activity with the EntF 
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CP substrate, if the activity with WT BpsA was completely eliminated, this may yet prove useful in 
some applications. Such an enzyme would exhibit no background activation with WT BpsA, which 
might be very useful as long as sufficient activity was retained with the EntF CP domain. Clones 4 
and 7 may be good examples of this, as it looks as if activity with WT BpsA has been almost 
completely removed.  
Due to the fact all seven EntD variants contained multiple (two or three) mutations, without 
further experimental data it is hard to draw firm conclusions about what the effect of individual 
mutations may have been. Clearly Y88N looks to be an important mutation, being present in six 
out of seven of the variants, including the top hit, Clone1. It would be of interest to examine the 
activity of an EntD clone with the single point mutation Y88N. As all of the other variants 
containing Y88N have less activity than Clone 1, it also seems likely that the other mutations 
present in these variants (Clones 2, 4, 5, 6 and 7) may be detrimental, or at best neutral. The use 
of site directed mutagenesis to generate a Y88N single mutant and then – one at a time – add in 
the additional mutations that were recovered, would enable a detailed comparison of the effects 
of each mutation on overall catalytic activity and selectivity. Unfortunately however, time 
constraints precluded these experiments from being performed. Instead, preliminary hypotheses 
were generated by analysing the location and nature of the different substitutions that appeared, 
and comparing these to the in vivo assay data. For example, Clone 5 contains the same two 
mutations as Clone 1 (Y88N and A45T) as well as the mutation W35L; Clone 5 has less activity (with 
both CP substrates) than Clone 1, so this implies W35L must be detrimental to overall enzyme 
activity. Clones 1 and 6 are also very similar, both containing the Y88N point mutation as well as 
one additional other mutation (A45T for Clone 1and L42Q for Clone 6). These additional mutations 
are in a similar location of the protein. While there is no solved structure available for EntD, 
alignments with type II PPTases that have had their structure solved (Bunkoczi et al., 2007; Jung 
et al., 2014; Reuter et al., 1999; Vickery et al., 2014) suggest that these mutations are likely to 
occur in the second alpha helix of the N-terminal of the enzyme, which may be involved in CoA 
binding (Reuter et al., 1999). A45T is a relatively conservative amino acid change whereas L42Q is 
not, and this more dramatic change may be responsible for the greater loss of total activity 
observed for Clone 6.  
The worst performing EntD variant (with both CP substrates) was Clone 4, which includes the 
mutation E112G. This position is equivalent to E109 in Sfp, which is important in Mg2+ binding 
(Reuter et al., 1999) - in a mutagenesis study the mutation E109D was found to completely ablate 
activity (Mofid et al., 2004). Recently this position was identified as the second residue in a triad 
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of residues (Asp-Glu-Glu) that are important in coordinating the Mg2+ ion (Wang et al., 2014). The 
second residue was found to be non-essential in this role, and an alternate residue to Glu is found 
in a number of different species. Gly was not one of the residues that was ever found at this 
position.  
Overall most of the mutations in recovered clones were in the N terminal domain of the protein. 
This is in contrast to other studies that have stated that the specificity for carrier protein 
recognition comes from the C terminal domain (Jiang et al., 2013; Tufar et al., 2014). However, it 
was suggested by Jiang et al. (2013) that while the C terminus was important for specificity, the N 
terminus was important in overall enzyme activity. This is consistent with the fact all of these 
variants (with N terminal mutations) did have a lot lower activity overall than the WT enzyme. 
The fact that this screen was a survival based screen on agar plates (i.e., only functional PPTases 
with the desired substrate specificity for the EntF CP domain could survive under iron limiting 
selection) meant that a large number of clones should have been able to be screened relatively 
easily. One of the limitations encountered in this work was that the library of EntD variants 
produced via error prone PCR was very small, and so only around 5000 clones were screened. 
Despite trying to improve this and determining that there was high vector quality with a good 
insert ratio and highly competent cells the library size was not able to be increased in the time 
available. Nonetheless, that there were still a good number of hits found indicates that the 
substrate specificities of PPTases may be relatively easily manipulated. 
Another limitation encountered was the large number of false positive hits that were detected. 
Out of the fifteen hits that were selected for a final verification step in section 6.2.3, eight were 
confirmed as having the sought-after selectivity while seven were false positive hits. As there was 
a problem with satellite colonies being found on screening plates, it was thought that this might 
be one reason for false positive hits. A completely non-functional PPTase could be recovered 
because it had scavenged enterobactin, appearing active with EntF, while also appearing to have 
lost activity with WT BpsA. However, this was only the case for one of the seven false positive hits, 
which was unable to activate either BpsA variant upon secondary verification (i.e., giving no 
indigoidine production in EcoBlue1 or EcoBlueE). This indicates that the additional steps taken to 
double-check activity with the EntF CP domain (either low-iron plate testing as in section 6.2.2.1 
or transforming a mixed plasmid population en masse into EcoBlueE as in section 6.2.2.2) were 
largely successful in eliminating any non-functional PPTases. The remaining six false positive hits 
had not lost activity with WT BpsA upon verification, and displayed activity levels in EcoBlue1 and 
EcoBlueE similar to that of WT EntD (indeed, although not mentioned previously, sequencing 
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revealed that three of these clones carried no mutations at all). Selection of these unimproved 
variants may have stemmed from the fact that there were inconsistencies in indigoidine 
production on the screening plates. However, as all potential hits were subsequently streaked 
onto pigment producing LB to confirm loss of indigoidine production, it seems more likely that 
these variants may have by chance accrued mutations in their bpsA reporter genes or plasmids 
that led to a diminished indigoidine output. Owing to the toxicity of indigoidine, instability in the 
BpsA plasmid has been seen before (Owen, 2010). During the verification step pBAD plasmids 
containing the EntD variants were retransformed into EcoBlue1 for verification where it was seen 
that they were indeed able to activate indigoidine synthesis.  
While this screen was specific for the EntD PPTase and relied on the fact that we had a ΔentD E. 
coli strain available, it could also be applied to the engineering of other PPTases. For example, if 
another PPTase knock out strain of a different siderophore-producing bacterial species was 
available, then the same principles could be applied. Based on the pilot results described in this 
chapter, further work in our laboratory is looking at performing an equivalent screen using the 
pcpS PPTase in P. aeruginosa. A conditional knock out of the essential gene pcpS has previously 
been created along with a chromosomally inserted E. coli acpS gene (Barekzi et al., 2004). The 
acpS gene allows activation of the pathways of primary metabolism necessary for growth, while 
not activating the siderophore pathways of secondary metabolism. Ongoing work in our lab is 
being performed by Masters student Jack Sissons (under my co-supervision) with the aim of 
evolving both PcpS and EntD so that they have complementary (i.e., non-overlapping) CP 
specificities. For EntD, the same screen will be performed as in this chapter but using the PvdD 
CP-substituted BpsA variant in place of WT BpsA, in order to obtain an EntD variant that retains 
activity with the native EntF CP domain and loses activity with the PvdD CP domain. The 
complementary study with PcpS will then be performed, in the ΔpcpS P. aeruginosa strain, to 
select for PcpS variants that lose activity with the EntF CP-substituted BpsA variant.  
As part of the screening method developed in this chapter, a second tier assay for recovering hits 
was investigated. Instead of relying on growth on low-iron media to select for variants which had 
activity with the EntF CP domain, a subset of variants already found to have lost activity with WT 
BpsA were transformed into the EntF CP-substituted BpsA variant strain, EcoBlueE, and selected 
based on indigoidine production in this strain. This was to overcome the problem of having to test 
potential hits to ensure they were not satellite colonies, which needed to be done individually and 
was time consuming. This approach was successful in uncovering four out of eight of the original 
hits during the course of this work, with two of these hits having identical sequences. There is the 
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potential to solely use this method in order to engineer PPTase selectivity. This would not be 
reliant on having a particular PPTase knock out strain, so would be a more flexible system, though 
would rely on having the appropriate CP-substituted BpsA variants available for screening. It 
would also have the disadvantage of not being a survival based system, with no easy way to select 
against non-functional PPTase variants.  
It remains to be seen whether the specificity of the EntD variants recovered here will translate to 
a specificity for the CP as stand-alone proteins or in a different context, i.e. with the CP or a 
derivative thereof attached to another protein in a labelling application. The fact that the EntF CP 
has essentially been tested both in the context of its native EntF NRPS as well as the BpsA NRPS is 
a good indication that the activity seen here will not just be specific to one situation. There is also 
the question of whether the CP domains here can be shortened to smaller peptide tags and while 
retaining the same properties, and further work by Jack Sissons in our lab is investigating this. 
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Chapter 7: Summary, Conclusions and future 
directions 
7.1 Research motivation 
The focus of this research was a class of natural product biosynthetic enzymes, the NRPSs, and the 
enzymes responsible for activating them, the PPTases. NRPSs are of interest due to the wide range 
of bioactive products they synthesise, with two key areas of research being the manipulation of 
existing NRPS enzymes, or the discovery of new enzymes, in order to create or find new bioactive 
natural products. PPTases are also important enzymes that have potential for use in a variety of 
applications, for which an understanding of the reaction between the CP domains of NRPSs and 
the PPTases is essential. This reaction was a key theme of this thesis, and the work presented here 
was motivated by the potential to use a unique NRPS, BpsA, to study this reaction further. 
The initial aim of this research was to use the model NRPS BpsA, expanding upon a series of 
versatile assays that were first developed as a part of the doctoral work of Dr Jeremy Owen. As 
part of this preceding work, a number of different CP domains were substituted into BpsA in order 
to investigate the interactions between the CP domain and the TE domain.  As a result of this, 
several functional CP-substituted BpsA variants were created. The first aim of this thesis was to 
further progress the CP-substitution work, focusing on specific interactions between these 
domains, in light of new information which contradicted some of Dr Owen’s previous conclusions. 
The second aim of this thesis was to utilise the engineered CP-substituted BpsA variants and apply 
them to a metagenomic screening method, to expand upon a small pilot metagenomics study that 
Dr Owen had performed using WT BpsA. During the course of this screening a number of novel 
PPTase genes were discovered, and these were investigated further, this time using BpsA to 
characterise the PPTases in terms of their activity and specificity. The motivation behind this large 
scale characterisation was to better understand the properties of these enzymes in order to 
discover promising PPTases for use in a variety of biotechnological applications, in particular 
PPTases that might exhibit a strong preference for specific CP domain sequences. Upon noticing a 
lack of any clear specificity of the PPTases tested for their CP substrates, the final aim of this work 
was to utilise the enzyme BpsA in a completely novel screen which could be applied in directed 
evolution experiments to narrow the specificity of a target PPTase. 
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7.2 Key findings 
7.2.1 Carrier protein substitutions in BpsA 
A greater understanding of the interactions between the different domains and/or modules of 
NRPS enzymes may increase our ability to manipulate these enzymes to create new and novel 
products. Currently such enzyme manipulation experiments generally result in enzymes with 
decreased function (Calcott and Ackerley, 2014). Previously, the NRPS BpsA has been used in CP 
substitution experiments, with CP domains being engineered within the BpsA NRPS in order to 
increase enzyme function, identified by an increase in indigoidine production levels. The first aim 
of this thesis was to examine features of CP domain substitutions that were likely to result in a 
functional CP-substituted BpsA enzyme.  During the course of Dr Owen’s previous substitution 
experiments he made two observations, both of which appeared to be important factors in 
whether or not substitutions would be functional. The characteristics of the CP domains that 
resulted in functional CP-substitutions were: 1) these CPs were located upstream from TE domains 
in their native context (consistent with the CP domain of BpsA being situated immediately 
upstream from the BpsA TE domain); and 2) these CPs exclusively had hydrophobic residues at 
positions +4 and +24 (relative to the invariant Ser). Subsequently, four CP domains were found 
which appeared to contradict these observations (these four CP domains being located upstream 
from TE domains in their native enzymes, but having the polar residue Thr at the +4 position). The 
goal of the work in presented in Chapter 3 was to use these four CP domains to test the previous 
observations, and to answer the question of whether the native location of the CP domain or the 
identity of the +4 residue was the more important factor in predicting successful CP domain swaps 
in BpsA. These four domains were all substituted into BpsA, and all were functional to some 
extent. This indicated that the original location of the CP domain was the more important factor 
in predicting the success of swaps. However, although functional, all substitutions showed 
substantial decreases in activity compared to the WT BpsA enzyme. 
The importance of the +4 residue, as well as the +24 residue, was also investigated using the CP 
domain PvdDCP1. Previous substitution into BpsA had shown that while the initial substitution 
was non-functional (PvdDCP1 was upstream from a C domain in its endogenous enzyme), 
functionality could be restored via directed evolution. Here, the PvdDCP1 domain was substituted 
into BpsA and site directed mutagenesis was used to create variants which contained all possible 
amino acids at the +4 and +24 positions, both individually and in combination. Results confirmed 
the importance of a hydrophobic residue at the +4 position, but this position appeared to be of 
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minor importance compared to the +24 position, with residue optimisation yielding smaller 
increases in indigoidine production.  The earlier work by Dr Owen had led to the hypothesis that 
the +24 position played a key role in the hydrophobic interface between the CP and the TE domain, 
with hydrophobic residues at this site leading to improved enzyme function. The work presented 
in this thesis demonstrated that a wider range of residues appeared to be tolerated at this position 
(although many of the most active mutants did contain a hydrophobic residue). The results 
suggested that not just the hydrophobicity but the size of the residue was also important, with 
smaller less bulky residues resulting in more active CP-substituted enzymes.  
The key findings from Chapter 3 were that both the location of a CP domain in its native NRPS 
enzyme (i.e., the identity of the domain that it is immediately upstream of) and the identity of 
residues at key positions are important in predicting functionality of substitutions. If either 
condition is met, there is a high likelihood of the resulting substitution being functional. A 
combination of these factors can also work together synergistically, with the +4 and +24 positions 
having a much greater effect when both were optimised, compared to either alone. The work in 
this thesis looked at interactions specifically in BpsA; this will potentially allow further BpsA 
variants to be created that could potentially be used in other applications (such as in the 
metagenomic screen performed in Chapter 4 of this thesis). The residues confirmed as being 
important here have also been identified as being important in interdomain communications in 
other NRPS enzymes, so these rules are likely to be more generally applicable as opposed to 
pertinent to just BpsA. 
7.2.2 Discovery of PPTases and natural product genes 
The mining of bacterial metagenomes from uncultivable microorganisms is an important tool in 
the search for new natural products or enzymes which may have biotechnological applications. 
The work presented in Chapter 4 describes a screen using BpsA to identify PPTases from a 
metagenomic sample. In this screen, eDNA was co-expressed in the presence of bpsA; if the eDNA 
insert contained a PPTase that was both expressed, and capable of recognising and activating 
BpsA, then the resulting indigoidine production led to the recovery of PPTase-containing clones. 
Two small insert eDNA libraries (the Sw library and the NZ library) were screened, using both WT 
BpsA and two CP-substituted variants. During the course of this research, 21 hits were found, each 
containing a novel PPTase. Eight of these hits (approximately 40% of the total) also contained 
evidence that they were part of a biosynthetic gene cluster. The fact that these were such small 
insert libraries means that some of the remaining PPTases may also have been present within 
biosynthetic gene clusters but the recovered fragment was not identifiable as such due to the lack 
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of surrounding DNA. For instance in two of the remaining inserts, the PPTase gene was the only 
ORF present, and in several other small inserts the PPTase gene was present at the edge of the 
insert, and may have in fact been adjacent to biosynthetic genes immediately to the right or left, 
that were not represented in the recovered insert. This suggests that, barring a statistical anomaly, 
40% might be expected to be the minimum number of PPTase genes that occur alongside natural 
product biosynthetic genes in nature, and therefore that using this screen is an excellent way to 
enrich for such genes. In fact a later screen, which used a derivative method to recover PPTase 
genes from a metagenomic library, found that up to 70% of the clones they recovered also had 
NRPS or PKS genes present (Charlop-Powers et al., 2013). Another key result that came out of 
Chapter 4 was that use of different CP-substituted BpsA variants successfully increased the 
number of hits that were recovered, presumably due to the fact that different PPTases were able 
to activate different CP domains. For example, three out of the seven hits from the Sw soil library 
and five out of fourteen hits from the NZ soil library were not recovered when the libraries were 
screened with WT BpsA.  
As well as providing a means for discovering new natural product biosynthetic genes, this is also a 
novel method for the discovery of PPTase genes. The use of a direct screen for the discovery of 
new PPTase genes has never previously been reported. As a family, PPTases do not produce a 
product that would be identifiable in any phenotypic screening. They also have low sequence 
homology, so any large scale discovery based on sequences has been difficult (Lambalot et al., 
1996). PPTases themselves have utility in a wide variety of biotechnological applications. Many of 
the PPTases currently used in these applications (e.g. Sfp, AcpS), are likely employed on a historical 
basis, i.e. these were among the first PPTases discovered and there has not been a comprehensive 
analysis or effort to find superior alternatives. Due to the fact that we had found such a large 
number of new PPTase enzymes in the course of this screen, plus the fact we could use BpsA in 
order to easily measure the activity and specificity of these enzymes, the characterisation of these 
PPTases became the subject of the next research chapter.    
7.2.3 Characterisation of PPTases 
In the various applications for which PPTases are employed, PPTases with either a particularly 
broad or particularly narrow substrate specificity for different CP domains are potentially 
advantageous in different applications. For instance a PPTase with a broad range of specificity 
would be generally useful for heterologous expression of NRPS/PKS genes. This may be especially 
useful in the future for engineered NRPS/PKS enzymes which may combine modules and therefore 
CP domains which have not existed in the same species before and may require an exceptionally 
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broad range PPTase; or for metagenome derived NRPSs or PKSs which again may require a unique 
PPTase to maximise their functionality. PPTases with narrower substrate specificity might also 
prove advantageous, for example in site specific protein labelling applications, either improving 
existing dual systems of labelling, or else enabling the specific labelling of three or more target 
sites.  
As one of the key results of the previous chapter had been recovery of a large number of novel 
PPTase enzymes, the next aim of this research was to characterise these eDNA PPTases. It was 
originally hypothesised that the screening method, whereby different PPTases had been 
recovered based on their ability to recognise different CP-substituted BpsA variants, would have 
selected for a subset of PPTases that had a narrow substrate specificity. To test whether this was 
in fact the case, PPTase genes were cloned individually into pET28a(+) expression vectors, and 
analysed in a series of in vitro and in vivo assays to monitor their activity with both WT and CP-
substituted BpsA variants. Unfortunately it became apparent that none of the eDNA PPTases 
exhibited a profoundly narrow CP domain substrate specificity, with each of the PPTases able to 
activate every CP-substituted variant of BpsA they were tested with. The enzymes also proved to 
be extremely difficult to purify, with only half of these eDNA PPTases able to be purified and 
characterised in vitro. Disappointingly, the majority of these exhibited very low activity in these in 
vitro tests. However, one of the eDNA PPTases, NZ 9, did appear to have a relatively high activity 
level, orders of magnitude higher than the other eDNA PPTases tested. NZ 9 was also evaluated in 
a competition assay, which assessed its ability to activate other CP domains relative to BpsA. It 
was found that NZ9 could activate all the CP domains it was tested against including both PCP and 
ACP domains. This, along with the fact it was so active in vitro (which implies the enzyme was 
relatively stable), may indicate that this could be a potential PPTase to use in applications that 
require a broad activity PPTase.  
A selection of other PPTases (Sfp, Gsp, MtaA and EntD), which had been characterised to some 
extent previously, were also tested via the competition assay, and all showed at least some degree 
of activity with all six CP domains they were tested with. This is consistent with published 
literature, which describes the majority of type II PPTases as having a broad substrate specificity. 
As none of the discovered eDNA PPTases nor any other PPTases tested appeared to possess an 
especially narrow substrate specificity, the final aim of this thesis employed directed evolution 
techniques in an attempt to narrow the specificity of a PPTase. 
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7.2.4 Engineering of PPTase substrate specificity 
In order to engineer a PPTase with narrow substrate specificity, a directed evolution strategy was 
developed. Some of the specific PPTase/CP pairs that have previously been developed have low 
efficiencies of the labelling reactions, or exhibit a level of background activation whereby PPTases 
are still able to label substrates they are meant to have lower activity with; so there is room to 
improve upon these systems. Other studies have focused in the past on evolving the CP substrates 
to create more specific PPTase/CP pairs, but prior to the present study no work had been 
performed in terms of engineering the PPTases themselves. As part of the work characterising the 
eDNA PPTases in Chapter 5, three of the PPTases had been cloned as truncated versions. It was 
noted that these different versions of the same PPTase displayed different levels of specificity with 
some of the CP-substituted variants tested. This provided a first indication that it should be 
possible to engineer the sequence of a PPTase in order to change its substrate specificity.  
A novel screen for the evolution of PPTase substrate specificity was presented in Chapter 6. A dual 
selection was developed wherein evolved variants of the PPTase entD were selected for on iron 
limiting media (selecting variants that retained the ability to activate the CP domains of the 
enterobactin siderophore synthesis pathway, one of which is the CP of EntF). These entD variants 
were co-expressed with the bpsA gene, and also selected for the loss of ability to activate the wild 
type BpsA CP, by selecting variants that exhibited decreased levels of indigoidine production. The 
result was the discovery of several variants with narrowed substrate specificity, i.e. those that had 
retained activity with their native CP substrates while losing activity with BpsA. The top variant, 
Clone 1, appeared to have an even greater activity with EntF than WT entD in an in vivo in liquid 
culture assay. However, when this variant was purified and tested in an in vitro kinetic assay the 
overall catalytic efficiency of this variant in fact appeared to be substantially decreased in 
comparison to WT. The reasons for this anomaly are unknown, but may reflect diminished stability 
of the evolved variant in vitro. Irrespective, it was concluded that the screen that was developed 
here is likely to prove effective when applied to a larger library size, and moreover has the ability 
to be adapted to evolve other PPTases as well, which will help in the goal to find multiple specific 
PPTase/CP pairs. 
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7.3 Critical evaluation of BpsA assays used in this study 
7.3.1 Comparison of results seen in in vivo vs in vitro BpsA assays 
There were several different approaches taken for measuring either BpsA or PPTase activity via 
indigoidine production. Indigoidine production was either measured in vivo, for the co-expression 
of bpsA and PPTase genes in E. coli, on solid media or in liquid media; or else measured in vitro for 
purified enzymes. Each approach has advantages but also limitations, and an understanding of 
these limitations is required in order to fully appreciate the appropriate situations to use each 
method, and also to understand any discrepancies in results when measuring the same enzymes 
across multiple assays. Measuring indigoidine production on agar plates is the most high 
throughput method, with millions of colonies able to be screened relatively easily. The time taken 
for indigoidine production to become apparent on agar plates can be taken as a rough estimate 
of PPTase activity, but this is the least quantitative method, particularly when using the scoop 
method for administration of IPTG. Due to the high throughput nature of this method it is best for 
situations where screening of large numbers of colonies is required, and so was used to find initial 
hits in both directed evolution and metagenomic screening (Chapters 3, 4 and 6). For a more 
quantitative approach, bpsA and PPTase containing strains were grown in liquid media and 
indigoidine production was quantitatively assessed through measurement of absorbance at 590 
nm. This is more of a medium throughput approach and is good when some level of activity is 
already known. One of the limitations of this method is that the assay has a relatively short linear 
range, and hence is not an effective means to measure the activity of PPTase or BpsA variants that 
vary greatly from one another. In practice this means that if using this method when the activities 
of the tested variants are too low, comparison with WT enzymes cannot be accurately made. This 
is largely due to the fact that indigoidine is unstable in aqueous solution, and either precipitates 
out of solution or converts to a colourless form. After a peak of indigoidine concentration is seen, 
the levels then appear to drop (e.g., Figure 5.5). Thus, when comparing two variants that have 
substantially different activities, at a given time point one variant may still be in a stage of 
increasing indigoidine production while the other may have already reached a peak and be 
decreasing. This problem of indigoidine instability is also seen in in vitro assays, but is not as much 
of an issue here as each reaction is run over a much shorter period of time (15-90 min) and 
measured at much smaller intervals. This is the most quantitative method, giving kinetic 
parameters for enzymes measured. However, it is also the most low throughput, as purified 
enzymes are required.  
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These measures of indigoidine production were often inconsistent when results for the same 
enzyme were compared in different assays. For example, in Chapter 3 some CP-substituted BpsA 
variants appeared slow acting on solid media and fast acting on liquid media, though these were 
both in vivo assays. The reasons for this were unclear but the liquid assay was likely more accurate 
(as they are more quantitative). Another difference seen for the solid vs. liquid media in vivo assays 
was dependent on the method of induction for the PPTase. For example, in Chapter 3, where CP-
substituted BpsA variants were tested for their ability to produce indigoidine, the solid media 
assay appeared to be more sensitive, with the strains containing the lowest activity variants able 
to produce indigoidine on solid media despite not producing measurable levels of indigoidine in 
liquid media. However, the opposite result was observed in Chapter 6, measuring the activity of 
the engineered entD variants. Here the liquid assay was more sensitive for the lowest activity 
variants and indigoidine production was seen in the liquid assay whereas none was seen on solid 
media. This is likely due to the different methods of induction employed, with the PPTases in 
Chapter 6 induced via the pBAD promoter using arabinose. Compared to IPTG induction, this is a 
tighter method of induction and levels of PPTase expression on solid media in this instance were 
likely too low for activity to be seen. The level of induction is therefore likely something that needs 
to be taken into account, especially with the solid agar assays being used more for larger screening 
efforts. If the goal of a screen was to recover PPTases with higher activity, then decreasing the 
levels of induction in agar plates may be the appropriate course of action. Conversely if the goal 
were to recover clones with even small amounts of activity, as might be the case with 
metagenomic screening, then higher amounts of induction would be required. 
 The other main issue was the difference seen between the in vitro method and the 
aforementioned in vivo screens. Often the activity levels seen in vitro were much lower than they 
had appeared to be in vivo. For example, in Chapter 5, Svp displayed no activity in vitro despite 
showing a high amount of activity in vivo. It was also seen in Chapter 6 where all of the evolved 
entD variants had extremely low activity compared to WT entD, which did not reflect in the results 
of the in vivo assays. One explanation for the inconsistencies seen may be due to problems with 
the stability of the purified protein. For many in vitro downstream applications a purified protein 
would be required, so this will require further investigation in future work.  
7.3.2 Limitations of the BpsA assays used to judge the specificity of 
PPTases 
As all of the assays used in this thesis to assess the activity of PPTases were based on the enzyme 
BpsA, this means they are only describing the ability of a given PPTase to activate BpsA, which is 
153 
 
not the native substrate of any of the PPTases tested here. In order to test the ability of PPTases 
to activate other CP domains, two methods were used. First the CP-substituted BpsA enzymes 
were employed, offering an alternative CP substrate for a given PPTase to activate while still 
producing indigoidine as the coloured product to report activity. This approach is limited however 
in terms of the range of CP domains that could be tested, as creating functional CP-swaps is a very 
laborious process.  The other way of testing the activity of a PPTase with alternative CP domains 
was to use the competition assay, where BpsA and any alternative CP domain compete for a pool 
of limited CoA, which allows calculation of the preference a given PPTase shows for the competing 
CP domain as compared to WT BpsA.  It is easier to test a wider variety of CP domains using this 
assay as no enzyme evolution is required, and therefore all of the CPs have their WT sequence. 
These cannot be compared directly due to the fact that each PPTase has a different level of activity 
with BpsA to begin with but an approximation can be calculated based on the kinetic parameters 
of the PPTases with respect to BpsA (Owen et al., 2011). This work will be done in the future for 
the PPTases investigated here. 
7.4 Future directions 
7.4.1 BpsA in metagenomic screening 
The work described in this thesis validated the use of BpsA as a tool for the discovery of both 
PPTase genes and their associated natural product biosynthetic gene clusters. As both of the 
libraries screened in the current study were small insert eDNA libraries, it was not possible to 
recover entire biosynthetic gene clusters. Future work will focus on the screening of libraries 
containing much larger eDNA fragments (using cosmids or bacterial artificial chromosomes) in 
order to discover entire biosynthetic gene clusters.  An advantage of finding complete gene 
clusters for natural product genes is that the gene clusters may be able to be functionally 
expressed in E. coli, or other suitable heterologous expression strains, and ultimately used to 
produce a novel natural product, as an alternative to chemical synthesis.  
In the screen described in this thesis, each of the CP-substituted BpsA variants were plasmid-
based, and libraries were screened repeatedly in different strains containing each plasmid. An 
option for improving upon this system for future experiments is to use genomic incorporation to 
integrate multiple bpsA variants into the chromosome of a single host strain. This would cut down 
on the amount of screening that needs to be done. Another way to improve upon this screen in 
the future would be the creation of even more CP-substituted BpsA variants, using even more 
diverse CP domains (e.g., including ACPs and ArCPs). The work described in Chapter 3 could be 
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used to guide the creation of such variants, i.e. by selecting CP domains that are found 
immediately upstream from TE domains in their native context. Low functioning substitutions 
could then be improved in a targeted fashion via site directed mutagenesis at the +4 and +24 sites, 
a more straight-forward approach than a completely random mutagenesis, and easier to 
implement. The combination of choosing CP domains (upstream from TE domains) that are more 
likely to be functional, and the knowledge of the exact residues to target if improvements in 
function are required, means that CP domains will overall be changed very little from their original 
sequence. This is an advantage as the whole point of using these CP-substituted variants is to 
present alternative sites of recognition for the PPTase enzymes. Helix II is thought to be the part 
of the CP domains that the PPTase recognises, and it is only the +4 residue that is in this helix, 
while the +24 residue is in helix III, indicating that evolving CP-substituted BpsA variants in this 
manner should not dramatically alter the site of PPTase recognition. 
An important factor to take into account however, is that the work in Chapter 5 indicated that all 
of the PPTases discovered in Chapter 4 could in fact recognise all of the CP-substituted BpsA 
variants, but some were just not adequately expressed within the eDNA inserts. Another future 
direction then would be to investigate ways of increasing the gene expression of the eDNA inserts. 
Increasing these expression levels may be of even more of a concern when looking at larger insert 
vectors like BACs (with a given PPTase likely to be even further away from any strong promoters 
the plasmid may possess).  Two approaches to increase expression may be to use alternative host 
strains, e.g. Streptomyces species that are better suited to heterologous expression of many 
natural product biosynthetic genes; or else using transposon mediated random insertion of 
promoters into the DNA fragments (Troeschel et al., 2010).There has also been work showing that 
expression of heterologous sigma factors in E. coli can result in these strains being able to 
recognise a wider number of heterologous promoters (Gaida et al., 2015). 
7.4.2 Engineering of PPTases to have altered CP substrate 
specificity 
The work in Chapter 6 showed that it was possible to engineer altered substrate specificity for the 
PPTase EntD, and the strategy developed here should be applicable to other PPTase enzymes. If a 
PPTase knock out strain is available, then variants can be screened in the same manner, selecting 
for siderophore production through growth on iron limiting plates. As part of ongoing work in our 
lab by Masters student Jack Sissons, EntD is being engineered to lose activity with a different CP 
substrate (the PvdDCP1 domain, screening for decreased indigoidine production in the reporter 
strain EcoBlueP). In parallel, the PPTase PcpS from P. aeruginosa is also being evolved to retain 
155 
 
activity with PvdDCP1 (through growth on iron limiting media, necessitating production of the 
NRPS pyoverdine) and to lose activity with the EntF CP-substituted variant of BpsA (variant 
libraries of pcpS being screened for loss of indigoidine production in the EcoBlueE reporter 
strain).The aim of this work is to create a complementary pair, an EntD variant which has activity 
with EntF and no activity with PvdD, and a PcpS variant which has activity with PvdD and none 
with EntF. These could then be used for the application of site specific protein labelling, and 
perhaps combined with existing specific PPTase/CP pairs and used to label a number of different 
proteins with no cross reactivity. 
The proof-of-principle EntD evolution study described here focused on the ability of EntD to 
recognise (or not recognise) the entire CP domain. The ability of the evolved variants to specifically 
activate a CP as a distinct protein, as opposed as a domain within BpsA, needs to be investigated 
further. Additional to this, ongoing work in our lab is also investigating the potential to use small 
protein tags in the place of an entire CP domain. Small tags based on the CP domain sequences 
are being designed and tested to see whether the PPTase is capable of activating them and still 
showing specificity. Another future direction is the use of BpsA to screen for such small tag 
sequences, by substituting just the helix II region of BpsA. This region has been substituted before 
by (Mofid et al., 2002), who showed that altering this region alone is enough to influence which 
PPTase activates a target CP domain. Another option for a future experiment would be to use a 
directed evolution approach to alter just this region, helix II of the BpsA, and thereby evolve a tag 
for greater specificity with a PPTase.  
The enzyme engineering that has been performed to alter the CP domain substrate specificity of 
EntD, and any possible future work to alter the specificity of other PPTases, could also be applied 
to better understand the interaction between a PPTase and CP domain. Though this interaction is 
important in the physiological function of PPTases, as well as for various PPTase applications, little 
is known about how PPTases recognise specific CP domains. Only one type II PPTase has had its 
structure solved together with a PCP partner, showing the regions that are important for the 
general interaction. Without the comparison of other CP domains, it is difficult to infer the extent 
to which this interaction may differ for different substrates, and what drives the specificity a 
PPTase has for one CP over another. A mutational analysis is another approach to answer these 
questions. A pattern may emerge if several PPTases are evolved (starting with entD and pcpS) for 
specificity with particular substrates.  
An important aspect of future work would be the need to tease apart individual mutations, as with 
so many multi-site mutants generated via epPCR it can be difficult to assess the role of specific 
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mutations. Mutations that are found repeatedly, such as Y88N in the evolved EntD variants 
(Chapter 6), need to be tested as single mutations. This also may help with the fact that all of the 
evolved entD variants appeared to have lost so much activity when tested in vitro. This may have 
been caused by protein instability which may in turn have been a result of introducing too many 
mutations into the WT enzyme. If we could elucidate only the key amino acids to change in order 
to alter substrate specificity, this may lead to more active evolved variants.  
7.5 Concluding remarks 
This thesis describes the development and implementation of several assays that use BpsA as a 
tool to give insights into both PPTases and CP domains. Firstly, further insights were gained about 
specific features of CP domains that promote formation of functional CP-substituted BpsA 
variants. Functional CP-substituted variants as well as WT BpsA were then used in a series of 
screens and assays to both discover and characterise novel PPTase enzymes. Upon finding all 
PPTases to have a broad specificity across the tested CP domains, a novel screen was developed 
in order to engineer PPTase substrate specificity. Also based on the activity of BpsA, this screen 
was used to engineer the PPTase EntD in a proof of principle experiment and was successful in 
creating a PPTase with more narrow substrate specificity. This will form the basis of future work 
for developing PPTase/CP pairs which have non-overlapping activities.  
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Appendix 1: BpsA as a tool to quantify L-glutamine 
Work was undertaken contributing to a project not directly relating to this thesis, the 
development of BpsA as a biosensor in order to quantify L-glutamine. My role in this work was to 
perform initial experiments testing the ability of BpsA to quantify L-glutamine in complex cell 
culture media (LB and DMEM), this resulted in a patent of which I was one of the co-authors 
(Ackerley et al., 2015). Following is a fact sheet produced by Viclink, Victoria University of 
Wellington’s commercialisation office.  
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Appendix 2: Sequences of synthesised genes 
Sequences in italics denote sequence that was added (e.g. containing restriction sites) to the gene 
Sfp 
CCCCCATATGAAAATCTACGGTATCTACATGGACCGTCCGCTGTCTCAGGAAGAAAACGAACGTTTCATG
ACCTTCATCTCTCCGGAAAAACGTGAAAAATGCCGTCGTTTCTACCACAAAGAAGACGCGCACCGTACCCT
GCTGGGTGACGTTCTGGTTCGTTCTGTTATCTCTCGTCAGTACCAGCTGGACAAATCTGACATCCGTTTCT
CTACCCAGGAATACGGTAAACCGTGCATCCCGGACCTGCCGGACGCGCACTTCAACATCTCTCACTCTGG
TCGTTGGGTTATCGGTGCGTTCGACTCTCAGCCGATCGGTATCGACATCGAAAAAACCAAACCGATCTCTC
TGGAAATCGCGAAACGTTTCTTCTCTAAAACCGAATACTCTGACCTGCTGGCGAAAGACAAAGACGAACA
GACCGACTACTTCTACCACCTGTGGTCTATGAAAGAATCTTTCATCAAACAGGAAGGTAAAGGTCTGTCTC
TGCCGCTGGACTCTTTCTCTGTTCGTCTGCACCAGGACGGTCAGGTTTCTATCGAACTGCCGGACTCTCAC
TCTCCGTGCTACATCAAAACCTACGAAGTTGACCCGGGTTACAAAATGGCGGTTTGCGCGGCGCACCCGG
ACTTCCCGGAAGACATCACCATGGTTTCTTACGAAGAACTGCTGTAAGTCGACCCCC 
 
Svp 
CCCCCATATGATCGCTGCTCTGCTGCCGAGTTGGGCTGTAACCGAACACGCCTTCACCGATGCGCCGGAC
GACCCGGTGAGCCTGCTTTTCCCGGAAGAGGCGGCACACGTGGCCCGTGCGGTTCCGAAACGCCTGCAT
GAATTTGCCACCGTCCGTGTTTGTGCTCGTGCGGCGTTGGGTCGCCTGGGCCTGCCTCCGGGCCCGCTGT
TACCGGGCCGTCGCGGCGCACCGTCCTGGCCGGACGGTGTAGTGGGTTCGATGACTCACTGTCAGGGTT
TCCGCGGTGCGGCTGTGGCACGAGCGGCTGACGCCGCTTCCCTGGGCATCGACGCTGAACCGAACGGTC
CGCTGCCGGATGGTGTTCTGGCAATGGTTAGTCTGCCGTCCGAACGTGAATGGCTGGCAGGTCTGGCCG
CTCGCCGCCCGGACGTCCATTGGGACCGTCTGCTGTTCAGCGCGAAAGAATCTGTGTTTAAAGCCTGGTA
TCCGCTGACCGGTCTGGAACTGGATTTCGATGAAGCGGAACTGGCGGTTGATCCGGACGCGGGTACCTT
CACTGCTCGCCTCCTGGTTCCGGGTCCGGTGGTAGGTGGCCGTCGTCTGGACGGCTTTGAAGGTCGTTGG
GCGGCAGGTGAAGGTCTGGTTGTTACCGCCATTGCGGTTGCAGCTCCAGCAGGCACCGCAGAAGAATCT
GCCGAGGGCGCCGGCAAAGAGGCTACTGCAGATGACCGCACTGCGGTTCCGTAAGTCGACCCCC 
 
Gsp 
CCCCCATATGATTGAAATGCTGTTCGTAAAAGTCCCGAACGAAATCGACCGTCACGTTTTCAATTTTCTGA
GCTCCAACGTTTCCAAAGAAAAACAACAGGCTTTCGTTCGCTACGTCAACGTTAAGGATGCTTATCGTTCC
CTGCTGGGCGAGCTGTTGATCCGCAAATACCTGATCCAGGTCTTAAACATCCCTAATGAAAACATCCTGTT
CCGTAAAAACGAATACGGCAAACCGTTCGTAGATTTCGACATTCACTTTAACATCTCTCACTCCGATGAAT
GGGTTGTTTGCGCTATTTCTAACCATCCGGTGGGTATCGACATTGAGCGTATCTCCGAGATCGACATCAA
GATCGCAGAACAGTTCTTCCACGAAAACGAATACATCTGGCTGCAGTCGAAAGCCCAAAACTCTCAGGTG
TCTTCTTTTTTTGAGCTGTGGACCATTAAAGAGAGCTATATTAAGGCCATTGGTAAAGGCATGTATATTCC
TATCAACTCTTTTTGGATCGATAAGAACCAGACTCAGACGGTGATTTATAAACAAAACAAAAAAGAACCG
GTTACCATCTATGAACCGGAACTGTTCGAAGGTTACAAGTGCAGTTGCTGCAGCCTTTTCAGCTCTGTTAC
GAACCTCAGCATCACCAAACTCCAGGTTCAGGAACTGTGCAACCTGTTCCTGGATTCTACCTTTAGCGAAA
ACAACAACTTCTAGGTCGACCCCC 
 
MtaA 
161 
 
CCCCCATATGCCGACTTCCAGCCCGGCTTTGCCGCTGCTGAAACTGCCGCCGGATGAAGTACACGTTTGG
ATTGTTGAACCGGAACGTATCACAGAGCCAGGTCTGCTCGAAAGCTACCGCGCGCTCCTAGATCCGGGC
GAACGCGACAAACAGCAGCGTTTCTACTTCGAACGTCATCGTCTGCAATACCTGGTTAGCCATGCGCTGG
TACGTCTGACCCTGAGTCGTTATGCCCCGGTTGCACCGGAAGCTTGGTCCTTTTCTGCGAACCAGTACGGT
CGTCCGGAAATCCGCGGTGAAGAAAAACCGTGGCTGCGTTTCAACCTGTCGCACACCGACGGTATGGCT
CTGTGCGCTGTCGCCCGTGATGTGGACGTAGGTGCAGATGTAGAGGACACCGAGCGCCGCGGTGAAACC
GTCGAAATCGCGGATTCTTTCTTCGCGCCGGCAGAAGTTGCGTCCCTGCGTGCTCTCCCGGTTAGCGGCC
AGCGTGAACGCTTTTTTGACTACTGGACCCTGAAAGAGGCGTACATTAAAGCTCGCGGGATGGGCCTGA
GCCTCCCGCTGGATCAGTTCGCGTTCGAAGTATCCCAGGGCCTGAGTACCCGCATTAGCTTCGACCCGCG
CCTGGTAGACGAACCGTCCCAGTGGCAGTTCGTCCGTTTTCGTCCGAGCCAGCGCCACGCAGCGGCGCTG
GCTGTCCGTCGTCCTTCCGAAGCGCCGCTGACCGTTCGTTTCCAACGTACCGTCCCGCTGCAGGACGATGC
ACCGGCTGAATATCTGAGCCGTGAGCGTATCCAGCCGCTGCGTCTCCGTATGCCGGGTGTTGGCGGCGG
TTGAGTCGACCCCC 
 
ACMSIII 
AGCTCTGCAGAGCTCGTCGAGCGCCCCGGCCGTGCACCGCGTACGCCGCAGGAACAGGTTGTCTGCGAA
CTGTTCGCGGAAGTGCTGGGTCGCCCGTTGGTTGGGGTCGATCAGGATTTCTTCGATCTGGGTGGTCACA
GCCTGCTGGCAACACGTCTTATCGCTCGTCTGCGTGCAGCGTTCGGTGTAGAACTGGGCTTACGTTCCCTG
TTCGAAGCACCTACGCCGGGTGGTATTGCAGCCCGTTTGGACCGCGAGGTCGCCCAGGAGTCTAGAAGC
T 
 
GrsB 
AGCTCTGCAGAGCTCGTCGAGCGCCCCTACGTGGCGCCGCGTAACGAAATCGAAGCACAGCTGGTACTG
ATTTGGCAAGAAGTTCTGGGTATCGAACTGATCGGCATCACCGACAACTTTTTCGAACTCGGTGGTCACTC
TCTCAAGGCAACGCTGCTCGTCGCGAAAATCTACGAATATATGCAGATCGAAATGCCACTGAACGTGGTG
TTCAAACACAGCACCATTATGAAAATTGCAGAATATATTACTCGCGAGGTCGCCCAGGAGTCTAGAAGCT 
 
TycC 
AGCTCTGCAGAGCTCGTCGAGCGCCCCTACGTAGCACCGCGTAACGCTACCGAACAACAGCTGGCAGCTA
TCTGGCAGGAAGTGCTGGGTGTGGAACCGATTGGCATCACCGATCAGTTCTTCGAACTGGGCGGTCACA
GCCTTAAGGCTACCCTCCTGATCGCGAAAGTGTATGAGTATATGCAGATCGAACTCCCGCTGAACCTGAT
TTTCCAGTATCCGACTATCGAAAAAGTGGCGGATTTCATTACCCGCGAGGTCGCCCAGGAGTCTAGAAGC
T 
 
Pris3 
AGCTCTGCAGAGCTCGTCGAGCGCCCCGGTCGTCCGCCACGTGGTCCACGCGAAGAAATCCTGTGTGGCC
TGTTCGCTGAAGTTCTGGGTGCACCGCGTGTTGGCACTGACGACAACTTCTTCGAACTGGGCGGTCACTC
TATGCTGGCCACCCGTCTGGTCGGCCGTGTAAAAACCGTCCTGGGTGCAGACATCGGTGTGCGTACTCTG
TTCGAAGCACCGACGGTTGCTGCTCTGGCAGCACGTATTGATCGCGAGGTCGCCCAGGAGTCTAGAAGCT 
 
162 
 
BlmI 
CCCCCATATGAGTGCGCCACGTGGTGAACGTACCCGTCGTCGCGCTCTGGAACGTGACATCGCAGCGATT
TGGGCAGAAACTCTCGGCCGTGATAGCGTTGGGCCGCATGAAGATTTCGCCGCACTGGGCGGCAACTCG
ATCCATGCGATCAAAATTACCAACCGTGTGGAAGAACTCGTCGATGCTGAACTTTCTATTCGTGTTCTGCT
GGAAACCCGTACCGTGGCTGGTATGACCGACCACGTACATGCTACCCTGACGGGTGAGCGTGACCGTTG
AGTCGACCCCC 
 
SgcC2 
CCCCCATATGTCTACTGTGTCCGACACCGCCGCAGGCTCTTCTCTGGAAGAAAAAGTGACGCGTATCTGG
ACCGGTGTGCTGGGCACGTCAGGTGAAGAAGGTGCGACCTTTATTGAACTGGGTGGTCAATCCGTTTCC
GCGGTCCGCATCGCAACTCGTATCCAGGAGGAACTGGACATCTGGGTAGATATCGGCGTGCTGTTCGAT
GATCCGGACCTGCCGACGTTCATTGCGGCTGTTGTGCGTACTGCCGATGCGGCTGGCGGCGAAGGTAGC
GGTACCCAGTGAGTCGACCCCC 
 
MtaF 
CCCCCATATGTCTGCGTTCGCTAACGCTCTGAGCTCTGCCGAACCGAGCCAGCGTGGCCAGCTGCTGGGC
TCCTACTTATGCGAACAGGTTGCACACCTGCTGAAGATGCCGGTTGCGAAACTGGACCCGGAACAGCCTT
TAAACTCAATGGGTATGGACAGCCTGCTGAGCCTGGAACTGAAACATAAGATTCACGCGGAAACCGGCA
TGGATGTACCGCTGGACGAAGTTCTGCAGGGCGCCTCAATCGCTAACCTGTCGATGCGCCTGGCGGAAC
GTATGGGTAATTCCGGCCAGGCCGCGTGAGTCGACCCCC 
 
TcmM 
CCCCCATATGCCTCAGATCGGCCTGCCGCGTCTGGTGGAGATCATTCGTGAATGCGCCGGCGATCCGGAC
GAGCGTGATCTGGACGGTGATATCCTGGACGTTACCTATCAGGATCTGGGTTACGACTCTATCGCTCTGC
TGGAAATCTCTGCAAAACTGGAACAAGATTTGGGCGTTTCTATTCCGGGCGAAGAACTGAAGACGCCAC
GCCATACGCTGCACCTGGTTAACACTGAAACCGCTGGTGAGGTTGCGTGAGTCGACCCCC 
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